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Abstract
In 2003, prostate cancer (PCa) is estimated to be the most commonly diagnosed
cancer and third leading cause of cancer death in Canada. During PCa population
screening, approximately 25% of patients with a normal digital rectal examination (DRE)
and intermediate serum prostate specific antigen (PSA) level have PCa. Since all patients
typically undergo biopsy, it is expected that approximately 75% of these procedures are
unnecessary. The purpose of this study was to compare the degree of efficacy of clinical
tests and algorithms in stage II screening for PCa while preventing unnecessary biopsies
from occurring. The sample consisted of 201 consecutive men who were suspected of
PCa based on the results of a DRE and serum PSA. These men were referred for
venipuncture and transrectal ultrasound (TRUS). Clinical tests included TRUS, age-
specific reference range PSA (Age-PSA), prostate specific antigen density (PSAD), and
free-to-total prostate specific antigen ratio (%fPSA). Clinical results were evaluated
individually and within algorithms. Cutoffs of 0.12 and 0.15 ng/ml/cc were employed for
PSAD. Cutoffs that would provide a minimum sensitivity of 0.90 and 0.95, respectively
were utilized for %fPSA. Statistical analysis included ROC curve analysis, calculated
sensitivity (Sens), specificity (Spec), and positive likelihood ratio (LR), with
corresponding confidence intervals (Cl). The %fPSA, at a 23% cutoff ({ Sens=0.92; CI,
0.06}, {Spec=0.4l; CI, 0.09}, {LR=1.56; CI, O.ll}), proved to be the most efficacious
independent clinical test. The combination of PSAD (cutoff 0.15 ng/ml/cc) and %fPSA
(cutoff 23%) ({Sens=0.93; CI, 0.06}, {Spec=0.38; CI, 0.08}, {LR=1.50; CI, 0.10}) was
the most efficacious clinical algorithm. This study advocates the use of %fPSA at a
cutoff of 23% when screening patients with an intermediate serum PSA and benign DRE.
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Glossary of Terms
Algorithm
A process which consists of steps, each depending on the outcome of the previous
step (Dirckx, 2001).
Benign prostatic hyperplasia
A condition in which tissue enlargement around the urethra occurs. As a result,
the urethra is compressed obstructing normal urine flow. Benign prostatic hyperplasia
may also cause enlargement of the prostate (Damjanov, 2000).
Diagnosis
The process in which the health status of an individual is determined as well as
the factors responsible for producing it (Last, 2001).
Efficacy
The extent to which a specific intervention, procedure, regimen, or service
produces a beneficial result under ideal conditions (Last, 2001; U.S. Congress, 1976).
Extraprostatic extension
Cancer that has extended beyond the edge or capsule of the prostate. The cancer
may have spread to adipose tissue, to anterior muscle, or in the perineural spaces of the
neurovascular bundles (Bostwick, 1997).
False negative
Negative test result in a person who possesses the attribute for which the test is
conducted (Last, 2001).
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False negative rate
The probability that an individual with a disease will have a negative test result
(Knapp & Miller, 1992).
False positive
Positive test result in a person who does not possess the attribute for which the
test is conducted (Last, 2001).
False positive rate
The probability that a disease-free individual will have a positive test result
(Knapp & Miller, 1992).
Gold standard
The definitive diagnosis attained by an acknowledged standard including biopsy,
surgery, autopsy, or long-term followup (Sackett, Haynes, Guyatt, & Tugwell, 1991).
Hyperechoic
Tumors that are denser than healthy tissue and thus appear as lighter spots on a
monitor or in a photo (McDougal & Skerrett, 1996).
Hypoechoic
Producing less echo signal on a transrectal ultrasound (Gelbard & Bentley, 1995).
Incidence
The proportion of new cases that have the disease over a period of time (Hulley &
Cummings, 1988).
Metastasis
The spread of cancer to other tissues or organs in the body including the bones or
lungs (Barrett, 2000).
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Negative predictive value
The probability that a person with a negative test result does not have the disease
(Hulley & Cummings, 1988).
Positive likelihood ratio
How likely a positive test result occurs in an individual with a particular disease
than in an individual without the disease (Greenhalgh, 1997).
Positive predictive value
The probability that a person with a positive test result will actually have a
particular disease (Sackett et aI., 1991).
Prevalence
The number of instances for a given disease or condition in a population at a
designed period of time (Last, 2001).
Prostate cancer
Characterized by the growth of a malignant tumor within the prostate gland
(Morganstern & Abrahams, 1996).
Receiver operator characteristic curve
A graphic means for assessing the ability of a screening test to discriminate
between healthy and diseased persons (Last, 2001).
Relative risk
The ratio of the risk of an outcome in people who are exposed to the risk factor to
the risk in those not exposed to the risk factor (Hulley & Cummings, 1988).
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Screening
The presumed identification of a disease by the rapid application of clinical tests
or procedures. Sensitivity, specificity, and accuracy are all characteristics of a screening
test (Last, 2001).
Sensitivity
The proportion of individuals with a particular disease who have a positive test
result (Hulley & Cummings, 1988).
Specificity
The proportion of individuals without a particular disease who have a negative
test result (Hulley & Cummings, 1988).
Stage II screening
Patients who have underwent population screening and require further evaluation
prior to a confirmed diagnosis.
True negative
The test result is negative and the patient does not have the disease (Hulley &
Cummings, 1988).
True positive
The test result is positive and the patient has the disease (Hulley & Cummings,
1988).
Tumor
When cancerous cells within the body reproduce and a mass of tissue develops
(Damjanov, 2000).
Stage II Screening for Prostate Cancer 15
Utility
Whether or not the patient is better off by undergoing the screening test or clinical
maneuver (Sackett et aI., 1991).
%fPSA
ACT
Age-PSA
ANOVA
AVC
BMI
BPH
ee
CI
em
CT
CZ
DNA
DRE
FM
FN
FP
LR
MEIA
MESH
ml
mm
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List of Abbreviations
Free-to-total prostate specific antigen ratio
a l-antichymotrypsin
Age-specific reference range PSA
Analysis of variance
Area under the receiver operator characteristic curve
Body mass index
Benign prostatic hyperplasia
Cubic centimeters
Confidence intervals
Centimeter
Computerized tomography
Central zone
Deoxyribonucleic acid
Digital rectal examination
Anterior fibromuscular stroma
False negatives
False positives
Positive likelihood ratio
Microparticle enzyme immunoassay
Medical subject headings
Milliliters
Millimeters
MRI Magnetic resonance imaging
ng Nanograms
NPV Negative predictive value
PCa Prostate cancer
PIN Prostatic intraepithelial neoplasia
PPV Positive predictive value
PSA Prostate specific antigen
PSAD Prostate specific antigen density
PZ Peripheral zone
ROC Receiver operator characteristic
Sens Sensitivity
Spec Specificity
TN True negatives
TP True positives
TRUS Transrectal ultrasound
TZ Transition zone
un Distal urethral segment
UP Proximal urethral segment
vv Vessels
yr Year
Zk Cohen's Kappa statistic
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Chapter I
Introduction
1.1 Theme
In Canada, prostate cancer (PCa) is estimated to be the most commonly diagnosed
cancer and third leading cause of cancer death after lung and colorectal cancer (Canadian
Cancer Society, 2003). In 2003, it is estimated that some 18,800 Canadian men will be
diagnosed with pea and further approximately 4,200 Canadian men will die from PCa
(Canadian Cancer Society, 2003). In 1998, the prevalence of PCa in Canada was 0.6%
(Canadian Cancer Society, 2003). The lifetime incidence of PCa is 1 in 8.3 men, while 1
in 28.1 will die from it (Canadian Cancer Society, 2003).
Currently, the most commonly accepted method of population screening for PCa
is a digital rectal examination (DRE) followed by a serum prostate specific antigen (PSA)
test (Catalona et aI., 1994; Cooner et aI., 2002; Crawford, Leewansangtong, Goktas,
Holthaus, & Baier, 1999; Grossfeld & Carroll, 2001). Population screening refers to the
presumed identification of a disease by the rapid application of clinical tests or
procedures (Last, 2001). As shown in Appendix 1, when DRE is normal and serum PSA
levels are <4.0 ng/ml, cancer is unlikely and there is little rationale in the patient
undergoing a biopsy procedure (Nixon & Brawer, 1997). However, the prostate biopsy is
routinely carried out on patients whenever the DRE is suspicious, regardless of the serum
PSA level (Ellis, Chetner, Preston, & Brawer, 1994; Karakiewicz & Aprikian, 1998;
Nixon & Brawer, 1997) or anytime serum PSA levels exceed 10.0 ng/ml regardless of
DRE results (Dincel et al., 1999; Ellis et aI., 1994; Nixon & Brawer, 1997). The dilemma
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with this population screening algorithm arises when the physician must decide whether
to further evaluate a patient who presents a normal DRE and a serum PSA level between
4.0 and 10.0 ng/ml (intermediate level) (Zisman, Leibovici, Kleinmann, Siegel, &
Lindner, 2000). It is when DRE results are normal and serum PSA levels are
intermediate that serum PSA testing has a poor specificity as the false positive rate ranges
from approximately 0.63 (Bare, Hart McCullough, 1994) to 0.91 (Deliveliotis et aI.,
1998). These high false positive rates can be brought about by benign prostatic
hyperplasia (BPH) (Lukes et aI., 2001), prostatitis (Barrett, 2000), age (Catalona, Smith,
Ratliff, & Basler, 1993), prostatic volume (Klingler et aI., 1998), and within 24 hours
after ejaculation (Tchetgen, Song, Strawderman, Jacobsen, & Oesterling, 1996). These
patients are subjected to unnecessary biopsies and the associated anxiety and stress of a
positive screening test (Aziz & Barathur, 1993), as well as the large associated financial
costs of these unnecessary procedures (Gann, Ma, Catalona, & Stampfer, 2002).
Increasing the number of unnecessary biopsies performed should not be the outcome of
improved cancer detection methods (Vessella et aI., 2000). Therefore, it is critical that
some form of discriminator is developed that prevents unnecessary biopsies in patients
with intermediate serum PSA (Zisman et aI., 2000). Approximately 21 % of patients who
are positive during the population screening phase have a normal DRE and intermediate
serum PSA level (Klingler et aI., 1998).
Early detection of localized cancer presents the only available option to reduce the
mortality rates from PCa, since no cure currently exists when PCa is in the advanced
stages (Crawford et aI., 1996). The frequency of early detection has escalated due to an
increase in public awareness and improved screening methods (Cersosimo & Carr, 1996).
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Although efforts have been made to improve early detection of PCa, no established
algorithm exists in providing a satisfactory predictive value or acceptable cost (Ozen et
aI., 2001). Prostate cancer screening will improve as more sensitive, specific, and cost-
effective screening techniques become available (Gambert, 2001). Currently, several
convenient clinical tests are employed during stage II screening for PCa when DRE
results are normal and serum PSA levels range from 4.0 to 10.0 ng/ml. Stage II screening
refers to patients who have underwent population screening and require further
evaluation prior to a confirmed diagnosis. These clinical tests include transrectal
ultrasound (TRUS) (Palken, Cobb, Simons, Warren, & Aldape, 1991), age-specific
reference range PSA (Age-PSA) (Oesterling, Jacobsen et aI., 1993), prostate specific
antigen density (PSAD) (Benson, Whang, Pantuck et aI., 1992), and free-to-total prostate
specific antigen ratio (%fPSA) (Catalona et aI., 1998). Typically, if anyone of these
clinical tests is positive, the patient is sent to undergo a biopsy procedure in order to
confirm a diagnosis. Since potential tradeoffs of sensitivity (Sens) and specificity (Spec)
exist, there is no current consensus on the optimal strategy for these various clinical tests
(American Urological Association, 2000). This is shown in Appendix 2.
Although there are various clinical tests to screen for PCa within the intermediate
serum PSA levels, previous research has neglected to employ these clinical tests within
an algorithm. Since no clinical test is accurate, a single test is usually inadequate for
producing an unambiguous decision during screening (Knapp & Miller, 1992). Utilizing
clinical tests such as TRUS, Age-PSA, PSAD, and %fPSA within various algorithms
may provide a higher sensitivity than utilizing these clinical tests independently.
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Despite the number of clinical tests for stage II screening PCa, measures of
validity including sensitivity and specificity vary significantly from one study to the next.
As screening articles demonstrate discrepancies in the indexes of efficacy for clinical
tests, well-controlled studies are required that incorporate proper clinical epidemiological
standards such as an appropriate patient spectrum, researcher blinding, and adopting the
current and accepted gold standard. Despite these discrepancies, clinical tests remain
popular for screening PCa. In the context of this study, it is important to define efficacy
as the extent to which a specific procedure, regimen, or service produces a beneficial
result under ideal conditions (Last, 2001; U.S. Congress, 1976). A beneficial result could
include improved quality of life, longer survival, or prevention of death for patients with
prostate cancer.
1.2 Objective
The objective of this study was to compare the degree of efficacy of independent
and clinical algorithms in stage II screening for PCa.
1.3 Hypothesis
It was hypothesized that the clinical algorithm TRUS and %fPSA set at a 0.90
sensitivity will be the most efficacious clinical algorithm in stage II screening for Pea.
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Chapter II
Review of Literature
2.1 Introduction
Prostate cancer is the most commonly diagnosed malignancy in men over the age of
50 years (Landis, Murray, Bolden, & Wingo, 1999). Worldwide, PCa is the sixth most
common form of cancer and the third most common in terms of new cases diagnosed
each year (Parkin, Bray, & Devesa, 2001). Currently, PCa is estimated to be the most
commonly diagnosed cancer and the third leading cause of cancer death in Canadian men
(Canadian Cancer Society, 2003). Prostate cancer accounts for 26.3% of new cases
diagnosed and 11.7% of cancer deaths in Canadian men (Canadian Cancer Society,
2003). Since 1973, the incidence of PCa has increased approximately 100% (Canadian
Cancer Society, 2003). Despite medical advances, PCa represents a significant
proportion of new cases and deaths each year.
2.2 Defining Cancer
All bodily cells are susceptible to mutations, a change in the chemical form of the
deoxyribonucleic acid (DNA) code (Barron & Thomas, 1996; Morganstern & Abrahams,
1996). Deoxyribonucleic acid, which is composed of genes, controls the cellular growth
and behavior of cells (Bostwick, MacLennan, & Larson, 1999). Mutations possess the
ability to change the genes in cells (Barron & Thomas, 1996). An average cell can
experience as many as 5000 mutations each day (Morganstern & Abrahams, 1996).
Therefore we have the potential to develop cancer at any point in time (Barron &
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Thomas, 1996). Most of these 5000 mutations within cells are harmless (Morganstern &
Abrahams, 1996). However, cancer may develop if the mechanism for reproduction is
affected by a mutation (Morganstern & Abrahams, 1996).
Generally, cells reproduce in a systematic fashion (Winawer, Shike, Bashe, &
Subak-Sharpe, 1995). However, cancer is a disease that initiates cells in the body to
grow unregulated, independently, and more rapidly than normal cells (Barron & Thomas,
1996; Morganstern & Abrahams, 1996). Compared to normal cells, malignant cells
possess an irregular shape, have an enlarged nucleus that contains an unusual number of
chromosomes or abnormal genes, and invade nearby tissue and organs (Damjanov, 2000).
In most cases, the immune system is quick to spot and repair any errors within cells
(Barron & Thomas, 1996). However, occasionally the immune system does not discover
the error and/or is not capable of repairing the damage created by the mutation (Barron &
Thomas, 1996). As a result, the cell begins to reproduce rapidly and changes its
characteristics as it grows (Barron & Thomas, 1996). A tumor is formed as malignant
cells continue to rapidly divide. The tumor's growth is often referred to as its doubling
rate (Bostwick et aI., 1999). Doubling rate is defined as the period of time it takes for the
number of tumor cells to duplicate (Bostwick et aL). These malignant cells begin to rebel
and interfere with the body's normal function (Barron & Thomas, 1996; Morganstern &
Abrahams, 1996). If left untreated, these cells weaken the body's defences, invade vital
organs, and cause eventual death by depriving normal cells of nourishment and space
(Barron & Thomas, 1996; McDougal & Skerrett, 1996; Morra & Potts, 1996). Since all
cancers are well known for their uncontrolled growth, cancer is considered a group of
diseases rather than a single disease (Bostwick et aL). However, each type of cancer has
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its own unique rate of growth, ideal metastasis site, and sensitivity to treatment
(McDougal & Skerrett, 1996).
Cancerous growths are often referred to as malignant tumors, while noncancerous
growths are referred to as benign tumors (Bostwick et aI., 1999). There are several
differences between malignant and benign tumors. Benign tumors are enclosed in a
capsule and resemble the tissue from which they have arisen from. Malignant tumors are
not encapsulated and show little resemblance to the tissues that they had arisen from
(Damjanov,2000). Malignant tumors grow faster than benign tumors due to the fact that
malignant tumors have more cells undergoing mitosis (cell division). Lastly, malignant
tumors can penetrate surrounding tissue and possess the ability to spread to other areas in
the body, while benign tumors do not possess these abilities (Damjanov, 2000). Warts,
cysts and polyps are all examples of benign tumors (Barron & Thomas, 1996). Malignant
tumors can be classified into three categories. Tumors that remain in the tissue from
where they initiated from are called localized tumors. Regional tumors have spread to
neighbouring tissue. Finally, metastasized tumors have spread to other regions in the
body (Bostwick et al.). When tumors metastasize, they are often composed of similar
patterns as the primary tumor (Brawn, Kuhl, Johnson III, Pandya, & McCord, 1990).
Occasionally, cancerous cells break away from the original site, enter the
bloodstream or lymphatic system, and spread throughout the body (Bostwick et aI.,
1999). This process, known as metastasis, makes cancer a deadly disease. Usually white
blood cells notice these cancerous cells passing through the bloodstream and destroy
them before they can do any damage (McDougal & Skerrett, 1996). However,
occasionally a cancerous cell breaks through a lesion in the lining of a blood vessel and
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excavates into a nearby tissue or organ (Bostwick et aI.; McDougal & Skerrett, 1996).
This cancerous cell becomes the nucleus of a new tumor, as cancerous cells grow on top
of one another in disorganized masses (McDougal & Skerrett, 1996). The tumors ability
to create new blood vessels and redirect blood flow and nutrients from normal cells helps
to promote the tumors growth. The new tumor resembles the tissue it originated from,
not the one it exists in (McDougal & Skerrett, 1996). The potential for a tumor to
metastasize is associated with three factors; the size or volume of the tumor, cell
differentiation, and microvessel density. The larger the tumor, the more likely the tumor
is to metastasize to nearby tissue. Poorly differentiated cancer cells are more likely to
spread than well-differentiated cancer cells. Finally, tumors with more blood vessels are
more likely to metastasize (Bostwick et aI.). How these three factors influence the ability
of a prostatic tumor to metastasis will be discussed in a later section. Four major types of
cancers exist and are categorized according to the type of tissue from which they
originated (Bostwick et al.).
2.2.1 Carcinoma
Carcinoma is the most common type of cancer and initiates in epithelial tissue
(Barron & Thomas, 1996). Epithelial tissue lines the outside of the body and the cavities
inside of the body as well (Barron & Thomas, 1996). It is a solid, hard tumor and arises
in visceral organs including the prostate, breast, lung, intestine, and skin (Baggish, 1996;
Bostwick et aI., 1999). Carcinomas metastasize through the circulatory or lymphatic
systems (Donatelle, Davis, Munroe, & Munroe, 2001).
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2.2.2 Sarcoma
Sarcomas develop in bone, muscle, cartilage, and fibrous tissue (Baggish, 1996).
Hard-tissue sarcomas occur in bones and cartilage, while soft-tissue sarcomas arise in
muscles, fibrous tissues, the abdomen, and heart (Winawer et aI., 1995). Sarcomas
metastasize through the blood (Donatelle et aI., 2001).
2.2.3 Lymphoma
Lymphoma develops in the lymph nodes and lymphatic system (Bostwick et aI.,
1999). The lymphatic system is part of the immune system (Barron & Thomas, 1996).
Lymphoma is classified as either Hodgkin's disease or non-Hodgkin's lymphomas
(Winawer et aI., 1995). Lymphomas metastasize through the lymphatic system
(Donatelle et aI., 2001).
2.2.4 Leukemia
Leukemia occurs when cancer invades the blood-forming parts of the body
(Donatelle et al., 2001). Leukemia is diagnosed in the circulatory system, usually in bone
marrow and the spleen (Bostwick et aI., 1999; Winawer et aI., 1995). It is characterized
by rapid growth and distorted development of white blood cells (Damjanov, 2000).
Although the cause of leukemia is unknown, it is believed that the development of this
disease could be attributed to two viruses: human T-cell leukemia/lymphoma virus-1 and
the Epstein-Barr virus. Both of these viruses have gain attention in the pathology of
leukemia since they infect B or T lymphocytes (Damjanov, 2000).
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2.3 Defining Prostate Cancer
Similar to other carcinomas, PCa begins with a single mutated cell reproducing
uncontrollably and unimpeded by the immune system, eventually becoming a tumor
within the prostate (McDougal & Skerrett, 1996). The pathogenesis of PCa involves
enlargement and variability of nuclear size (Damjanov, 2000). Prostate cancer cells
contain more cells that undergo mitosis and thus grow faster than normal cells
(Damjanov, 2000). Erosion of the basal cell layer, which allows the tumor to invade
other structures within the body is also a characteristic of PCa (Garnett & Oyasu, 1989).
Since the growth of the tumor is initiated by an event within the prostate gland, the tumor
is classified as a primary cancer (Morganstern & Abrahams, 1996).
Prostate tumors have a hard lump texture (McDougal & Skerrett, 1996). Since
approximately 99% of all prostate cancers originate in the glandular units or acini of the
prostate, PCa is identified as an adenocarcinoma (Bostwick et aI., 1999). Prostate cancer
usually occurs in the peripheral zone since it is the main glandular region of the prostate
(Bostwick et aI.). Approximately 70% of all prostate cancers occur in the peripheral
region of the prostate (McNeal, Redwine, Freiha, & Stamey, 1988). The remaining 30%
of prostate cancers originate in the transition zone (20%) and central zone (10%)
(McNeal, Redwine et aI., 1988).
Compared to other cancers, PCa can be one of the least fatal cancers an individual
can have and is often treatable if detected early since it has a large doubling rate (Aziz &
Barathur, 1993). Stamey and Kabalin (1989) found that clinically staged cancers A and
B have a doubling of at least 2 years. Schmid, McNeal, and Stamey (1993) observed a
longer doubling time for clinically staged cancers A and B as 80% and 58% of these
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cancers, respectively had a doubling time >4 years. Therefore a patient with latent
prostatic cancer will likely die from other circumstances before they die or suffer from
PCa (Gittes, 1991). Eighty percent of clinically staged C cancers had a doubling time of
>4 years, while 60% of staged D cancers had a doubling time <2 years (Schmid et aI.,
1993). The Gleason score is also associated with doubling time. Approximately 76% of
cancers with a Gleason score ~6 have a doubling time of 4 years or more, whereas 71 %
of cancers with a Gleason score ~7 have a doubling time that is <4 years (Schmid et aI.).
The staging of cancer and Gleason score will be discussed in more detail later on in their
respective sections.
Stamey and colleagues (1993) suggest that tumors are clinically significant when
they exceed 0.5 mI. If a tumor is less than 0.5 ml, the patient does not typically require
therapy regardless of age. The patient will probably die with PCa rather than from it
since tumors which are less than 0.5 ml would require approximately 12 years to attain a
volume of 4 ml if it's doubling time was 4 years (Schmid et aI., 1993; Stamey et aI.,
1993).
Extraprostatic extension is most likely to occur in the posterolateral and anterior
regions of the prostate since capsular weakness encloses the neurovascular bundles and
anterior fibromuscular stroma, respectively (Lee et aI., 1991; Littrup & Bailey, 2000;
Stamey, McNeal, Freiha, & Redwine, 1988; Villers, McNeal, Redwine, Freiha, &
Stamey, 1989). Tumors can also penetrate the prostatic capsule at the apex of the
prostate (McNeal, Villers, Redwine, Freiha, & Stamey, 1990). These regions will be
discussed in more detail in the anatomy and physiology section. Typically only tumors
that are aggressive can penetrate the prostate capsule without passing through the
Stage II Screening for Prostate Cancer 29
perineural space (Villers et aI., 1989). Stamey and colleagues (1988) found that 83% of
tumors >4.0 ml showed capsular penetration of 1 cm or more.
When tumors grow, they tend to spread toward the prostatic capsule of the
prostate (McNeal, 1969). Prostate cancer may also grow and push through the capsule
and invade the bladder, urethra, and/or seminal vesicles (Baggish, 1996). In addition, the
tumor may eventually spread to other areas in the body as well (Morganstern &
Abrahams, 1996). Tumors that metastasize exhibit a more aggressive pattern of invasive
growth (Hoedemaeker, Vis, & Van Der Kwast, 2000). Bubendorf and colleagues (2000)
found that approximately 40% of tumors metastasized to the lymph nodes with the
paraaortic lymph nodes being the most frequently involved followed by the pelvic lymph
nodes (Bubendorf et aI., 2000). Saitoh and colleagues (1990) confirmed these results as
they found that 63% of patients had lymph node metastasis with the paraaortic lymph
nodes being the most common site for metastasis. The fact that the paraaortic lymph
nodes had a higher frequency of metastases is surprising. However, it could be explained
two ways. It could be speculated that metastases can skip the pelvic lymph nodes and
involve the paraaortic nodes initially, or a paraaortic lymph node metastasis can originate
from a metastasis in the spine (Bubendorf et aI., 2000). Physicians frequently examine
these lymph nodes to determine if cancer has spread beyond the prostate. Other sites of
metastases were the bone (31.5%), lungs (16%), liver (8.7%), and pleura (7.3%)
(Bubendorf et aI., 2000). Approximately 90% of bone metastasis is present in the spine
(Bubendorf et aI., 2000). When PCa spreads to other areas of the body, it is referred to as
metastatic PCa rather than bone cancer or liver cancer (Morra & Potts, 1996). The
physician may order a computerized tomography (CT) scan to check for pelvic or
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swollen distant lymph nodes (Beahrs, Henson, Hutter, & Kennedy, 1992). However, CT
scanning should only be performed on patients with a serum PSA level >25 ng/ml
(Flanigan et aI., 1996). Magnetic resonance imaging (MRI) may also be employed to
check distant lymph nodes and bone for cancer (Beahrs et aI., 1992). Perhaps the most
accurate technique to determine if cancer has spread to nearby lymph nodes is through a
staging pelvic lymphadenectomy. However, a staging pelvic lymphadenectomy is
unnecessary for patients with a Gleason score of ~6 and a serum PSA level ~10 ng/ml
because when combined, these two variables display a sensitivity of 0.98 for predicting
the risk of pelvic lymph node metastasis (Narayan et aI., 1994). A bone scan and chest x-
ray may also be ordered to check the pelvis, spine, and lungs for possible signs of
metastatic pea (Morra & Potts, 1996). However, a bone scan should only be ordered
when serum PSA levels are above 10 ng/ml, a tumor is staged T3 or higher, or a poorly
differentiated tumor is present (Gleave et aI., 1996).
As mentioned previously, the potential for a tumor to metastasize is associated
with the volume of the tumor, cell differentiation, and microvessel density (Bostwick et
aI., 1999). The risk of progression to the lymph nodes or seminal vesicles is directly
correlated with the volume of the tumor (McNeal et aI., 1990). When tumors are smaller
than 4 cc and capsule penetration is greater than 1 cm, progression to the lymph nodes
and seminal vesicles occurs 17% of the time. The prevalence of progression increases to
60% and 83% when tumor volume was between 4 and 12 cc and greater than 12 cc,
respectively. When capsule penetration was greater than 1 cm, lymph node metastases
were observed in 19% of tumors under 12 cc and 56% of tumors larger than 12 cc
(McNeal et aI.). Gleason score is also correlated with nodal metastases. The incidence of
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nodal disease increases for grades 2 to 4 (5%), grades 5 and 6 (22%), grade 7 (34%), and
grades 8 to 10 (51%) (Sands, Zagars, Pollack, & von Eschenbach, 1994). Bigler,
Deering, and Brawer (1993) found that prostate tumors had an increase in capillary
density and a 2-fold increase in the total number of vessels compared with benign
prostatic tissue. In addition, Brawer, Deering, Brown, Preston, and Bigler (1994)
observed an increase in microvessel density as the pathologic stage increased. The mean
microvessel density for organ confined tumors and pelvic lymph node metastasis was
81.2 and 114.2 vv/mm2, respectively (Brawer et aI., 1994). Weidner, Carroll, Flax,
Blumenfeld, and Folkman (1993) found an association between metastasis and
microvessel count, as there was a 1.55-fold increase in the risk of metastasis for every
additional 10 microvessels. Lissbrant, Stattin, Damber, and Bergh (1997) showed an
association exists between microvessel density and cancer-specific survival. Patients
who had tumors with <135 microvessels survived an average of 131 months, whereas
patients diagnosed with tumors containing >135 microvessels survived 63 months
(Lissbrant et aI., 1997).
Symptoms for PCa usually do not appear until the tumor has grown to a
substantial size or has spread beyond the gland (McDougal & Skerrett, 1996). Typically,
the first symptom is an induration or hardening of the prostate found when performing a
DRE. An elevated serum PSA level is also one of the first signs of the presence of Pea.
Other symptoms for PCa include frequent urination at night, painful urination and
ejaculation (Barrett, 2000), blood in the urine or semen (Winawer et aI., 1995), and a
weak urine stream (McDougal & Skerrett, 1996). Difficulty starting and stopping
urination may also occur if a tumor were to press against the urethra (McDougal &
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Skerrett, 1996). Constipation may occur as the tumor grows large enough to press into
the rectum. Weight loss and loss of erection may occur as the tumor hinders the nerves
or blood vessels that regulate erectile function (McDougal & Skerrett, 1996). Scott Jr.,
Mutchnik, Laskowski, and Schmalhorst (1969) found that patients with PCa experience
obstructive symptoms (38%), irritative symptoms (56%), and back pain (6%). Catalona
and colleagues (1994) calculated the positive predictive value for specific symptoms of
PCa including hematuria (36%), dysuria (26%), frequency (22%), urgency (21 %), weak
urine stream (23%), and bone pain (21 %). The presence of these symptoms did not differ
between subjects with and without PCa. Therefore symptoms for PCa can often represent
other illnesses or conditions that are widespread with aging (Catalona et al., 1994).
2.4 Anatomy and Physiology of the Prostate Gland
The prostate gland is a chestnut-shaped gland located in the pelvis below the
urinary bladder, anterior to the rectum, and posterior to the pubic bone and pubic
symphysis (Cersosimo & Carr, 1996; O'Rahilly, 1986). The apex of the prostate gland
(end closest to the pubic bone) points inferiorly, while the base of the gland (end closest
to the bladder) points superiorly and slightly anteriorly (Hoedemaeker et aI., 2000). The
prostate gland is surrounded by connective and fatty tissue (Hoedemaeker et aI.).
Skeletal muscle also surrounds the anterior portion of the prostate (Ayala, Ro, Babaian,
Troncoso, & Grignon, 1989). Figure 2.1 illustrates the location of the prostate gland.
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Figure 2.1. The Location of the Prostate Gland
(Morra, M., & Potts, E. (1996). The prostate cancer answer book:
An unbiased guide to treatment choices. New York: Avon Books.)
A neurovascular bundle is located posterolateral to the apex, mid portion, and
base of the prostate gland (Lepor, Gregerman, Crosby, Mostofi, & Walsh, 1985). The
prostatic arteries of the prostate gland originate from the inferior vesical and middle
rectal arteries, which are derived from the internal iliac artery (Moore & Agur, 1995).
The prostate gland is innervated by sympathetic fibers from the inferior hypogastic
plexus and parasympathetic fibers from sacral nerves 2, 3, and 4 (Moore & Agur, 1995).
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The prostate gland is comprised of an anterior, a posterior, a median, and two
lateral lobes (Cersosimo & Carr, 1996). The anterior lobe, which is anterior to the
urethra, is predominantly fibromuscular and contains very little glandular tissue (Moore
& Agur, 1995). The posterior lobe is posterior to the urethra and inferior to the
ejaculatory ducts (Moore & Agur, 1995). The median lobe is positioned between the
urethra and ejaculatory ducts (Moore & Agur, 1995). Finally, the lateral lobes, which
make up a major part of the prostate, lie on both sides of the urethra (Moore & Agur,
1995).
The prostate gland can vary in size, however at its greatest diameters it is typically
4 cm in the transverse plane, 3 cm in length and 2 cm in the sagittal plane (O'Rahilly,
1986). The overall growth rate of the prostate gland is 2.36±3.52 cc/yr. However, during
the age of 56 to 65, prostate growth has been shown to peak as high as 4.15±4.98 cc/yr
(Williams et aI., 1999). After the age of 65 years, the growth rate for the prostate gland
steadily declines. The prostate gland consists of three anatomical zones: a peripheral
zone comprising of approximately 65% of the normal gland, the central zone comprising
25% of the gland, and a transition zone comprising 10% of the gland (Chamberlain,
Melia, Moss & Brown, 1997). Figure 2.2 displays the three zones of the prostate gland.
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Figure 2.2. Zones of the Prostate Gland
(McNeal, J. E. (1988). Normal anatomy of the prostate and changes in benign prostatic
hypertrophy and carcinoma. Seminars in Ultrasound, CT, and MR, 9(5), 329-334.)
Extending laterally, posteriorly, and inferiorly, the horseshoe shaped peripheral
zone (PZ) runs from the base to the apex of the prostate gland (McNeal, 1968; McNeal,
1969). The peripheral zone begins to expand anteriorly at the level of the verumontanum
(McNeal, 1968). However, opposite sides of the peripheral zone do not come in contact
with each other. Inferior to the verumontanum, the peripheral zone is the only zone that
exists in the apex of the prostate (McNeal, 1968). Approximately 70% of the glandular
tissue arises in the peripheral zone (McNeal, 1981). Not only is the peripheral zone more
susceptible to cancer, it is also a likely source of prostatitis (O'Rahilly, 1986).
The central zone (CZ) resembles a wedge of tissue as it includes the median lobe
and portions of the posterior and lateral lobes (McNeal, 1969). The central zone extends
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from the verumontanum, anteriorly to the capsule of the prostate gland (McNeal, 1968).
The central zone surrounds the ejaculatory ducts and makes up the majority of the
prostate gland's base (McNeal, Redwine et aI., 1988). The central zone is comparatively
immune to development of carcinoma (McNeal, 1968). The central zone constitutes
approximately 25% of the glandular tissue of the prostate (McNeal, 1981).
Extending anteriorly from the ejaculatory ducts, the transition zone (TZ), which
surrounds the urethra, is covered by the anterior fibromuscular stroma, which covers the
anterior surface of the prostate gland (McNeal, Redwine et aI., 1988). Posteriorly and
laterally, the transition zone is bound to the peripheral zone and superiorly to the central
zone (McNeal et al.). Of the three zones, benign prostatic hyperplasia usually occurs in
the transition zone (McNeal, 1988). One hypothesis for the over-abundance of BPH in
the transition zone is the interaction of glandular tissue and the anterior fibromuscular
stroma (McNeal, 1981). Since BPH occurs in the transition zone, this zone may enlarge
to comprise as much as 90% of the prostate gland (McNeal, 1981). In fact, enlargement
of the transition zone is the main reason for an increase in the size of the prostate in
patients younger than 70 years of age (McNeal, 1978). Tumors found in this zone are not
palpable by digital rectal examination. Tumors that invade the urinary bladder
(Hoedemaeker et aI., 2000) and anterior fibromuscular stroma (McNeal et aI., 1990) are
usually located in the transition zone.
The prostatic urethra, approximately 3 cm in length, passes through the center of the
prostate gland (O'Rahilly, 1986). The prostatic urethra extends from the base to the apex
of the prostate (O'Rahilly, 1986). It is divided into two segments; the proximal urethral
segment (UP) and the distal urethral segment (UD). Approximately halfway between the
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apex of the prostate and bladder neck, the proximal urethral segment takes an alterative
path as it turns anteriorly 35 degrees relative to the distal urethral segment. A smooth
muscular sphincter (s) is found to encircle the proximal urethral segment. A similar
striated muscular sphincter (s) is found along the distal urethral segment (McNeal, 1981).
The verumontanum is located on the posterior wall of the distal urethral segment at
the point where the proximal urethral segment changes direction (McNeal, 1981). The
verumontanum encompasses a region of the prostate where the ejaculatory ducts exit into
the urethra (Baggish, 1996).
Relatively flattened in the anteroposterior dimension (McNeal, 1968), the prostate
gland is covered by a thin membrane capsule that is approximately 1 to 2 mIn and
composed of smooth muscle and collagen fibers (Sattar, Noel, Vanderhaeghen,
Schulman, & Wespes, 1995). The capsule of the prostate gland is incomplete at the apex
of the gland and difficult to determine at the base (Sattar et aI., 1995). Therefore, the
prostatic capsule is not a true capsule (Ayala et aI., 1989). The anterior fibromuscular
stroma (fm) is located at the anterior surface of the prostate (McNeal, Redwine et aI.,
1988). Since it is non-glandular, pea cannot develop in the anterior fibromuscular
stroma. The anterior fibromuscular stroma appears to have no function (McNeal, 1981).
The prostate gland has two functions. The primary function of the prostate gland
is to produce secretions that liquefy and neutralize coagulated semen formed at
ejaculation (Lilja, 1985). The secondary function of the prostate gland is to assist in the
release of urine from the bladder (Cersosimo & Carr, 1996).
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2.5 Etiology and Pathophysiology
Although the cause of PCa is unknown, several risk factors have been proposed
(Cersosimo & Carr, 1996). These risk factors have been separated into either
controllable or uncontrollable. Examples of controllable risk factors would be
environment, smoking, diet, weight, and physical activity. It is believed that the
environment in which an individual works may play an important role in determining
whether or not a person acquires PCa. Aronson, Siemiatycki, Dewar, and Gerin (1996)
found that 19% of prostate cancers are attributed to occupational exposures including
metallic and aluminum alloy dust, liquid fuel combustion products, lubricating oils and
greases, hydrocarbons from coal, formaldehyde, and diesel engine emissions. Seidler,
Heiskel, Bickeboller, and Elsner (1998) found that an individual's odds of developing
PCa were 3.7 and 2.1 when exposed to diesel fuel or fumes and hydrocarbons for 25
years or more than individuals who were not exposed, respectively. Occupations
including electrical power workers, water and railway transport workers, aircraft and
metal product fabricators, and structural metal erectors would have consistent contact
with these occupational exposures (Aronson et aI., 1996). Band, Le, Fang, Threlfall, and
Gallagher (1999) confirmed the results of Aronson and associates as they found an
increased risk of PCa for individuals who worked in electrical power plants (5.3), aircraft
(15.5), metal product fabricators (1.7), and structural metal products (1.6). Farmers are
also at an increased risk for PCa. Parker, Cerhan, Putnam, Cantor, and Lynch (1999)
concluded that farmers had a relative risk of 1.7 for developing PCa. Similarly, Parker
and associates (1999) also concluded that the relative risk of developing PCa was 2.0 for
farmers when the exclusion of well differentiated localized tumors had occurred. This
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would suggest that farming could be associated with more aggressive forms of PCa.
Band and associates (1999) also concluded that the odds of farmers developing PCa was
2.12 compared to individuals who never been involved in farming. Farmers may be at an
increased risk of pea since they constantly are exposed to diesel fuel/fumes and
hydrocarbons. Cerhan and associates (1997) found that current smokers had a relative
risk of 2.2 and 8.7 for developing PCa and advanced or aggressive forms of PCa
compared to individuals who had never smoked, respectively. Cerhan and associates
(1997) also found a dose response relationship between the number of cigarettes smoked
per day and PCa. Evidence suggests that a high-fat diet may increase the risk of
developing PCa. Le Marchand, Kolonel, Wilkens, Myers, and Hirohata (1994)
concluded that the relative risk of PCa had increased for intake of beef (1.6), milk (1.4),
and high-fat animal products (1.6). Michaud and associates (2001) also concluded that
men had a increased relative risk of developing metastatic PCa if they regularly
consumed red meat (1.72), dairy products (1.66), and a combination of the two (2.30). It
is hypothesized that the consumption of fat increases the production of testosterone,
which accelerates the growth of PCa cells (Barrett, 2000). Weight can also increase the
risk of PCa. Men who weighed more than 86.3 kg had a relative risk of 1.6 for PCa
(Cerhan et aI., 1997). Similar to weight, a man with a body mass index (BMI) >27.8
kg/m2 had a relative risk of 1.5 for PCa. Men with a BMI >27.8 kg/m2 had a relative risk
of 3.1 for the most aggressive forms of PCa (Cerhan et aI., 1997). Surprisingly, Cerhan
and associates (1997) found that highly active men had a relative risk of 1.6 for PCa
compared to men who were inactive. This conclusion could possibly be explained by the
fact chronically ill, older men may not be observed as often for PCa since other
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conditions may take precedence. In addition, these men may also be on low fat diets,
which would reduce the risk of PCa (Cerhan et aI., 1997).
Uncontrollable risk factors include age, ethnic group, family history, and prostatic
intraepithelial neoplasia (PIN). The risk of PCa increases dramatically with age. In fact,
approximately 86% of cases occur in men over the age of 60 years (Canadian Cancer
Society, 2003). Davidson, Bostwick and associates (1995) found that the relative risk for
PCa was 3.5 for males who were over the age of 65. Ethnicity can significantly increase
the odds of an individual being diagnosed with PCa. Prostate cancer is the leading cause
of cancer death for African Americans over the age of 50 years (Landis et aI., 1999). The
African American population has a higher incidence and mortality rate of PCa than
Caucasians (Smith, Catalona, & Bullock, 1996). The African American population has a
35% higher incidence rate for PCa than the Caucasian population (Parkin et aI., 2001). In
addition, the African American population has approximately twice the prevalence of
PCa than the Caucasian population, approximately 9% versus 4%, respectively (Merrill
& Morris, 2002). Moul and colleagues (1995) concluded that the tumor volumes of
African Americans were 1.3 to 2.5 times greater than Caucasians. On average, African
Americans were 3 years younger than Caucasians when diagnosed with cancer (Moul et
aI., 1995). Barroso Jr. and colleagues (1999) found that 9.9% of African Americans had
a Gleason score >7 compared to 4.9% of Caucasians. This suggests that African
American men develop PCa at a younger age and have more aggressive forms of PCa.
Asian men, on the other hand, have the lowest rate of PCa among any other ethnic group
(Parkin et aI.). Approximately 10% of all prostate cancers are attributed to genetics
(Garcia-Schurmann & Coffey, 1997). Genetic processes can bring about instability and
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variations in the structure of cells and DNA resulting in PCa (Garcia-Schurmann &
Coffey, 1997). Men had twice the odds of developing PCa if they had a first-degree
relative diagnosed with PCa compared to men with no family history (Steinberg, Carter,
Beaty, Childs, & Walsh, 1990). In addition, men with two or three affected first-degree
relatives had a five and II-fold increased risk of PCa, respectively. Bratt, Damber,
Emanuelsson, and Gronberg (2002) have shown that hereditary PCa occurs 6 years
earlier, at 68 years of age, than sporadic PCa. Genetic inheritance, common
environmental exposures and dietary patterns could be several reasons behind the
association between family history and PCa (Steinberg et aI., 1990). Prostatic
intraepithelial neoplasia has often been linked as a precursor to PCa (Davidson,
Bostwick, et aI., 1995). Shephard, Keetch, Stahl, and Humphrey (1995) found that on
follow-up biopsies, 63% of their cases were diagnosed with PCa on the same side that
prostatic intraepithelial neoplasia had been observed during the initial biopsy. Park,
Shinohara, Grossfeld, and Carroll (2001) found that cancer was diagnosed on the first
follow-up biopsy in 91 % of these patients. Davidson, Bostwick and associates (1995)
found that individuals diagnosed with high-grade PIN had a relative risk of 14.9 for
developing PCa compared to those individuals who were not diagnosed with high-grade
PIN.
Controversy exists as to whether serum hormones are associated with the etiology
of PCa. It is believed that testosterone is converted into dihydrotestosterone and thus
increases the growth of prostate cells (Shaneyfelt, Husein, Bubley, & Mantzoros, 2000).
Shaneyfelt et aI. 2000 found that men with serum testosterone levels in the highest
quartile were approximately twice as likely to develop PCa compared to men who had
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serum testosterone levels in the lowest quartile. However, Mohr, Feldman, Kalish,
Longcope, and McKinlay (2001) found no association between serum hormones,
including testosterone and dihydrotestosterone, and developing PCa.
It is believed that the mechanism of PCa involves frequent tissue damage and
restoration in the presence of oxygen and nitrogen (De Marzo, Marchi, Epstein, & Nelson
1999). External forces including a virus, hazardous chemicals in food, polluted air, or
exposure to radioactivity may damage tissue and accelerate carcinogenesis (Morganstern
& Abrahams, 1996). Nitric oxide and hydrogen peroxide are released from inflammatory
cells and interact with DNA in epithelial cells to produce permanent alterations including
mutations (Weitzman & Gordon, 1990). Increased inflammatory atrophy occurs, as more
epithelial cells are lost (De Marzo, Putzi, & Nelson, 2001). As a result carcinogen-
detoxifying enzymes become lost and genetic damage transpires (De Marzo et aI., 2001).
Genetic damage accumulates as low-grade PIN becomes high-grade PIN and eventually a
tumor develops within the prostate (De Marzo, Putzi, et al.). High-grade PIN is believed
to be a precursor for PCa, since an increased frequency of high-grade PIN occurs in
prostates that contain cancer (Park et aI., 2001) and both share similar characteristics
including nuclear enlargement (McNeal & Bostwick, 1986) and increased basal layer
disruption (Bostwick & Brawer, 1987).
2.6 Sextant Biopsy
Digital rectal examination and serum PSA are two clinical tests that are typically
part of the population screening for PCa. Often, if one or both of these clinical tests
yields an abnormal outcome and PCa is suspected, the physician will arrange for the
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individual to undergo a biopsy. The biopsy procedure is considered the gold standard in
diagnosing PCa (Hodge, McNeal, Terris, & Stamey, 1989; Rabbani, Stroumbakis, Kava,
Cookson, & Fair, 1998).
A biopsy is a procedure that uses a needle to extract small pieces of tissue to
determine if cancer is present (Barron & Thomas, 1996; Morra & Potts, 1996). The
prostate biopsy procedure involves a needle being inserted into the prostate through one
of two routes; through the rectum (transrectal) or through the perineum (transperineal)
(Lavoipierre, 2000). The transrectal ultrasound-guided biopsy is the most frequently
used biopsy test since it has the ability to locate suspicious areas on the prostate and
detect smaller cancers (Langer, 1999; Palken et aI., 1991). The transrectal ultrasound is
also generally tolerated better, simpler, and faster than the transperineal approach
(Lavoipierre, 2000). Normally, a minimum of six tissue samples are taken from various
regions of the prostate including the apex, the middle, and the base of both the right and
left lobes (Hodge et aI., 1989; Presti Jr., 2000). These six biopsies are taken from the mid
lobe in the parasagittal plane halfway between the lateral border and midline of the
prostate (Chang, Shinohara, Bhargava, & Presti, Jr., 1998). This procedure is called a
sextant biopsy (Barrett, 2000). Hodge and colleagues were the first to develop the
process of random systematic biopsies. Figure 2.3 demonstrates the areas from which
these six cores are taken.
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Figure 2.3. Areas of Biopsy
Eskew, L. A., Woodruff, R. D., Bare, R. L., & McCullough, D. L. (1998). Prostate cancer
diagnosed by the 5 region biopsy method is significant disease. The Journal of Urology, 160(3), 794-796.
During the sextant biopsy, a biopsy needle passes through both the peripheral
and transition zones (Chang et aI., 1998). Biopsy cores are extracted from various areas
on the prostate in order to get a true representative sample of the entire prostate. If a
problem area is detected in other areas of the prostate, the physician may take additional
biopsy cores (Morra & Potts, 1996).
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The transperineal biopsy is performed in a similar manner as the transrectal
biopsy except the needle is inserted through the perineum of the patient. The physician's
finger passes through the rectum to help assist the biopsy needle to the target area of the
prostate (Baggish, 1996; Gelbard & Bentley, 1995). The transperineal biopsy is often
used in men who may be at high risk for complications with a transrectal biopsy (Morra
& Potts, 1996). Although the transperineal biopsy requires a local anesthetic to numb the
skin (Baggish, 1996), the transperineal biopsy has demonstrated a lower risk of infection
compared to the transrectal biopsy, due to the fact that this type of biopsy does not
involve the needle passing through the rectum (Baggish, 1996; Gelbard & Bentley,
1995). As a result, the transperineal biopsy does not require an enema or antibiotics
(Baggish, 1996). Both biopsy procedures are referred to as core biopsies since the needle
of the biopsy slices a cylinder-shaped core from the prostate.
Prostatic tissue samples from the biopsy are taken to a pathologist specializing in
diagnosing cancer (Barrett, 2000). By examining the shape and size of the prostatic cells
and comparing them to normal healthy cells, the pathologist can tell if cancer is present,
and establish the Gleason score for the cancer (Barrett, 2000; Bostwick et aI., 1999).
Therefore, the TRUS-guided sextant biopsy procedure is not only used to diagnose PCa,
it also has a role the treating of PCa.
The biopsy also possesses the ability to diagnose prostatic intraepithelial
neoplasia. As previously mentioned, PIN has been shown to be a precursor to PCa.
Therefore, the physician will often recommend the patient undergo a biopsy every 3 to 6
months if PIN is diagnosed (Park et aI., 2001; Wood, 2001).
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The TRUS-guided sextant biopsy has frequent minor complications (Rodriguez &
Terris, 1998). Rodriguez and Terris (1998) concluded that minimal or no discomfort
occurred in 75% of their subjects. Aus, Hermansson, Hugosson, and Pedersen (1993)
found similar results as 92% of the patients who underwent a TRUS-guided biopsy
reported minor or no discomfort. Rectal bleeding and blood in urine are common side
effects of a biopsy (Aus et al., 1993; Rodriguez & Terris, 1998). Rodriguez and Terris
(1998) found 84% of their subjects had some hematuria immediately after the TRUS-
guided sextant biopsy and this hematuria persisted for 3 to 7 days after the procedure for
47% of these men. Patients taking aspirin or other blood thinners should be cautious
about having a biopsy (Bostwick et aI., 1999; Gelbard & Bentley, 1995; Morra & Potts,
1996). Patients should refrain from taking these types of medications at least a week
before their biopsy (Morra & Potts, 1996). Aus and colleagues found that the risk of
infection from the biopsy procedure is less than 1% when antibiotics were administered
to their patients.
Although the TRUS-guided sextant biopsy is crucial for the diagnosis of PCa, it is
not a flawless procedure and consideration should be taken when examining the results
(Rabbani et al., 1998). The TRUS-guided sextant biopsy has a tendency to underestimate
the presence of cancer (Norberg et aI., 1997). Therefore, negative biopsy results do not
always predict the absence of a tumor (Salomon et aI., 1999). Norberg and colleagues
(1997) and Rabbani and colleagues have shown that the TRUS-guided sextant biopsy
misses approximately 15% and 23% of tumors, respectively. Lately, there has been a
trend to obtain additional biopsies in the peripheral zone along with the traditional sextant
cores. Eskew, Bare, and McCullough (1997) introduced the five region biopsy procedure
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and concluded this particular procedure detected 35% more cancers than the sextant
biopsy procedure. The five region biopsy procedure includes the sextant biopsies as well
as two biopsies from each lateral aspect in the gland and three biopsies from the midline
of the prostate (Eskew et aI., 1997). Figure 2.3 demonstrates the areas from which these
additional cores are taken.
2.7 Clinical Tests
The high mortality rate of PCa is due to the asymptomatic nature of the condition
until it is in its advanced stages and may have spread beyond the prostate (Catalona et aI.,
1993). Although there is an abundance of imaging and biochemical tests, screening for
PCa remains marginally effective and inconsistent (Wolf Jr., Shinohara, Carroll, &
Narayan, 1993). Enhancing early detection is crucial to reduce mortality since PCa is
often curable when it is organ confined and no cure exists for PCa when it is at the
advanced stage (Babaian, Kojima, Ramirez, & Johnston, 1996; Kane et aI., 1992). An
accurate cancer test would have a sensitivity of 1.00 and specificity of 1.00 and no test at
this point fulfills these requirements (Aziz & Barathur, 1993).
2.7.1 Digital Rectal Examination
The DRE is the principal screening method used in population screening for PCa
(Applewhite, Matlaga, McCullough, & Hall, 2001). The DRE is a simple, quick, and
inexpensive procedure (Cupp & Oesterling, 1993), yet it can be very embarrassing and
uncomfortable for the patient. This technique allows the physician to be aware of the
prostate's morphology, including any irregularities or nodules that could be cancerous
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(Applewhite et aI., 2001). DRE has been the traditional and essential method for
evaluating the prostate gland and continues to be recommended as part of an annual
assessment (Cupp & Oesterling, 1993). The DRE should be integrated into an annual
physical checkup for every man over the age of 50 (Cupp & Oesterling, 1993). Men who
are African American or have a family history of PCa should begin annual digital rectal
examinations by age 45 years or sooner (American Urological Association, 2000; Cupp
& Oesterling, 1993; von Eschenbach, Ho, Murphy, Cunningham, & Lins, 1997).
However, 70% of men over the age of 50 years do not receive an annual DRE
(McDougal & Skerrett, 1996). Furthermore, evidence suggests that men who partake in
regular digital rectal examinations are 50% to 70% less likely to die from PCa in
comparison to similar groups of men who do not undergo regular digital rectal
examinations (Jacobsen et aI., 1998).
A healthy prostate should feel smooth, elastic, and firm (McDougal & Skerrett,
1996). Under normal conditions, the prostate should feel like the tip of your nose
(Bostwick et aI., 1999). Cancer begins as a small, hard lump or nodule that will
eventually develop into a larger nodule with several more lumps emerging (Bostwick et
aI.). Therefore, cancer is suspected if the physician feels hard spots or nodules on the
prostate. As the physician palpates the prostate gland, he/she attempts to feel for any
abnormalities in size, shape, and/or consistency in the gland (Baggish, 1996).
Abnormalities may also include distinct nodules, focal induration, or a diffusely hard
prostate (Applewhite et al., 2001). A biopsy procedure is conducted despite the patient's
serum PSA level if an abnormality is felt during a DRE (Ellis et aI., 1994; Karakiewicz &
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Aprikian, 1998). Tumors of 0.2 ml or more can easily be palpated by digital rectal
examination (Stamey et al., 1988).
Abnormalities on the prostate do not ensure an individual has PCa since various
other conditions can mimic PCa. Prostate infections or prostatic calculi (small stones)
within the prostate may produce abnormalities similar to PCa (Barrett, 2000). BPH could
possibly be present if the physician detects an enlarged prostate (Bostwick et aI., 1999).
A prostate that is tender to the touch often suggests prostatitis (Barrett, 2000). Therefore,
additional diagnostic testing must be performed in order to ensure that cancer does exist
(Barrett, 2000).
The DRE is a very subjective clinical test (Applewhite et al., 2001; Naito,
Kimiya, Hasegawa, & Kumazawa, 1988). Often times the results of the DRE are
described differently by different examiners or the same examiner at different times (Ellis
et aI., 1994; Naito et aI., 1988). Smith and Catalona (1995) concluded that the agreement
between urologists on whether DRE results are suspicious for PCa is fair. The accuracy
of the digital rectal examination relies solely on the physician performing this clinical test
and his/her experience in establishing the size, consistency, nodularity, and asymmetry of
the prostate gland (Baggish, 1996). Slight changes within the prostate can be more easily
detected by an experienced urologist rather than by a family physician (Baggish, 1996).
A family physician would require a more obvious change within the prostate gland in
order to notice any abnormalities. Turner and Brewster (2000) found that over a 3-year
period, 42% of medical students and 68% of interns/residents had felt fewer than five
malignant prostate glands. In addition, 41 % of medical students and 16% of
interns/residents did not feel confident about their ability to give an opinion based on the
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DRE findings (Turner & Brewster, 2000). Although the physician may not detect
nodules or other abnormalities does not ensure the patient is cancer free. Due to its
subjectivity, the DRE lacks sensitivity (Applewhite et al.; Wolf Jr. et aI., 1993). In fact,
the DRE has been shown to miss 0.23 to 0.45 of all prostatic tumors (Catalona et aI.,
1994; Cooner et aI., 2002). The specificity of the DRE can range from 0.15 to 0.47
(Cooner et al., 2002; Eskew et aI. 1997). When serum PSA levels are between 4.0 and
10.0 ng/ml, the sensitivity and specificity of the DRE is 0.71 and 0.67, respectively
(Klingler et aI., 1998). The digital rectal examinations lack of sensitivity can also be
attributed to its inability to detect microscopic cancerous nodules existing on the prostate.
In addition, tumors can inhabit certain regions of the prostate the physician cannot
palpate (Cooner et aI., 2002; Hauzeur, Corbusier, Vanden Bossche, & Schulmann, 1990).
As many as 40% of cancers may develop anterior to the midline of the prostate and
consequently the physician would be unable palpate these tumors (McNeal, Price,
Redwine, Freiha, & Stamey, 1988). Tumors can exist deep inside the prostate without
developing a lump on the gland.
Although this procedure has the ability to detect tumors, DRE usually detects
tumors that are relatively large, in their advanced stage, and often not curable (Scardino,
Weaver, & Hudson, 1992). While DRE has limitations, it should not be neglected during
annual physicals (Bostwick et al., 1999). It continues to be the first line of defence
against cancer of the prostate.
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2.7.2 Serum Prostate Specific Antigen
The recent increase in the incidence of PCa is essentially due an increase in public
awareness and more frequent detection through routine monitoring of serum PSA levels
(Waterbor & Bueschen, 1995). Prostate specific antigen, a member of the human
kallikrein family (Lukes et al., 2001), is a glycoprotein first identified in prostatic tissue
by Ablin, Bronson, Soanes, and Witebsky (1970) and Ablin, Soanes, Bronson, and
Witebsky (1970). Amino acids make up 93% of the molecular mass of PSA, while
saccharides represent the remaining 7% (Lukes et aI., 2001). Prostate specific antigen,
which is abundant in all 3 zones of the prostate gland, is produced almost exclusively by
secretory glandular epithelial cells (Barry, 2001; Hammerer, McNeal, & Stamey, 1995;
Kamoi & Babaian, 1999; Lukes et aI., 2001), which line the acini and ducts of the
prostate gland (Bare et aI., 1994; Lukes et al., 2001). Prostate specific antigen is secreted
into the prostatic ducts, into the urethra, and is present in the seminal plasma (Oesterling,
1991). The function of PSA is to pursue specific proteins, semenogelin I and II and
fibronectin, within seminal fluid and initiate liquefaction and improve the motility of
sperm (Lukes et al., 2001).
Under normal conditions, very little PSA enters the bloodstream (American
Urological Association, 2000; Oesterling, Cooner, Jacobsen, Guess, & Lieber, 1993). It
is only when the integrity of the prostate is disturbed by prostatic disease that PSA can
enter the bloodstream (American Urological Association, 2000). In order for PSA to
enter the bloodstream, it must pass through the prostatic basal membrane, stroma,
capillary basal membrane, and capillary endothelial cells (Lukes et aI., 2001). Hammerer
and colleagues (1995) concluded that PSA most likely leaves the prostate gland and
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enters the bloodstream through the transition zone. Serum PSA levels are affected by
both the concentration of PSA produced and the ability of PSA to enter the bloodstream
(Barry, 2001; Ellis & Brawer, 1993).
Serum PSA is one of the most commonly used clinical population screening tests
for PCa (Gambert, 2001). Along with the digital rectal examination, serum PSA is a
recommended practice for population screening men over the age of 50 for PCa (Aziz &
Barathur, 1993) or younger for men at high risk for PCa (von Eschenbach et aI., 1997).
The serum PSA test analyzes the total concentration of serum PSA in a blood sample.
Traditionally, a serum PSA value of 4 ng/ml is considered the threshold value for
screening of PCa (Lukes et al., 2001). Therefore a serum PSA level less than 4 ng/ml is
considered normal (von Eschenbach et aI.). Approximately 7% of men with PCa have a
normal serum PSA level (Rietbergen, Kranse, Kirkels, De Koning, & Schroder, 1997).
Men with PCa and serum PSA levels ranging from 0 to 4 ng/ml have been shown to
demonstrate organ confined cancer (64%), capsular penetration (32%), positive seminal
vesicles involvement (3%), and positive lymph node involvement (1 %) (Partin et aI.,
1997). A serum PSA reading between 4.0 and 10 ng/ml is considered borderline and
difficult to interpret. It is within this intermediate range that there is a substantial overlap
of serum PSA levels between BPH and PCa (Deliveliotis et aI., 1998). A false positive
rate of 77% exists when serum PSA levels range from 4.0 to 10.0 ng/ml (Akdas et aI.,
1995). Partin and colleagues (1997) found that when serum PSA levels were between 4.1
and 10.0 ng/ml, patients with PCa often demonstrated organ confined cancer (50%),
capsular penetration (40%), positive seminal vesicles involvement (6%), and positive
lymph node involvement (3%). Additional testing should be requested if an individual
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exhibits a serum PSA level within this range. A serum PSA level of 10 ng/ml or more
strongly implies one may have PCa (Gambert, 2001) and should seek a full diagnostic
regimen to reveal malignant cells (Graves, Wehner, & Stamey, 1990). Approximately
55% of men with serum PSA levels over 10 ng/ml have PCa (Cooner et aI., 2002; Dincel
et aI., 1999). When serum PSA levels ranged from 10.1 to 20.0 ng/ml, Partin and
colleagues (1997) concluded that patients with PCa had often demonstrated organ
confined cancer (35%), capsular penetration (46%), positive seminal vesicles
involvement (10%), and positive lymph node involvement (9%).
Cancerous cells are one of the most important reasons why elevated levels of
serum PSA occur. Through the use of the Yang Pros-Check assay, it has been
determined that serum PSA levels increase 3.5 ng/ml/gm when PCa is present (Kabalin,
McNeal, Johnstone, & Stamey, 1995; Stamey et aI., 1989). Autopsy results have shown
that tumors that exceed 1 ml in volume produce enough serum PSA to exceed the normal
range of 0 to 4.0 ng/ml (Brawn et aI, 1991). Kabalin and colleagues (1995) observed an
increase in serum PSA levels for tumor volumes of 0 to 3 cc (8.9 ng/ml), >3 to 6 cc (17.4
ng/ml), >6 to 12cc (25.5 ng/ml), and >12 cc (67.0 ng/ml). Therefore, serum PSA levels
are also strongly correlated with cancer volume. Stamey and colleagues (1989) found a
strong correlation between serum PSA levels and tumor stage. Serum PSA levels
increased significantly for tumors staged B1 (10.0 ng/ml), B2 (17.3 ng/ml) and D1 (73.5
ng/ml). Gleason score can also increase serum PSA levels. Gleave and colleagues
(1996) also concluded that mean serum PSA levels for well, moderately, and poorly
differentiated tumors were 6, 11, and 29 ng/ml, respectively (Gleave et aI., 1996).
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Although malignant cells produce elevated levels of serum PSA, several other
confounding factors can also influence the concentration of serum PSA (Babaian et aI.,
1996). Increased levels of serum PSA can be attributed to ejaculation (Klingler et aI.,
1998; Lukes et aI., 2001), race (Moul et aI., 1995), age (Catalona et aI., 1993), and
prostate volume (Klingler et aI., 1998; Partin et aI., 1990). Increases in serum PSA will
also be observed in diseases such as benign prostatic hyperplasia, prostatitis, and some
urological interventions (Lukes et aI., 2001). Prostatic intraepithelial neoplasia does not
significantly increase serum PSA levels (Alexander, Qian, Wollan, Myers, & Bostwick,
1996).
Ejaculation during sexual intercourse has been shown to influence serum PSA
levels. Although serum PSA concentrations return to normal after 24 hours in 92% of
cases, serum PSA levels can increase by as much as 41 % within 1 hour after ejaculation
(Tchetgen et aI., 1996). For precise serum PSA readings, one should refrain from sexual
activity for a minimum of 2 days prior toa serum PSA test (Barrett, 2000).
African Americans also have significantly higher levels of serum PSA
(Henderson, Eastham, Culkin, Whatley, & Sartor, 1996; Smith et al., 1996). Moul and
colleagues (1995) found that African Americans have a mean serum PSA level of 14.00
ng/ml, whereas Caucasians had a mean serum PSA level of 8.29 ng/mI. Barroso Jr. and
colleagues (1999) concluded similar results as African Americans had an average serum
PSA level of 13.2 ng/ml and Caucasians had an average serum PSA level of 11.2 ng/mI.
Smith et al. (1996) suggested the use of a serum PSA cutoff <4.0 ng/ml for screening
PCa in African Americans.
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Oesterling, Jacobsen and associates (1993) found that serum PSA levels increased
approximately 3.2% per year. Individuals >70 years of age have two to three times
higher levels of serum PSA when compared to individuals 5:.70 years of age (Catalona et
aI., 1993). Oesterling, Jacobsen and associates (1993) believed an increase in serum PSA
levels with increasing age is due that an increase in the size of the prostate gland.
Babaian, Miyashita, Evans, and Ramirez (1992) supported this observation as they
revealed a positive correlation between prostate gland volume and patient's age.
The prostate gland has two episodes of growth. From the time of birth, the
prostate gland continues to grow until the age of 20 when it reaches its normal size
(Barrett, 2000). The prostate gland will remain this size until the age of 45 when it
generally begins a 2nd growth (Tortora & Grabowski, 1996). Partin and associates
(1990) and Kane and associates (1992) concluded that serum PSA levels are positively
correlated with prostate volume. Serum PSA levels increase approximately 38% per 10
cm3 of prostate gland volume (Babaian et aI., 1992). Therefore, as prostatic volume
increases, so do serum PSA levels. Nadler, Humphrey, Smith, Catalona, and Ratliff
(1995) found that prostate volume was one of the most important factors contributing to
elevations in serum PSA levels.
Benign prostatic hyperplasia is characterized by an inability to urinate, weak urine
stream, an increased frequency in urination, and painful urination (Damjanov, 2000).
Benign prostatic hyperplasia is source of elevated serum PSA levels (Dalva, Akan,
Yildiz, Telli, & Bingol, 1999). In fact, BPH is the most common condition leading to
increased levels of serum PSA in the blood (Barrett, 2000). Hammerer and colleagues
(1995) concluded that serum PSA levels do not increase as a result of BPH, but there is a
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strong correlation between BPH volume and serum PSA levels. As prostatic tissue
reproduces, cells within the tissue produce serum PSA, thereby creating more serum PSA
than normal. For every gram of prostatic enlargement, 0.3 ng/ml of serum PSA is
produced by BPH (Yang Pros-Check assay) (Stamey et aI., 1987). Although BPH and
PCa can exist at the same time, BPH has not been shown to increase an individual's risk
for PCa (Bostwick et aI., 1999).
Prostatitis is one of the most common prostate disorders men can encounter as
25% of urinary problems are related to prostatitis (Barrett, 2000). Prostatitis is a term
used to describe any disorder that causes inflammation or infection of the prostate gland
(Giovannucci, 2001). Symptoms include fever, chills, painful urination and ejaculation,
an inability to urinate or empty the bladder during urination, blood in the semen, and
persistent bladder infection (Barrett, 2000). Nadler and colleagues (1995) discovered that
62.6% of men with elevated serum PSA levels and 27.4% with normal serum PSA levels
had at least one biopsy with acute inflammation. In addition, Nadler and colleagues
found that 98.6% of patients with elevated serum PSA had at least one biopsy specimen
that was positive for chronic inflammation compared to 77.4% of patients with normal
serum PSA levels. Nadler et al. found that inflammation was one of the most important
factors contributing to elevations in serum PSA levels.
Some urological interventions have been shown to increase PSA levels in the
blood (Lukes et aI., 2001). Bossens,Van Straalen, De Reijke, Kurth, and Sanders (1995)
found that serum PSA levels increase significantly, a maximum of 1.7-fold, after a DRE
is performed. A physician should delay taking serum PSA measurements for
approximately 3 days (Bossens et aI., 1995) to one week following DRE and TRUS
(Yuan et aI., 1992).
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Oesterling, Rice, Glenski, and Bergstralh (1993) found that
transurethral resection of the prostate and needle biopsy increased serum PSA levels by
an average 5.9 ng/mI. Bossens and colleagues and Oesterling, Rice and colleagues
(1993) found that serum PSA levels increased 3-fold and 2.6 fold, respectively, from
baseline levels after needle biopsy. The reason for an increase in serum PSA levels after
prostatic biopsy is due to the biopsy disrupting the architectural integrity of the prostate
gland (Yuan et aI., 1992). With the exception of DRE and TRUS, an individual should
wait 4 to 6 weeks before experiencing a serum PSA test in order to allow serum PSA
levels time to return to normal (Oesterling, Rice et aI.; Yuan et aI., 1992).
Taking specific types of medication can also affect serum PSA levels in patients.
Proscar is a medication used to promote hair growth in balding men and treat BPH
(Barrett, 2000). Proscar has been shown to suppress the hormone dihydrotestosterone,
which decreases prostatic volume and thus decreases the amount of serum PSA produced
(Gormley et aI., 1992). Approximately 50% of the patients studied by Gormley and
associates (1992) had a 20% or more decrease in the size of their prostate. Therefore,
serum PSA levels are often cut in half when patients take Proscar (Oesterling et aI.,
1997). However, physicians can obtain reliable serum PSA levels in these patients by
doubling their serum PSA level (Oesterling et aI., 1997).
Although various serum PSA assays exist, several assays have shown to be highly
correlated with one another. Leewansangtong, Goktas, Lepoff, Holthaus, & Crawford
(1998) have concluded that the Tandem-R and Abbott AxSYM assays were highly
correlated when serum PSA levels were <25 ng/mI. Patel, White, and Ward (2000) found
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that the AxSYM, Liaison, Kryptor, Elecsys, Immulite, and CanAg assays demonstrated
similar serum PSA levels and therefore were not significantly different from one another.
To date, serum PSA is considered to be the most precise and vital markers for
early detection of PCa (Gambert, 2001; Lukes et aI., 2001). Davidson, Bostwick and
associates (1995) have concluded that males with an abnormal serum PSA level have a
relative risk of 3.6 for developing PCa. However, the serum PSA test has demonstrated a
lack of sensitivity and specificity and therefore should not be considered the exclusive
population screening test for PCa (Cupp & Oesterling, 1993). The sensitivity of the
serum PSA test ranges from 0.35 (Crawford et aI., 1999) to 0.81 (Ohori, Dunn, &
Scardino, 1995), whereas the specificity ranges from 0.36 (Aziz & Barathur, 1993) to
0.78 (Egawa et aI., 1995). Since the serum PSA test has a high false positive rate, serum
PSA is considered a specific marker for prostatic epithelium and not specific for PCa
(Benson & Olsson, 1994; Benson, Whang, Olsson, McMahon, & Cooner, 1992; Dincel et
aI., 1999). Serum PSA has also been shown to detect cancers that are indolent and would
not produce clinical symptoms or affect the survival of the patient (von Eschenbach et aI.,
1997).
2.7.3 Transrectal Ultrasound
Since it provides an accurate depiction of the prostate, the TRUS is most
commonly used for targeting the needle biopsies when abnormal DRE findings and/or
elevated serum PSA levels are present (Altman & Resnick, 2001; Applewhite et aI.,
2001). However, TRUS can also be utilized as a clinical stage II screening test to further
evaluate the prostate when DRE and/or serum PSA levels exhibit abnormal results
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(Cooner et al., 2002; Littrup & Bailey, 2000). The development of TRUS has enabled
physicians to determine the size and anatomy of the prostate with remarkable accuracy
(Langer, 1999). The TRUS has been proven to be more sensitive than DRE in detecting
PCa (Lee & Littrup, 1992).
Since normal prostatic cells and cancerous prostatic cells have different
densities, they display different shadows on the ultrasound image (Morra & Potts, 1996).
Malignant tissue usually has a greater density than normal tissue (Kelly, Lees, &
Rickards, 1993). Therefore tumors usually appear as hypoechoic areas (dark spots) in the
peripheral zone (Lee et aI., 1986). Poorly differentiated tumors are more visible on the
monitor than well-differentiated tumors (Baggish, 1996). Shinohara, Wheeler, and
Scardino (1989) discovered that 60% of tumors diagnosed were visualized as hypoechoic
areas on TRUS. Lee and colleagues (1986) and Sheth, Hamper, Walsh, Holtz and
Epstein (1991) found that all prostate tumors located in the peripheral zone were
hypoechoic. However, not all hypoechoic areas in the peripheral zone are cancerous.
Hamper, Sheth, Walsh, Holtz and Epstein (1991) and Sheth and colleagues (1991) found
that 16 to 63% of hypoechoic lesions were benign. Hypoechoic lesions can often
resemble BPH (Tzai, Lin, Yeh, & Chow, 1995), ejaculatory ducts, a thickened fibrous
prostatic capsule (Shinohara et aI., 1989), prostatitis (Hamper et aI., 1991), scarring after
transurethral resection of the prostate, and prostatic intraepithelial neoplasia (Sheth et aI.).
Tumors may also appear as isoechoic areas. Ellis and Brawer (1994) and Shinohara and
associates found that 25% and 39% of tumors were isoechoic, respectively. Although
isoechoic and hypoechoic cancers have similar mean Gleason scores, hypoechoic cancers
have higher mean serum PSA levels (Ellis & Brawer, 1994). The odds of detecting PCa
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through the utilization of the transrectal ultrasound are 2.77 (Egawa et aI., 1995). If the
physician suspects PCa based on the results of the transrectal ultrasound, a biopsy could
be requested.
Color Doppler imaging is often used in conjunction with the transrectal
ultrasound. Color Doppler imaging is able to distinguish areas within the prostate that
have an increased blood flow. Color flow is typically absent in a normal prostate and in
BPH, while elevated when prostatitis or cancer is present (Kelly et aI., 1993). Similar to
TRUS, color Doppler imaging can detect high-grade tumors easier than low-grade tumors
(Shigeno, 19awa, Shiina, Wada, & Yoneda, 2000). This is the result of aggressive tumors
being known for having an increased blood flow (Brawer et aI., 1994). However, it has
been concluded that color Doppler imaging is not as sensitive as TRUS in screening for
PCa (0.68 versus 0.75) (Shigeno et aI., 2000). Shigeno and colleagues suggested that
color Doppler imaging should be combined with transrectal ultrasound to improve the
sensitivity of both clinical tests. However, Kelly and colleagues found that the addition
of color Doppler imaging to the transrectal ultrasound provided very little additional
value to the screening of PCa.
Although the transrectal ultrasound procedure is highly operator-dependent, it has
shown the ability to detect tumors as small as 0.05 cc (Terris, Freiha, McNeal, & Stamey,
1991) and tumors that are not palpable by the DRE (Cersosimo & Carr, 1996). Tumors
located anteromedially and anteriorly on the prostate gland can only be visualized and
accurately localized by TRUS (Tzai et aI., 1995). Unfortunately, TRUS cannot detect
every tumor in the anterior region of the prostate as Sheth and colleagues (1991)
concluded that TRUS could not detect eight of the nine tumors found in the transition
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zone. Since the TRUS has the ability to detect a number of tumors that are not palpable,
it is believed to be the best clinical test available for producing images of the prostate
(Cersosimo & Carr, 1996).
Table 2.1 provides a summary of the article that examined the efficacy of the
transrectal ultrasound. Deliveliotis and colleagues (1998) determined the sensitivity and
specificity of TRUS to be 0 and 0.81, respectively. However, only 3 of the 34 patients in
this study had PCa. These cancers could have easily been missed by the TRUS,
especially if these cancers were small in volume or in areas such as the transition zone.
This would explain why Deliveliotis and colleagues (1998) had a sensitivity of O.
Deliveliotis and colleagues (1998) had originally enrolled 42 patients in their sample;
however 8 patients were eliminated from the analysis since they had positive DRE
results.
Table 2.1: Summary of Transrectal Ultrasound Article
Reference Patients Sens Spec
Deliveliotis et al. (1998) 34 0 t 0.81 t
PPV
ot
NPV
0.89 t
LR
Ot
Sens=Sensitivity; Spec=Specificity; PPV=Positive Predictive Value; NPV=Negative Predictive Value; LR=Positive Likelihood Ratio.
t Calculated using existing data reported in the literature.
Deliveliotis et al. (1998) originally enrolled 42 patients.
2.7.4 Age-Specific Reference Range Prostate Specific Antigen
Since serum PSA values display a strong correlation with age, Oesterling,
Jacobsen et al. (1993) introduced the age-specific reference ranges for serum PSA.
Rather than having one specific serum PSA cutoff for all ages, Oesterling, Jacobsen, and
colleagues (1993) developed a separate serum PSA cutoff for different age categories.
Younger patients were assigned a lower serum PSA cutoff, whereas older patients were
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assigned a higher serum PSA cutoff. By lowering the upper limit of normal for serum
PSA levels in younger patients, the sensitivity of Age-PSA is enhanced (Oesterling,
Jacobsen et aI., 1993). In addition, increasing the upper limit in older men reduces the
false positive rate due to age, an increase in prostatic volume, benign prostatic
hyperplasia, and other benign conditions (Oesterling, Jacobsen et aI., 1993). However,
the cancers that are missed in older men are more likely to be aggressive (Partin et aI.,
1996).
Table 2.2 summarizes the article that examined the efficacy of Age-PSA.
Catalona and colleagues (2000b) concluded that Age-PSA enhanced specificity when
serum PSA levels were between 4.0 to 10.0 ng/ml and the prostate gland was palpably
benign. However, Age-PSA did not have a high sensitivity as it missed 20% of cancer
patients (Catalona et aI., 2000b). As a result, Age-PSA should not be used to distinguish
between PCa and benign prostatic diseases when the prostate gland is palpably benign
and serum PSA levels are between 4.0 and 10.0 ng/mI.
Table 2.2: Summary of Age-Specific Reference Range Prostate Specific Antigen
Article
Reference
Catalona et ale (2000b)
Patients
773
Sens
0.80 t
Spec
0.27 t
PPV
0.51 t
NPV
0.59 t
LR
1.10 t
Sens=Sensitivity; Spec=Specificity; PPV=Positive Predictive Value; NPV=Negative Predictive Value; LR=Positive Likelihood Ratio.
t Calculated using existing data reported in the literature.
2.7.5 Prostate Specific Antigen Density
Prostate specific antigen density, a refinement of the serum PSA test, is often
helpful in further evaluating patients for PCa. Introduced by Benson, Whang, Pantuck et
ale in 1992, PSAD was utilized in an effort to distinguish between PCa and BPH. PSAD
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is determined by dividing a patient's serum PSA level by the volume of the prostate
(Benson, Whang, Pantuck et aI., 1992; Brawer, Aramburu, Chen, Preston, & Ellis 1993).
Since it is impossible to accurately determine the number of epithelial cells within the
prostate gland, prostate volume is used to estimate the number of epithelial cells in the
prostate (Benson, Whang, Pantuck et aI., 1992). Prostate volume is estimated by the
transrectal ultrasound utilizing the formula; 1[/6 x (length x width x height) (Benson,
Whang, Pantuck et aI., 1992; Presti Jr., 2000). Wolff and colleagues (1995) found that
this formula exhibited a correlation coefficient of r2 =0.83 and therefore was accurate in
estimating the volume of the prostate gland. PSAD is remarkably effective when serum
PSA levels are within the borderline range of 4.0 to 10 ng/ml, whereby overlaps between
cancer and BPH are common (Bossens et aI., 1995; Deliveliotis et aI., 1998). Dincel and
colleagues (1999), Benson, Whang, Olsson, and colleagues (1992) and Seamen and
colleagues (1993) recommend a cutoff of ~0.12 and ~0.15 ng/ml/cc when serum PSA
levels are within the intermediate range of 4.0 to 10.0 ng/mI.
The rationale behind PSAD is that normal and benign epithelial cells require a
specific amount of stromal support to maintain normal structure and function (Benson &
Olsson, 1994). Therefore a limited number of normal prostate epithelial cells can occupy
a given prostate volume and thus a specific amount of serum PSA is produced in normal
origin (Applewhite et aI., 2001; Benson, Whang, Pantuck et aI., 1992; Seaman, Whang,
Cooner, Olsson, & Benson, 1994). Once this limit of serum PSA is surpassed, cancerous
cells must occupy the prostate since cancerous cells do not follow the same epithelial-
stromal ratio as normal and benign cells (Benson, Whang, Pantuck et aI., 1992).
Cancerous cells grow by expansion and infiltration, whereas BPH grows by expansion
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(Benson, McMahon, Cooner, & Olsson, 1993; Benson & Olsson, 1994). This infiltration
can affect PSA but minimally affect prostate gland volume (Benson & Olsson, 1994).
When pea is present, increases in serum PSA levels are disproportional to the size of the
prostate (Bostwick et aI., 1999). However, in benign prostatic hyperplasia, increases in
serum PSA levels correspond to the amount of prostatic enlargement (Bostwick et aI.). In
most instances, the likelihood of PCa increases as PSAD increases.
Although a promising procedure, the accuracy of PSAD is limited by the ability to
accurately assess serum PSA levels and the ability of the TRUS to accurately measure the
volume of the prostate (Van Iersel, Witjes, de la Rosette, & Oosterhof, 1995; Zlotta,
Djavan, Marberger, & Schulman, 1997). PSAD would be significantly enhanced if one
could accurately determine the exact number of cells within a given prostatic volume
(Seaman et al., 1993; Seaman et aI., 1994).
Table 2.3 provides a summary of the articles that outline the efficacy of PSAD
when serum PSA levels are between 4.0 and 10.0 ng/ml and the prostate is palpably
benign. Using a cutoff of 0.15 ng/ml/cc, the sensitivity for PSAD ranged from 0
(Klingler et aI., 1998) to 1.00 (Deliveliotis et aI., 1998), while the specificity ranged from
0.44 (Luboldt, Bex, Swoboda, Husing, & Rubben, 2001a) to 0.93 (Dincel et aI., 1999).
At a cutoff of 0.15 ng/ml/cc, Deliveliotis et aI. (1998) and Luboldt et al. (2001a)
concluded that PSAD was able to distinguish between those with and without PCa when
DRE results were negative and serum PSA levels were intermediate. Dincel et aI. (1999)
also concluded that PSAD could enhance the accuracy of serum PSA, but only when a
cutoff of ~0.12 ng/ml/cc was utilized. Numerous studies found that PSAD could not
discriminate between PCa and benign prostatic conditions when utilizing a cutoff of
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~0.15 ng/ml/cc (Catalona et aI., 2000b; Cookson, Floyd, Ball, Miller, & Sarosdy, 1995;
Klingler et al., 1998; Ozen et aI., 2001; Vleeming, de Craen, de Reijke, van Andel, &
Kurth, 1996). With the exception of Deliveliotis et aI. (1998), at least 25% of cancers
would not have been detected by PSAD. Catalona and colleagues (2000b), Dincel and
colleagues (1999), and Vleeming and colleagues (1996) demonstrated similar
sensitivities, 0.59, 0.60, and 0.60, respectively. However, Dincel and colleagues (1999)
calculated this sensitivity utilizing a cutoff of 0.12 ng/ml/cc, whereas the other two
studies employed a cutoff of 0.15 ng/ml/cc. Deliveliotis et aI. (1998) and Luboldt et aI.
(2001a) calculated similar specificities at 0.45 and 0.44, respectively. Cookson and
associates (1995) and Ozen and associates (2001) also calculated similar specificities
(0.61) in their studies. None of the articles that examined PSAD, showed similar
sensitivities and specificities due to the fact that each of these articles had various errors
in their study design.
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Table 2.3: Summary of Prostate Specific Antigen Density Articles
Reference Cutoff Patients Sens Spec PPV NPV LR
Catalona et ale (2000b) 0.15 773 0.59
Cookson et aI. (1995) 0.15 44 0.13 0.61 0.07 0.76 0.33 t
Deliveliotis et aI. (1998) 0.15 34 1.00 0.45 t 0.15 t 1.00 t 1.82 t
Dincel et aI. (1999) 0.12 95 0.60 0.75 0.39 0.88 2.40 t
Dincel et aI. (1999) 0.15 95 0.50 0.93 0.67 t 0.88 t 7.14 t
Klingler et aI. (1998) 0.15 28 0
Luboldt et aI. (2001a) 0.15 0.75 0.44 0.20 1.34 t
Ozen et aI. (2001) 0.15 134 0.67 0.61 0.13 t 0.96 t 1.72 t
Vleeming et aI. (1996) 0.15 73 0.60 0.50 0.08 t 0.94 t 1.20 t
Sens=Sensitivity; Spec=Specificity; PPV=Positive Predictive Value; NPV=Negative Predictive Value; LR=Positive Likelihood Ratio.
t Calculated using existing data reported in the literature.
Cutoffs were measured in nglml/cc, except Ozen et aI., (2001) whose cutoff was measured in nglml/f.1I.
Deliveliotis et aI. (1998) originally enrolled 42 patients.
Klingler et aI. (1998) originally enrolled 77 patients.
Luboldt et aI. (2001a) originally enrolled 11,644 patients. It could not be determined how many patients in this study had intermediate
serum PSA levels and benign DRE results.
Vleeming et aI. (1996) originally enrolled 144 patients.
2.7.6 Free-to-Total Prostate Specific Antigen'Ratio
Generally, serum PSA circulates through the blood in two forms: bound serum
PSA and free serum PSA (Barrett, 2000; Presti Jr., 2000). Bound PSA is chemically
joined to proteins traveling through the blood (Bostwick et aI., 1999). As much as 85%
of serum PSA can be complexed to <X1-antichymotrypsin (ACT), while lesser amounts are
bound to <X2-macroglobulin (Stenman et aI., 1991). Free serum PSA remains unattached
(Bostwick et aI.). The serum PSA produced by PCa is more likely to fasten to ACT than
the serum PSA produced by BPH (Littrup & Bailey, 2000). As a result, men with PCa
typically have a lower level of free serum PSA than those without PCa (Littrup & Bailey,
2000; Lukes et aI., 2001). Therefore the lower the %fPSA, the more likely the patient has
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PCa. Conversely, the higher the %fPSA the more likely the patient has BPH. As a
result, %fPSA has demonstrated the ability to distinguish between patients with benign
prostatic disease and patients with PCa when serum PSA levels fall between 4.0 and 10.0
ng/ml and DRE is non-suspicious (Catalona et aI., 1998, 2000a, 2000b).
A number of hypotheses have been presented as to why men with PCa have lower
levels of free serum PSA. Bjork and colleagues (1994) proposed that BPH nodules
stimulate less ACT, which may produce conditions that are less than optimal for the
binding of serum PSA and ACT. Contrary to BPH, PCa produces both serum PSA and
ACT, which may enhance the complex formation between serum PSA and ACT (Bjork et
aI., 1994). Another hypothesis stated that only 20% of serum PSA produced by BPH is
enzymatically active (Chen, Chen, & Stamey, 1997). Therefore, serum PSA produced by
BPH would remain relatively free since fewer complexes between serum PSA and ACT
would be produced (Chen et aI., 1997).
Similar to serum PSA levels, a patient's free serum PSA level is influenced by
several factors including age, prostate volume, and prostatitis. Oesterling and colleagues
(1995) concluded that free serum PSA concentrations increased approximately 2.8% per
year. Stephan, Lein, Jung, Schnorr, and Loening (1997) demonstrated that a positive
correlation exists between prostate volume and %fPSA. Chronic prostatic inflammation
may also affect results of %fPSA. Jung and associates (1998) found that patients with
chronic prostatitis displayed decreased results for %fPSA compared to those with BPH.
This trend is similar within individuals that are diagnosed with PCa. Therefore, similar to
serum PSA, free serum PSA is nonspecific for PCa (Jung et aI., 1998).
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Although %fPSA appears to be more accurate than the serum PSA, it is still
susceptible to produce false negative results (Bostwick et al., 1999). The decision for an
optimal cutoff depends on the desire for the highest level of cancer detection versus a
reduction in the false positive rate (Littrup & Bailey, 2000). An accepted threshold for
%fPSA has yet to be resolved because different researchers apply different criteria to
determine the %fPSA cutoff (American Urological Association, 2000; Klingler et aI.,
1998; Lein, Stephan, Jung, Schnorr, & Loening, 1998). Two-thirds of the authors
reviewed by Lein and colleagues (1998) determined the cutoff for %fPSA based on a
specific sensitivity or specificity. This specific sensitivity or specificity was set at 0.90 or
0.95. The remaining third of the studies examined by Lein and colleagues determined the
cutoff for %fPSA based on a receiver operator characteristic (ROC) curve or on identical
values of 0.80 for sensitivity and specificity. It has not been determined whether %fPSA
should be based upon a specific sensitivity or specificity level.
Table 2.4 summarizes the articles that examined the efficacy of free-to-total
prostate specific antigen ratio. Numerous studies have concluded that %fPSA is useful in
differentiating between patients with PCa and those with benign prostatic diseases
(Catalona et aI., 1998, 2000a, 2000b; Dincel et aI., 1999; Haese, Dworschack, & Partin,
2002; Luboldt, Swoboda, Borgermann, Fomara, & Rubben, 2001b; Vessella et aI., 2000).
Therefore, %fPSA can reduce the number of unnecessary biopsies performed in patients
with normal DRE results and serum PSA levels between 4.0 and 10.0 ng/mI. In fact,
Catalona and colleagues (2000a) concluded that %fPSA could reduce the number of
unnecessary biopsies performed in both Caucasians and African Americans by 20% and
17% respectively, while maintaining a sensitivity of 0.95.
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When employing a sensitivity of 0.90, cutoffs for %fPSA ranged from 20%
(Martinez-Pineiro et aI., 2000) to 38% (Dincel et aI., 1999). When set a sensitivity of
0.90, the specificity for %fPSA ranged from 0.11 (Dincel et aI., 1999) to 0.40 (Vessella et
aI., 2000). Martinez-Pineiro et ale (2000) and Vessella et aI. (2000) demonstrated similar
specificities at 0.39 and 0.40, respectively. When a cutoff that maintained a minimum
sensitivity of 0.95 was established for %fPSA, the specificity of %fPSA ranged from 0.11
(Dincel et aI., 1999) to 0.32 (Martinez-Pineiro et aI., 2000). When the sensitivity for
%fPSA was established at 0.95, the cutoffs ranged from 20% (Luboldt et aI., 2001b) to
39% (Dincel et al., 1999). At a sensitivity of 0.95, three studies conducted by Catalona
and colleagues (1998, 2000a, 2000b) determined the specificity of %fPSA to be 0.20.
Catalona and colleagues (2000a) (when only examining the African American
population) and Luboldt and colleagues (2001b) demonstrated almost similar
specificities, 0.17 and 0.15, respectively.
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Table 2.4: Summary of Free-to-Total Prostate Specific Antigen Ratio Articles
Reference Cutoff Patients Sens Spec PPV NPV LR
Sensitivity 0.90
Catalona et aI. (1998) 22% 773 0.90 0.29 0.55 t 0.75 t 1.27 t
Dincel et aI. (1999) 38% 95 0.90 0.11 0.21 t 0.80 t 1.01 t
Haese et al (2002) 24% 756 0.91 0.24 0.34 t 0.86 t 1.20 t
Martinez-Pineiro et ale (2000) 20% 180 0.90 0.39 0.30 0.93 1.48 t
Ozen et aI. (2001) 30% 134 0.91 0.21 0.08 t 0.96 t 1.15 t
Vessella et aI. (2000) 24% 297 0.90 0.40 0.43 t 0.89 t 1.50 t
Sensitivity 0.95
Catalona et aI. (1998) 25% 773 0.95 0.20 0.53 t 0.79 t 1.19 t
Catalona et aI. (2000a) 25% 726 0.95 0.20 0.54 t 0.81 t 1.19 t
Catalona et aI. (2000a) 25% 726 0.95 0.17 0.51 t 0.78 t 1.15 t
Catalona et aI. (2000b) 25% 773 0.95 0.20 0.53 t 0.79 t 1.19 t
Dincel et aI. (1999) 39% 95 0.95 0.11 0.22 t 0.89 t 1.07 t
Luboldt et aI., (2001b) 20% 633 0.95 0.15 0.16 t 0.95 t 1.12 t
Martinez-Pineiro et aI. (2000) 22% 180 0.95 0.32 0.29 0.96 1.40 t
Vessella et al. (2000) 26% 297 0.96 0.27 0.40 t 0.93 t 1.32 t
Sens=Sensitivity; Spec=Specificity; PPV=Positive Predictive Value; NPV=Negative Predictive Value; LR=Positive Likelihood Ratio.
t Calculated using existing data reported in the literature.
Haese et al. (2002) originally enrolled 1,602 patients.
Luboldt et al. (2001b) originally enrolled 11,644 patients.
Vessella et al. (2000) originally enrolled 692 patients.
2.7.7 Combined Clinical Tests
Clinicians often administer multiple screening tests in an attempt to achieve an
unequivocal diagnosis (Knapp & Miller, 1992). To date, only one clinical study has
evaluated the efficacy of clinical algorithms when DRE results are non-suspicious and
serum PSA levels are intermediate. Table 2.5 provides a summary of this article. Ozen
and colleagues (2001) concluded that by combining the use of PSAD and %fPSA, half
the patients with intermediate serum PSA levels and normal DRE results would be saved
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from the complications and morbidity of the prostate biopsy, while only 10% of patients
with PCa would have been completely missed. The cutoffs that were utilized for PSAD
and %fPSA were >0.18 ng/ml/JlI and <21 %, respectively.
Table 2.5: Summary of Combined Clinical Tests Article
Reference Patients Sens Spec PPV NPV LR
Ozen et aI. (2001) 134 0.90 0.55 0.14 t 0.99 t 2.00 t
Sens=Sensitivity; Spec=Specificity; PPV=Positive Predictive Value; NPV=Negative Predictive Value; LR=Positive Likelihood Ratio.
t Calculated using existing data reported in the literature.
2.8 Grading Prostate Cancer
After a patient has been confirmed with PCa, the next step is to assign a grade to
the cancer (Barrett, 2000). The most common scale for grading cancer is the Gleason
scale, which was first introduced by Gleason and Mellinger in 1974 (King, 2000). The
Gleason score indicates the aggressiveness of the tumor as well as provide adequate
information about the prognosis and decision for treatment (Koksal et aI., 2000). The
Gleason score of the tumor is an important determinant in the likelihood of progression
(Brawn et aI., 1990; Davidson, Hop et aI., 1995).
The lower an individual's Gleason score, the better the prognosis for the
individual and less likely the cancer is to metastasize. Scores ranging from 2 to 4
indicate slow-growing, well-differentiated tumors (Presti Jr., 2000). These tumors tend
to be smaller than poorly-differentiated tumors (Scott Jr. et aI., 1969). Scores ranging
from 5 to 7 suggest a moderately differentiated tumor (Cersosimo & Carr, 1996). This
tumor could be either slow or fast-growing depending on the duration of the cancer
(Barrett, 2000). Scores from 8 though 10 indicate an aggressive tumor that is poorly
differentiated and fast-growing (Cersosimo & Carr, 1996).
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The Gleason score is associated with a patient's age. Kabalin and colleagues
(1995) found that the odds of a patient over the age of 40 years developing a Gleason
grade of 4 or 5 increases by a factor of 1.65 for each decade. Only 35% of patients
between the age of 41 and 50 have a Gleason grade of 4 or 5, whereas 75% of patients
over the age of 70 have a Gleason grade' of 4 or 5 (Kabalin et aI.). More importantly, the
Gleason score is directly associated with mortality rates (Gleason & Mellinger, 1974;
King, 2000). Sebo and colleagues (2001) found that the Gleason score is highly
correlated with extraprostatic extension. Sebo and colleagues (2001) concluded that men
with a Gleason score of 7 were at least 4 times more likely to encounter extraprostatic
extension than men with a Gleason score of 4,5, or 6. Men with a Gleason score of 8 or
9 were almost 12 times more likely to have experienced extraprostatic extension
compared to men have tumors with Gleason scores of 6 or less (Sebo et al., 2001).
It has been shown that little agreement exists between the biopsy Gleason score
and the prostatectomy Gleason score. The overall accuracy of the biopsy in predicting
the true Gleason score of the tumor has ranged from 45% (Koksal et aI., 2000) to 58.3%
(Narain et al., 2001). In addition, the biopsy Gleason score and the prostatectomy
Gleason score have been shown to differ by one Gleason score in 44% of these patients
and differ by two or more Gleason scores in 11% of patients (Koksal et aI., 2000).
2.9 Staging Prostate Cancer
Once an individual is diagnosed with PCa, the physician will assign a stage to the
cancer from the results of the DRE, serum PSA test, TRUS, total
prostatoseminovesiculectomy, or pelvic lymph node dissection (Beahrs et aI., 1992;
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Schroder et aI., 1992). A CT scan can also be utilized to stage cancer (Hricak et aI.,
1987). Tumor stage is determined at two situations, clinical evaluation and after surgical
removal of the prostate gland (Hoedemaeker et aI., 2000). The stage of the cancer is
dependent upon three factors: tumor size, tumor location (confined to the prostate or
metastasis to other areas) and, Gleason score (Davidson, Hop et al., 1995; Schroder et aI.,
1992). Staging the cancer conveys to other health care professionals the local extent of
the tumor, since this influences therapy (Ekici et aI., 1999). Staging of PCa also provides
the foundation for deciding which form of treatment the patient should undertake and the
prognosis for the individual (Brawn et aI., 1990; Mattfeldt, Kestler, Hautmann, Gottfried,
2001). The TNM and ABCD systems have been identified as two systems for staging
cancer (Cersosimo & Carr, 1996).
The TNM system is an international system (Morra & Potts, 1996) and the most
widespread method in the United States for distinguishing the progression of PCa
(Barrett, 2000). In the TNM system, the letter T stands for primary tumor and denotes
the degree of cancer in and surrounding the prostate gland (Barrett, 2000). The letter N
stands for nodes and indicates whether or not the cancer has invaded the surrounding
lymph nodes (Hoedemaeker et aI., 2000). The letter M stands for metastasis and
designates that the PCa has multiplied and spread to other organs (Barrett, 2000). Each
capital letter is accompanied by a number ranging from 0 to 4 indicating the tumor stage
(Bostwick et aI., 1999). Stage 0 indicates no evidence of cancer (Barrett, 2000). Stage 1
represents early cancer or latent cancers that are confined to the prostate gland. These
tumors are generally smaller (Hoedemaeker et aI.). During this stage, there are no
symptoms or signs present (Whitmore Jr., 1956). The particles are microscopic and
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therefore cannot be detected by DRE or TRUS (Barrett, 2000). These tumors are
discovered unexpectedly while examining prostate chips removed during transurethral
resection (Grignon & Sakr, 1996) or through biopsy prompted by elevated serum PSA
levels (Hoedemaeker et al.). During stage 2, the cancer is still in its early stage and
remains restricted within the capsule of the prostate. However, now it can be detected by
DRE or TRUS (Hoedemaeker et al.). The subcategories within stage 2 are defined by the
cancers extent of involvement of the two lobes of the prostate (Grignon & Sakr, 1996).
In stage 3, unilateral or bilateral extraprostatic extension has occurred (Grignon & Sakr,
1996). These tumors have a higher chance of spreading to the lymph nodes and
demonstrate a life-threatening prognosis after radical prostatectomy (Hoedemaeker et
al.). No evidence of distant metastases is present (Whitmore Jr., 1956). Finally, in stage
4, the cancer has progressed to adjacent structures including the bladder, rectum, and
pelvic wall (Grignon & Sakr, 1996). The cancer has become more advanced and
conclusive evidence of metastases exist (Whitmore Jr., 1956). A lower case letter further
divides each tumor stage. The lower case letters a, b, or c specifies the location of the
cancer. Appendix 3 elaborates and clarifies the TNM system. From 1986 to 1993, the
proportion of stage 1 and IV tumors have decreased by 21 % and 9%, respectively, while
stage 3 tumors have remained constant and stage 2 tumors have increased by 29.4%
(Mettlin, Murphy, Ho, & Menck, 1996). The increase in stage 2 tumors may be
attributed to an increased use of serum PSA testing and DRE. Staging of tumors can be a
beneficial prognostic index (Bailar III., Mellinger, & Gleason, 1966). Schmidt and
colleagues (1986) concluded that a 5-year survival rate for each of the four stages was
85%, 77%, 65.5%, and 30%, respectively.
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The ABCD system uses the letters A through D to represent four major stages of
PCa (Cersosimo & Carr, 1996). The letters A through D are used to indicate
approximately the same four stages of the TNM system (Morra & Potts, 1996). Even
though this system is less precise because it has fewer subcategories, it is still used to
stage PCa (Barrett, 2000). A number ranging from 0 to 2 follows each letter in this
system. These numbers represent details about each stage (Barrett, 2000). The letters A
and B indicate that the cancer is confined to the prostate gland, while the letters C and D
specify that the cancer has metastasized to other areas in the body. Appendix 3 illustrates
the ABCD system.
The digital rectal examination is the most common method used for staging PCa
(Ekici et al., 1999; Smith Jr. et aI., 1997). However, the overall accuracy of staging for
DRE is approximately 61 % (Hricak et aI., 1987). Huch Boni and colleagues (1995)
calculated the accuracies for the endorectal coil MRI (87.9%), body coil MRI (75.8%),
TRUS (69.6%), DRE (63.6%), and serum PSA at a cutoff of 50 ng/ml (57.6%). Ekici
and colleagues (1999) also calculated the overall accuracy for DRE (22%), TRUS (65%),
MRI (65%), and the combined use of TRUS and MRI (57%). Ekici and colleagues
(1999) concluded that TRUS should be utilized for determining the local extent of
prostatic cancer. Huch Boni and colleagues (1995) concluded that optimal the approach
for staging PCa would be to combine endorectal coil MRI and serum PSA values. Hricak
and colleagues (1987) also concluded that the MRI was the optimal modality for staging
PCa. When attempting to stage PCa, under staging typically occurs, as the physician's
estimate is lower than it should be (Hoedemaeker et aI., 2000). Although it consistently
under stages, the DRE has been the preferred method for staging prostate cancers during
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the population screening phase (Vapnek, Hricak, Shinohara, Popovich, & Carroll, 1994).
TRUS has been shown to be more accurate in determining the stage of cancer than DRE,
although TRUS also demonstrates significant understaging (Vapnek et al., 1994). Huch
Boni and colleagues (1995) found that under staging had occurred in patients who
underwent endorectal coil MRI (6%), body coil MRI (18%), TRUS (30%), and DRE
(36%). Regardless the method, staging PCa can provide the patient with helpful
information on the severity of the disease and possible treatment options (Ekici et aI.,
1999).
2.10 Treating Prostate Cancer
The aim of treatment is to extend the natural history of PCa with comfort, or at
the very least provide comfort to patients (Whitmore Jr., 1956). When the diagnosis for
PCa has been established, difficult decisions must to be made pertaining to the choice of
adequate treatment including options such as radical prostatectomy, irradiation, watchful
waiting and/or hormone therapy.
In order to ensure complete removal of malignant tissue and thus eliminate the
possibility of a new tumor developing, most physicians prefer radical prostatectomy
(Morganstern & Abrahams, 1996). In fact, from 1986 to 1993, the proportion of patients
undergoing a prostatectomy has increased from 9.9% to 29.2% (Mettlin et aI., 1996).
Radical prostatectomy refers to removal of the pelvic lymph nodes and total excision of
the prostate gland (Oesterling, 1996). Radical prostatectomy is often reserved for men
who are in reasonably good health and have a life expectancy of at least 10 years
(Gelbard & Bentley, 1995). Radical prostatectomy is most effective when the tumor is
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localized (Drachenberg, 2000; Fleming, Wasson, Albertsen, Barry, & Wennberg, 1993).
Two types of radical prostatectomy exist: the retropubic approach and the perineal
approach.
The retropubic approach is the most common form of prostate removal since the
surgeon has better access to the prostate and can use the same incision to remove the
lymph nodes (Barrett, 2000). General anesthesia may be used to put the patient to sleep.
In this procedure, the incision is made in the lower abdomen (Oesterling, 1996). If
cancer is detected within the lymph nodes, the physician may either proceed with surgery
or close the incision without removing the prostate (Barrett, 2000). If removed, the
lymph nodes are often sent to a pathologist. The physician will try to preserve the nerves
on either side of the prostate, which control erections (Barrett, 2000). Recovery in the
hospital requires approximately 2 to 3 days (Oesterling, 1996).
The perineal approach is similar to the retropubic approach. However, the
incision is made between the anus and the scrotum (Oesterling, 1996). Laparoscopic
pelvic lymph node dissection has created a renewed interest in the radical perineal
prostatectomy (Resnick, 1996). The advantage of the radical perineal prostatectomy is
the avoidance of an incision in the abdominal region (Resnick, 1996). The disadvantages
to this approach are that it is difficult for the surgeon to preserve the neurovascular
bundles and the inability to reach the lymph nodes (Oesterling, 1996).
Twenty-four months following radical prostatectomy, Stanford and associates
(2000) found that 44.2% of men were unable to have any erections and 59.9% of men
reported that erections were not firm enough for sexual intercourse. In addition, of the
men who were potent at baseline, 72.4% reported that their erections were not firm
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enough for intercourse after 18 months. Stanford and associates (2000) also reported that
frequent urinary leakage or total incontinence was experienced by 8.4% of patients at 24
months.
The proportion of patients receiving radiation therapy has increased from 26.7%
in 1986 to 30.1% in 1993 (Mettlin et aI., 1996). High doses of radiation can be
administered by external beam radiation therapy or through brachytherapy (Morton,
Harrison, & Peschel, 1986). External-beam radiation is recommended for men with
localized advanced cancer (stage C cancer), a life expectancy of ten years or more, and
men who would be ineligible for surgery due to health problems (Gelbard & Bentley,
1995). External beam radiation is ineffective when PCa has spread to the lymph nodes
(Gelbard & Bentley, 1995). External-beam radiation involves high-energy x-rays to kill
cancerous cells (Gelbard & Bentley, 1995). External-beam radiation can pose a problem
to nearby healthy cells as they can also be killed along with the cancerous cells
(Morganstern & Abrahams, 1996). Treatments are usually given 5 days a week for
approximately 6 to 7 weeks (Barrett, 2000). Shipley and associates (1999) concluded
that the 5-year disease-specific survival rate for external-beam radiation was 65.8% for
patients with Tlb, TIc, and T2 prostate tumors. In the study conducted by Nguyen,
Pollack, and Zagars (1998), 30% of patients treated with radiation therapy reported
incontinence to be a problem, 25% of patients had weaker urine stream, 24% of patients
reported a greater frequency of nocturia, and 37% of patients had more frequent bowel
movements. In terms of sexual function, the number of patients who could achieve a full
erection had decreased by 49% after radiation therapy (Nguyen et aI., 1998).
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Brachytherapy involves implanting seeds of radiation on to the prostate gland.
Brachytherapy is typically used for tumors clinically staged Tl and T2a, whereas
clinically staged T2b and T2c tumors are treated with a combination of external
irradiation and brachytherapy (Syed et aI., 2001). Brachytherapy can deliver as much as
three times the amount of radiation to the prostate than could be safely given by external
beam methods, while causing less damage to healthy cells (Barrett, 2000; Gelbard &
Bentley, 1995). Typically 12 to 22 tiny capsules containing iodine 125 or palladium are
surgically implanted transperineally into the tumor (Morganstern & Abrahams, 1996;
Syed et aI., 2001). Once implanted, the seeds emit a continuous stream of radiation.
Syed and colleagues (2001) achieved a disease-specific survival rate of 97% for
brachytherapy after a minimum follow-up of 25 months. Acute gastrointestinal and/or
genitourinary toxicity occurred in 20% and 10% of patients, respectively who underwent
brachytherapy (Syed et aI., 2001). The disadvantage of brachytherapy is the inability to
alter the position of the seeds once implanted (Syed et al., 2001). Survival rates for
brachytherapy are typically higher than survival rates for external beam radiation since
increased amount of radiation received through external beam radiotherapy can decrease
of the quality of life of patients compared to those that were treated brachytherapy
(Krupski, Petroni, Bissonette, & Theodorescu, 2000).
Patients who participate in watchful waiting are gambling that they will not die
from pea but from other causes such as cardiovascular disease (Gelbard & Bentley,
1995). Watchful waiting is recommended for patients with early or localized disease,
low-grade cancer (Gleason score of 2 to 4), a short life expectancy (less than 10 years)
and/or those who may decline surgery and radiation (Drachenberg, 2000). In other
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words, watchful waiting should only be recommended when the tumor is not believed to
be a significant threat to the life or comfort of the patient (Whitmore Jr., 1956). The
proportion of patients receiving watchful waiting has decreased from 41.8% in 1986 to
21.6% in 1993 (Mettlin et aI., 1996). Typically, these cancers are discovered at the time
of treatment for BPH (Drachenberg, 2000). Watchful waiting involves monitoring the
progression of the tumor through regular digital rectal examinations and serum PSA tests
(Drachenberg, 2000). Johansson and colleagues (1992) found that after 10 years of
follow-up, only 8.5% of patients died from PCa. Steineck and colleagues (2002)
discovered that men who were randomized to watchful waiting were 35% and 27% less
likely to have erectile dysfunction and urinary leakage, respectively compared to those
who had undergone radical prostatectomy. However, these men were 16% more likely to
have urinary obstruction. Advantages to watchful waiting include avoiding side effects
that are associated with other treatments. Furthermore, watchful waiting is inexpensive
(Barrett, 2000). One disadvantage of watchful waiting is that curable cancers are
allowed to grow to a stage, whereby they cannot be cured (Morganstern & Abrahams,
1996).
The testes are the major source of androgen production in the male human body.
Since most prostatic tumors are androgen dependent (Huggins & Hodges, 1941),
treatment of PCa should be aimed at either eliminating androgen secretion or preventing
the effects of androgens on tumors (Gaillard-Moguilewsky, 1991). Hormone therapy
reduces the levels of serum testosterone and thus diminishes the stimulation of normal
prostate and PCa cells (Ornstein, Rao, Johnson, Charlton, & Andriole, 1996). Therefore
the size of the prostate gland and prostate tumor is reduced and thus the tumor can be
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targeted by radiotherapy (Messing et aI., 1999). Hormone treatments including
orchiectomy, estrogen or luteinizing hormone-releasing hormone agonist can suppress
testicular androgen secretion. It is well accepted that men with extraprostatic or
metastatic pea undergo androgen deprivation (Herr & O'Sullivan, 2000). Hormone
therapy is also recommended for men with high-grade tumors (Newling, 2001) or men
with concerns about radiation therapy (Fowler Jr., Bigler, Kolski, & Yee, 1998).
Cause specific survival rates for patients treated with hormone therapy at 5 and 8
years is 92% and 80%, respectively (Fowler Jr., Bigler, White, & Duncan, 2002).
Occasionally, hormone therapy is combined with radiation therapy. Bolla and colleagues
(1997) compared the usage of radiotherapy alone to the combination of radiotherapy
therapy and Zoladex. Bolla and colleagues (1997) found that overall survival rates were
79% in the combined treatment group and 62% in the radiotherapy group. It was also
discovered that 78 patients in the radiotherapy group had disease progression compared
to 20 patients in the combined treatment group. It was concluded that the combined
treatment of radiotherapy and Zoladex improves the local control and survival in patients
with locally advanced PCa (Bolla et aI., 1997).
Karling, Hammar and Varenhorst (1994) found that 68% of patients who
underwent castration experienced hot flashes during treatment. Approximately 48% and
40% of patients continued to experience hot flashes 5 years and 8 years after treatment,
respectively. Approximately 13% of patients undergoing orchiectomy experienced
osteoporotic fractures compared 1% of patients who were not treated by orchiectomy
(Daniell, 1997). Herr and O'Sullivan (2000) found that androgen deprivation therapy
could cause fatigue, decreased physical activity, additional emotional distress, and an
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overall decrease in general health in men who are at risk of tumor progression.
Goserelin, a luteinizing hormone releasing hormone, has been associated with increased
fatigue in 66% of patients. Goserelin was also linked to declines in potency, virility, and
an increase in nausea/vomiting (Stone, Hardy, Huddart, A'Hern, & Richards, 2000).
Men treated with bicalutamide are likely to have experienced breast pain and
gynecomastia (Iversen et aI., 2000). The combination of flutamide and finasteride has
been linked to excessive breast development and tenderness, diarrhea, and a reduction in
potency in patients (Ornstein et aI., 1996).
Although it is typically used to assist in population screening, serum PSA levels
are often used to monitor a patient's response to therapy. All successful treatments
should cause serum PSA levels to decrease or become undetectable (Oesterling, Rice et
aI., 1993). The evaluation of serum PSA levels can be a reliable indicator for
distinguishing between patients with encouraging and discouraging responds to hormone
therapy (Miller, Ahmann, Drach, Emerson, & Bottaccini, 1992) and can assist physicians
in predicting the duration of the treatment (Soloway & Matzkin, 1993). Those patients
with increasing levels of serum PSA appear to have a high risk for PCa progression
(Miller et aI., 1992).
2.11 Systematic Literature Review of Screening Studies
A systematic review was conducted using the Pubmed and Ovid medline
databases in an attempt to retrieve articles that pertain to screening PCa. Relevant
medical subject headings (MESH) and non-MESH terms were entered into both medline
databases. These terms included prostate cancer, prostate neoplasm, prostate cancer
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pathology, screening, intermediate PSA levels, normal DRE, AxSYM PSA, TRUS,
PSAD, %fPSA, Age-PSA, TRUS-guided biopsy, sensitivity, and specificity. These terms
were used independently and in BOOLEAN combination. Human and English limits
were also utilized in each database in an attempt to narrow down each search.
Furthermore, research articles were taken from the reference list of initial articles that
were gathered from the medline databases. In total, 14 articles were retrieved for the
period from 1995 to 2002.
2.11.1 Criteria for Study Evaluation
Screening tests that adhere to accepted methodological standards can eliminate
inadequate screening tests, improve the quality of screening test information, reduce
health care costs, and improve patient care (Reid, Lachs, & Feinstein, 1995). The
aforementioned 14 articles were evaluated on a 4-point scale (Sackett et aI., 1991). This
4-point scale is utilized to appraise articles on their usage of appropriate scientific
methods when evaluating the efficacy of clinical tests in stage II screening for PCa. The
criteria employed to evaluate these 14 articles includes the following questions: i) Was
the clinical test evaluated in a suitable patient sample which included an appropriate
spectrum of mild, and severe, along with patients with different but commonly confusing
disorders? ii) Was the acceptable gold standard utilized for the diagnosis of the particular
disorder or condition? iii) Was an independent, blind comparison employed? iv) Was
the utility of the clinical test determined? Appendix 4 summarizes the results of the 14
articles that were evaluated for the systematic review.
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2.11.2 Appropriate Spectrum of Patients
The true value of a clinical test can only be established when the study sample
resembles that seen within a clinical practice (Jaeschke, Guyatt, & Sackett, 1994). If the
sample of patients is not specified, the reported measures of accuracy may have limited
clinical application (Reid et aI., 1995). A standard similar to Reid and colleagues was
utilized to determine whether or not the articles reviewed had an appropriate spectrum of
patients. Each of the reviewed articles needed to mention at least four of the five
following descriptors: eligibility criteria, age distribution, mean and/or median age,
disease stage and/or Gleason score, and race distribution. Approximately 86% (12 of 14)
of the articles reviewed did not mention four of the five aforementioned descriptors.
Catalona et aI. (2000a), Haese et aI. (2002), Luboldt et aI. (2001a, 2001b), Martinez-
Pineiro et aI. (2000), and Ozen et aI. (2000) were the only articles that mentioned the
eligibility criterion that was employed to recruit their sample of patients. The other eight
articles failed to mention the inclusion/exclusion criteria for their study. With the
exception of Klingler et aI. (1998) every article presented the age distribution of their
patients, however, Deliveliotis et aI. (1998) and Ozen et aI. (2001) did not mention the
mean/median age of their patients. Haese and associates was the only study to mention
the Gleason score of the tumors that were diagnosed in their study. The other studies
failed to mention the stage and/or Gleason score of the tumors that were diagnosed and
therefore it is difficult to determine if these studies incorporated a sample of patients that
had mild and severe cases of PCa. Finally, Catalona et aI. (1998, 2000a, 2000b) and
Vessella et aI. (2000) were the only studies that provided information about the race
distribution of their sample of patients. Despite the importance of enrolling an
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appropriate spectrum of patients, Catalona et aI. (2000a), and Haese et aI. were the only
studies to acknowledge at least four of the five aforementioned characteristics.
2.11.3 Acceptable Gold Standard
The accuracy of a clinical test to detect a particular disease/disorder is best
determined by comparing it with the truth (Jaeschke et aI., 1994). The "gold standard"
refers to a definitive diagnosis attained through the use of an acknowledged standard
(Sackett et aI., 1991). Regardless of the results from the clinical test, every patient within
a study sample must undergo the gold standard (Sackett et aI.). For PCa, the gold
standard is considered to be a biopsy that obtains a minimum of six biopsy cores (Hodge
et aI., 1989; Rabbani et aI., 1998). Approximately 86% (12 of 14) of the articles
reviewed performed a biopsy on every patient within the sample and obtained a minimum
of six biopsy cores. Luboldt and colleagues (2001a) and Vleeming and colleagues (1996)
reported the only studies that failed to meet the gold standard criteria. Some of the
patients in these studies had less than six biopsy cores taken.
2.11.4 Blinded Comparison
Expectation or review bias can be introduced into a study when the clinical test
and gold standard are not appraised independently and objectively during their
interpretation (Reid et aI., 1995). Conscious or unconscious expectation bias can only be
prevented when the clinical test and gold standard are examined in a blinded fashion
(Sackett et aI., 1991). If any of the aforementioned articles did not mention whether or
not blinding of the researchers had taken place, it was assumed that blinding had not
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occurred. Despite the importance of blinding, only 21% (3 of 14) of the articles that
examined the efficacy of clinical tests in stage II screening for PCa had reported
performing an independent assessment of the clinical tests and biopsy. Catalona and
colleagues (1998, 2000b), and Luboldt and colleagues (2001b) were the only studies to
blind their researchers.
2.11.5 Utility
The ultimate criterion for a clinical test is whether or not the patient would be
better off having undergone the procedure (Sackett et aI., 1991). When determining the
utility of a clinical test, it is important to consider the appropriate role of the clinical test
being examined, if the clinical test is feasible, and the risk of complications for patients
undergoing the clinical test (Sackett et aI.). Each of the 14 articles reviewed had stated
the utility of the clinical tests being evaluate~. The majority (11 of 14) of articles
demonstrated the utility by acknowledging the clinical test's sensitivity and specificity.
Catalona and colleagues (2000b), Deliveliotis and colleagues (1998), and Klingler and
colleagues (1998) were the only studies not to calculate sensitivity and specificity when
determining the efficacy of a particular clinical test. Catalona and colleagues (2000b)
calculated the sensitivity and specificity for the Age-PSA, PSAD and %fPSA and stated
the utility for all three of these clinical tests. However, the sensitivity and specificity for
Age-PSA was calculated for various age categories of the entire sample and not
calculated for the overall sample. Deliveliotis and colleagues (1998) determined the
utility of PSAD by observing the data and demonstrating that no patient's diagnosis was
missed using PSAD suggesting perfect sensitivity. Deliveliotis and colleagues (1998)
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did not directly evaluate the efficacy of TRUS and therefore did not completely examine
the utility of the TRUS. Klingler et al. (1998) determined the utility of PSAD by stating
that PSAD did not detect one cancer.
2.11.6 Summary of Systematic Literature Review
Overall, all articles reviewed failed to achieve a 4-point rating. Approximately
36% (5 of 14) of the articles reviewed scored a 3-point rating. Of these five articles,
three articles failed to enroll an appropriate spectrum of patients and two articles
neglected to mention if the physicians performing the clinical tests were blinded. Of the
remaining nine articles, seven articles achieved a 2-point rating. All seven studies
neglected to mention whether the researchers were blinded and failed to incorporate an
appropriate spectrum of patients. Two studies attained a I-point rating. Both Luboldt et
al. (2001a) and Vleeming et al. (1996) neglected to include an appropriate spectrum of
patients, failed to obtain a minimal of six biopsy cores during the biopsy procedure, and
neglected to mention whether the researchers were blinded. Table 2.6 outlines the results
from a systematic review pertaining to the 14 articles that were used to evaluate the
efficacy of clinical tests in stage II screening for PCa.
2.12 Summary
Prostate cancer is the most commonly diagnosed cancer and third leading cause of
cancer death in Canadian men. Early detection of PCa is critical since PCa is often
curable when it is localized. Although an abundance of clinical tests exist, screening for
PCa remains partially ineffective and inconsistent. This is especially evident when serum
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PSA levels are intermediate and DRE results are benign. When these results are
demonstrated, only 25% of patients have PCa. Increasing the number of unnecessary
biopsies performed must not be a result of improved cancer detection methods.
Therefore, a discriminator capable of preventing unnecessary biopsies in patients is
required. Clinical tests including TRUS, Age-PSA, PSAD, and %fPSA are utilized to
further evaluate patients when serum PSA levels range from 4.0 ng/ml to 10.0 ng/ml and
normal DRE results occur. With the exception of %fPSA, these independent clinical
tests have not demonstrated the ability to differentiate between patients with and without
PCa. Therefore it is essential to evaluate the efficacy of combined clinical tests when
screening within the second stage for PCa.
Furthermore, it is necessary for research articles to conform to specific
methodological standards. If these standards are not followed, it is then difficult for
physicians to be confident that the results from other articles will apply to their patients
and practice. Therefore, it is essential that research studies enroll an appropriate
spectrum of patients, utilize an acceptable gold standard to determine a definitive
diagnosis of the disease, incorporate a blind comparison between the clinical test and the
gold standard, and determine the diagnostic utility of the clinical test. By incorporating
appropriate methodological standards, physicians can make better decisions concerning
how to screen patients for PCa within their practice based on evidence-based medical
literature.
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Table 2.6: Systematic Review of Clinical Tests for Stage II Screening Prostate
Cancer
Reference ASP AGS RB U Rating
Catalona et ale (1998) ~ 0 0 0 3
Catalona et al. (2000a) 0 0 ~ 0 3
Catalona et al. (2000b) ~ 0 0 0 3
Cookson et al. (1995) ~ 0 ~ 0 2
Deliveliotis et al. (1998) ~ 0 ~ 0 2
Dincel et al. (1999) ~ 0 ~ 0 2
Haese et ale (2002) 0 0 ~ 0 3
Klingler et al. (1998) ~ 0 lRl 0 2
Luboldt et al. (2001a) ~ ~ ~ 0 1
Luboldt et al. (2001b) ~ 0 0 0 3
Martinez-Pineiro et al. (2000) ~ 0 ~ 0 2
Ozen et al. (2001) lRl 0 lRl 0 2
Vessella et al. (2000) lRl 0 lRl 0 2
Vleeming et al. (1996) ~ ~ lRl 0 1
ASP=Appropriate Spectrum of Patients; AGS=Acceptable Gold Standard; RB=Researcher Blinding; U=Utility.
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Chapter III
Methodology
3.1 Introduction
In order to ensure the validity of a screening test, it is essential that the design
eliminate all bias and incorporate precision (Sackett et aI., 1991). The purpose of the
current study was to compare the degree of efficacy of individual clinical tests and
clinical algorithms in stage II screening for PCa when DRE results are non-equivocal,
with intermediate PSA levels.
3.2 Study Sample
Between January 14, 1997 and January 21, 1999, a total of 446 consecutive male
patients were recruited for a study. Each subject was clinically suspected of pea based
on the results of a DRE and/or serum PSA test performed by their family physician.
Each subject was referred to The Princess Margaret Hospital in Toronto for a transrectal
ultrasound and biopsy procedure. Inclusion criteria included all subjects suspicious for
PCa based on either a positive DRE and/or serum PSA test (2:4ng/ml). Exclusion criteria
consisted of those patients who would not consent to participate in this study and patients
who were not suitable for the prostate biopsy procedure for reasons such as; 1) urinary
infection, bleeding disorders or usage of anticoagulating medications, 2) patients who had
undergone any prostate manipulation within the last seven days, and 3) patients who
underwent a prostate biopsy procedure prior to the start of this study. Subjects were then
eliminated from this study for the following reasons; 1) an abnormal DRE 2) a serum
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PSA level below 4.0 ng/ml or 3) a serum PSA level exceeding 10.0 ng/m!. For the
purpose of this study, the actual sample size was 201 patients. A post-hoc sample size
determination was employed based upon an initial population of 446 patients (Appendix
5). The expected proportions for prevalence (0.37), sensitivity (0.89), and specificity
(0.10) were selected from Age-PSA, which was determined to be the least efficacious
clinical test. Based on the stage II sample size of 201 patients used in this study, a 95%
confidence level (a=0.05) would allow for a maximum error of 3.5%.
3.3 Research Design
A consecutive sample was chosen for this cross-sectional research study. This
study was approved by both the Toronto Hospital Committee for Research on Human
Subjects on December 5, 1996 and the Brock University Research Ethics Board on July
16, 2002. Initially, patients were notified about the details of the study, how the data
would be stored and utilized, and that this data could be used for several different studies
including this current study. Each patient signed a letter of informed consent prior to
performing any clinical test. Consent had been obtained from each patient before any
clinical test was performed. The consent, ethics, and data forms are provided in
Appendices 6, 7,8.
3.4 Measurement of Serum Prostate Specific Antigen
A 20 cc blood sample was taken from each patient using a standard venipuncture
technique. The AxSYM Total PSA assay (Abbott Laboratories, Canada) was used to
determine serum PSA levels for each subject. The AxSYM Total PSA assay is based on
Stage II Screening for Prostate Cancer 92
Microparticle Enzyme Immunoassay (MEIA) technology. Reagents and serum samples
that were analyzed within 24 hours were stored at 2-8°C. Otherwise, older serum
samples were stored at ~ -20°C. Serum samples, calibrators, controls, and reagent packs
were loaded into the sampling center of the AxSYM Total PSA assay (Vashi et aI., 1997).
Serum samples (184 Ill) and all required reagents were pipetted by the sampling probe
into various wells of the reaction vessel (Abbott Laboratories, 1999). Reagents included
anti-PSA coated microparticles, assay diluent, and anti-PSA alkaline phosphatase
conjugate. The reaction vessel was then transferred to the processing center where
further pipetting was performed. The serum sample, anti-PSA coated microparticles, and
assay diluent were incubated together in the reaction vessel. During incubation, the PSA
within the serum sample attached to the anti-PSA coated microparticles (Abbott
Laboratories, 1999). A fraction of the reaction was transferred and attached to a matrix
cell. Unbound material was washed from the matrix cell and the anti-PSA alkaline
phosphatase conjugate was added into the matrix cell and attached to the antibody-
antigen complex. Again, the unbound material was washed from the matrix cell. Finally,
4-methylumbelliferyl phosphate was added to the matrix cell and the MEIA optical
assembly measured this product. Using a calibration curve, the concentration of serum
PSA in the sample was determined (Abbott Laboratories, 1999). The process took
approximately 15 to 25 minutes (Smith & Osikowicz, 1993). Unexplained serum PSA
values ~4 ng/ml were considered suspicious for Pea.
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3.5 Digital Rectal Examination
During a digital rectal examination, the patient was either bent over against the
examination table or lay on his side on the examination table. After donning a lubricated
examination glove, the physician inserted his/her index finger into the patient's rectum
until the prostate gland was reached. Once the physician's finger reached the prostate
gland, the physician palpated the prostate through the rectal wall by using a side to side
sweeping motion across the outside of the prostate in an attempt to detect cancerous
lesions (McDougal & Skerrett, 1996). The physician used this sweeping motion across
the peripheral zone of the prostate since most tumors develop within the outer portion of
the prostate (Barrett, 2000). Along with this sweeping motion, the physician may have
gently pressed once or twice on the prostate in an attempt to detect deep-rooted tumors
(McDougal & Skerrett, 1996).
As the physician palpated the prostate gland, he/she attempted to feel for any
abnormalities in size, shape, and/or consistency in the gland (Baggish, 1996).
Abnormalities may also have included distinct nodules, focal induration, or a diffusely
hard prostate (Applewhite et aI., 2001). The patient was suspected of pea if any
unexplained abnormalities were felt.
3.6 Transrectal Ultrasound
An enema to wash out the rectum was administered to the patient on the morning
of the TRUS procedure (Altman & Resnick, 2001). While the patient was lying on the
left side of their body, a second DRE was performed. The DRE was performed to
identify any palpable prostatic abnormalities including a lump or hard spot that requires
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attention during the TRUS examination (Applewhite et aI., 2001). Once the DRE ruled
out any rectal pathology that would prevent the safe insertion of the transrectal ultrasound
probe, the probe was inserted into the rectum of the patient. The TRUS was preformed
with the Philips lIDI 3000 ultrasound machine using a C9-5 ICT transducer (Philips,
Bothell, WA). The prostate gland was viewed in the transverse plane first. The seminal
vesicles were viewed, followed by the bladder neck, the mid-gland and lastly the apex.
After the transverse plane was examined, imaging in the sagittal plane was performed in
the right, mid, and left regions of the prostate gland (Altman & Resnick, 2001;
Applewhite et aI.). If the physician observed any hypoechoic areas during the TRUS, the
patient was suspected of PCa.
3.7 Age-Specific Reference Range Prostate Specific Antigen
Age-PSA involved examining the patient's serum PSA level relative to their age.
The recommended reference range for Age-PSA is ~2.5 ng/ml for men aged 40 to 49
years; ~3.5 ng/ml for men aged 50 to 59 years; ~4.5 ng/ml for men aged 60 to 69 years;
and ~6.5 ng/ml for men aged 70 to 79 years (Littrup & Bailey, 2000; Oesterling,
Jacobsen et aI., 1993). Subjects demonstrating serum PSA levels that exceed their age-
specific cut-off were considered suspicious for Pea.
3.8 Prostate Specific Antigen Density
Prostate specific antigen density was calculated by dividing the amount of serum
PSA by the volume of the prostate gland (Benson, Whang, Pantuck et aI., 1992). The
volume of the prostate gland was calculated by employing the TRUS, which scanned the
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length, width, and height of the prostate gland. These measurements were used in the
prolate ellipse volume calculation; n/6 x (height of the prostate x length of the prostate x
width of the prostate) (Benson, Whang, Pantuck et aI., 1992). The length of the prostate
was measured from the internal to external sphincter (Lavoipierre, 2000). The width of
the gland was measured in its maximum dimension in the transverse plane. The height of
the prostate was measured in its maximum dimension in the sagittal plane (Lavoipierre,
2000).
Two cutoffs were examined for PSAD. The current study considered cutoff
values of ~0.12 ng/ml/cc and ~0.15 ng/ml/cc as positivity criterion for PSAD. The cutoff
~0.12 ng/ml/cc was employed since it has been determined to be the most efficacious
cutoff by Dincel and colleagues (1999). The ~0.15 ng/ml/cc cutoff was utilized since
Seamen and associates (1993) recommend this cutoff when serum PSA levels are within
the intermediate range. In addition, the 0.15 ng/ml/cc cutoff is the most common cutoff
utilized for PSAD.
3.9 Free-to-Total Prostate Specific Antigen Ratio
A total of 20 cc of blood was taken using a venipuncture. Venipuncture was
performed prior to the TRUS and the TRUS-guided biopsy. The AxSYM Free PSA
assay (Abbott Laboratories, Canada) was employed to determine %fPSA levels for each
patient. The AxSYM Free PSA assay is based on MEIA technology. Reagents and
serum samples that were analyzed within 24 hours were stored at 2-SoC. Otherwise,
older serum samples were stored at ~ -20°C. Serum samples (167 JlI) and all required
reagents were pipetted by the sampling probe into various wells in the reaction vessel.
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Reagents included anti-PSA (mouse, monoclonal) coated microparticles, assay diluent,
anti-free PSA (mouse, monoclonal) alkaline phosphatase conjugate, and specimen
diluent. The reaction vessel was then transferred to the processing center where further
pipetting was performed. The serum sample, anti-PSA coated microparticles, and assay
diluent were incubated together in the reaction vessel. During incubation, the PSA within
the serum sample bound to the anti-PSA coated microparticles. A fraction of the reaction
was transferred to a matrix cell where it bound to the matrix. Unbound material was
washed from the matrix cell and the anti-free PSA alkaline phosphatase conjugate was
added into the matrix cell and bound to the antibody-antigen complex. Again, the
unbound material was washed from the matrix cell. Finally, 4-methylumbelliferyl
phosphate was added to the matrix cell and this product was measured using the MEIA
optical assembly. Through the use of a calibration curve, the concentration of free serum
PSA in the sample was determined (Abbott Laboratories, 1997). The process took
approximately 15 to 25 minutes (Smith & Osikowicz, 1993). The %fPSA was calculated
for each patient as (free PSA/serum PSA) x 100%. Currently, no traditional cutoff exists
for %fPSA. Cutoffs that provided a sensitivity of 0.90 and 0.95 respectively were
employed for %fPSA. These various criterion were decided upon based on Lein and
colleagues (1998) who found that most of the research studies they reviewed utilized
similar criterion for determining the cutoff for %fPSA.
3.10 Transrectal Ultrasound-Guided Biopsy
All patients underwent a TRUS-guided biopsy. All patients received antibiotic
prophylaxis using 500 mg of ciprofloxacin. Patients were instructed to take one tablet
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(500 mg) every 12 hours beginning the night before the biopsy was to be administered.
A total of six tablets were administered to the patient. In addition, patients underwent a
Fleet enema 2 hours prior to the TRUS-guided biopsy procedure. During the TRUS-
guided biopsy, the patient was instructed to lie on their left side while the physician
inserted a lubricated ultrasound probe into the patient's rectum. A Bard Magnum biopsy
gun with an 18-gauge needle (Bard, Covington, GA) was inserted through a channel in
the ultrasound probe. With the help of the images provided by the ultrasound probe, the
physician used a biopsy gun to propel a fine, hollow, spring-loaded needle into specific
areas of the prostate (Barrett, 2000). A minimum of six biopsy cores were taken from the
prostate gland. Each biopsy core was 20 x 0.5 mm. Biopsy cores were taken from the
base, middle, and apex of the right and left lobes, respectively (Hodge et aI., 1989).
Biopsy cores were also taken from the midline and/or far lateral aspect in larger prostate
glands. Additional cores were also taken from any suspicious hypoechoic areas on the
prostate as shown by the TRUS. All biopsy specimens were sent to a pathologist in order
to be analyzed for PCa. By examining the shape and size of the prostatic cells and
comparing these cells to normal healthy cells, the pathologist could tell if the patient had
cancer (Bostwick et aI., 1999; Barrett, 2000). A Gleason score was assigned to any
tumor that was diagnosed. The Gleason score indicated the aggressiveness of the tumor.
The pathologist assigned a primary grade to the predominant pattern of cancer and a
secondary grade to the pattern of cancer that was the second most commonly observed
(Gleason & Mellinger, 1974). When only one pattern was observed in an entire
specimen, then the same value was assigned to both the primary and secondary grade
(Gleason & Mellinger, 1974). The Gleason scale ranged from 1 to 5, with 1 being the
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least aggressive and 5 being the most dangerous form of cancer (Barrett, 2000). Grade 1
referred to cells that were similar to healthy cells in shape and spacing (McDougal &
Skerrett, 1996). A grade of 2 was assigned when cancer cells were more irregular in size
and shape and arranged more freely (Bostwick et aI., 1999). The cancer is well-
differentiated for both grades 1 and 2 (Bostwick et aI., 1999). Grade 3 referred to
cancerous cells that were more extensive in size and shape. These cells fused collectively
into large, abnormal clusters that were dispersed throughout the prostate gland (Barrett,
2000). This cancer was moderately differentiated (Bostwick et aI., 1999). Grade 4 was
assigned when numerous cells were merged together to form irregular and distorted
masses that were dispersed randomly and had begun to break through the stroma and
invade adjacent tissues (Bostwick et aI., 1999). Grade 5 was assigned when the
cancerous cells had collected into large, dispersed masses, which had infested adjacent
tissues and organs. A grade of 5 resembles a sheet of tumor cells (Morra & Potts, 1996).
Once the two most prominent types of cancer cells are assigned a grade, these two grades
are added together in order to establish the patient's Gleason score (Pan, Potter, Partin, &
Epstein, 2000).
3.11 Clinical Algorithms
Since many clinical tests are imprecise, an independent clinical test rarely results
in an unambiguous diagnosis (Knapp & Miller, 1992). Consequently, clinicians often
administer multiple clinical tests in an attempt to achieve an unequivocal diagnosis
(Knapp & Miller, 1992). Four independent clinical tests which included TRUS, Age-
PSA, PSAD, and %fPSA were examined in this study. These four independent clinical
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tests were utilized to produce numerous clinical algorithms that were examined in this
study. The various cutoffs that have been established for PSAD and %fPSA were
considered within the clinical algorithms.
3.12 Algorithm Criteria
Parallel testing was employed for each clinical algorithm. Therefore if one of the
clinical tests within the clinical algorithm was positive, the subject was suspected of PCa.
If the clinical tests within the clinical algorithm were unanimously negative, then the
subject was not suspected of PCa.
3.13 Data Management
This study utilized a secondary dataset courtesy of Dr. Ants Toi (M.D.) of The
Princess Margaret Hospital, Toronto, Canada. This dataset was entered in the software
program NCSS 2000 (Hintze, 1998).
3.14 Data Coding
Data was coded by assigning either a 0 or 1 to each clinical test result. The
number 0 implied that subjects were not suspicious for PCa for a particular clinical test
based upon the predetermined cutoff. The number 1 identified subjects who were
suspicious for PCa for a specific clinical test based upon the established cutoff. Every
subject was assigned a 0 or 1 for each clinical test. Every subject was also assigned
either a 0 or 1 for the variable "cancer". A subject was assigned a 0 for the variable
"cancer" if they obtained a score of 1 to 4 from the pathology report. This indicated that
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the patient was not diagnosed with PCa. From the pathology report, a score of 1 meant
no cancer, a score of 2 indicated low-grade PIN, a score of 3 represented high-grade PIN,
and a score of 4 represented atypia. If the score from the pathology report was 5 to 7, the
subject was assigned a 1. This indicated that the patient was diagnosed with PCa as a
score of 5 represented microscopic PCa, a score of 6 indicated PCa, and a score of 7
signified another type of cancer.
3.15 Data Checking and Cleaning
The secondary dataset was checked for missing data. Missing data consisted of
the Gleason score of three tumors and lobe location of five tumors. Since minimal data
was missing, every subject within this dataset was used in this study. Frequency
distributions and histograms were performed on all variables in an attempt to identify
"outliner" data.
3.16 Statistical Analysis
The computer software programs NCSS 2000 (Hintze, 1998) and Webulator©
(Montelpare & McPherson, 1999) were used for the statistical analysis. Analysis was
divided into five sections: i) subject demographics, ii) prostate gland and tumor
characteristics iii) clinical tests, iv) positivity criterion for free-to-total prostate specific
antigen ratio, and v) Stage II screening efficacy of clinical tests and algorithms. Each
section used appropriate statistical analysis to evaluate the data collected for this study.
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3.16.1 Subject Demographics
Frequency distributions were used to calculate the prevalence of benign
conditions a well as prevalence of cancer based on the results from the TRUS-guided
biopsy procedure. Frequency distributions were also used to summarize the ages of each
patient. Descriptive statistics including mean, range, and standard deviation were
calculated for the age of patients. An analysis of variance (ANOVA) was performed in
order to identify differences in age between subjects who were positive and negative for
PCa. The acceptable level of significance is established at a=O.05.
3.16.2 Prostate Gland and Tumor Characteristics
Descriptive statistics including mean, range, and standard deviation was
calculated for the volume of the prostate gland. An ANOVA was performed in order to
identify differences in prostatic volume between subjects positive and negative for PCa.
The acceptable level of significance is established at a=O.05. Frequency distributions
were used to summarize the Gleason scores of each tumor.
3.16.3 Clinical Tests
Frequency distributions were used to summarize the number of patients who were
identified as positive and negative for PCa based on the results from the TRUS, Age-
PSA, PSAD, and %fPSA. Descriptive statistics including mean, range, and standard
deviation were calculated for serum PSA levels, PSAD levels, and %fPSA levels. An
ANOVA was utilized to determine significant differences between serum PSA, PSAD,
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and %fPSA levels for patients who were positive and negative for PCa. The acceptable
level of significance is established at a=0.05.
3.16.4 Positivity Criterion For Free-to-Total Prostate Specific Antigen Ratio
The positivity criterion for %fPSA was determined by employing a ROC curve.
Cutoffs that provide a minimum sensitivity of 0.90 and 0.95 were employed for %fPSA.
Consequently, there were two cutoffs utilized for %fPSA.
3.16.5 Stage II Screening Efficacy and Contribution of Clinical Tests and Algorithms
Measures of sensitivity, specificity, and positive likelihood ratio (LR), were used
to determine the efficacy of each clinical test and combined clinical algorithm.
Sensitivity is calculated as the number of true positives (TP) divided by the sum of true
positives and false negatives (FN). Specificity is calculated as the number of true
negatives (TN) divided by the sum of true negatives (TN) and false positives (FP). The
positive likelihood ratio was calculated as the sensitivity divided by I-specificity (false
positive rate). Both positive and negative predictive values were also calculated. The
positive predictive value (PPV) is calculated as the number of TP divided by the sum of
the TP and FP. The negative predictive value (NPV) is calculated as the number of TN
divided by the sum of TN and FN. Confidence intervals (CI) were determined for
sensitivity, specificity, positive likelihood ratio, and positive and negative predictive
values. Cohen's Kappa statistic (ZK) was utilized to determine the overall agreement
beyond chance between the clinical tests or algorithms and the gold standard biopsy test.
The acceptable level of significance is established at a=0.05. In an attempt to further
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determine the efficacy of clinical tests and algorithms, the area under the ROC curve
(AVC) was examined. Finally, the McNemar chi-square was employed to measure
significant differences between clinical tests and algorithms for sensitivity, specificity,
positive predictive value, and negative predictive value. The McNemar chi-square was
only utilized for clinical tests and algorithms that obtained a minimum sensitivity of 0.90.
Again, the acceptable level of significance is established at a=0.05.
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Chapter IV
Results
4.1 Subject Demographics
The prevalence of PCa in this sample of 201 patients was 37±7% (74 +PCa and
127 -PCa). Of the 74 patients with PCa, 30 and 20 patients were diagnosed with cancer
on the right lobe and left lobe of the prostate, respectively. There were 19 patients
diagnosed with cancer on both lobes of the prostate. The distribution of benign
conditions is shown in Table 4.1. Benign prostatic hyperplasia, the most prevalent
benign condition, was observed in 68% of patients. Atrophy and high PIN occurred in
45% and 31% of patients, respectively. Inflammation of the prostate was the least
identified benign condition (18%). As shown in Table 4.1, with the exception of high
PIN, the majority of cases occurred in both sides of the prostate rather than one specific
side.
Table 4.1: Summary of Benign Conditions
Clinical Test Right Lobe Le(tLobe Both Lobes Total
BPH 24 32 81 137
Atrophy 14 21 56 91
High PIN 21 25 16 62
Inflammation 5 10 21 36
The mean age of the patients was 63.55±7.23 years (range 39 to 86 years). Age
stratification included 1 patient below 40 years of age, 8 patients between 40 to 49, 49
patients between 50 to 59, 110 patients from 60 to 69, 31 patients between 70 to 79, and 2
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patients over 80 years of age. Analysis of variance demonstrated a significant difference
(p<0.05) in the mean age between patients with positive (65.03±0.83 years) and negative
PCa (62.68±0.64 years). Figure 4.1 outlines the number of patients diagnosed with and
without PCa according to age-specific categories. No significant difference (p>0.05) in
age was found between patients with and without PCa in any of the age categories.
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Figure 4.1. Number of Patients Diagnosed With and Without Prostate Cancer
For Specific Age Categories
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4.2 Missing Data
The secondary dataset used in the present study had few missing data. Firstly,
the lobe location of five tumors was not specified. In addition, the Gleason score of three
tumors was not provided and therefore it could not be determined whether or not these
tumors were aggressive. Finally, two patients within this study were over 80 years of
age. When developing Age-PSA, Oesterling, Jacobsen et al. (1993) failed to design a
PSA reference range for patients over the age of 80. Consequently, these two patients
were excluded when calculating the results for the independent Age-PSA test.
4.3 Prostate Gland and Tumor Characteristics
The average prostate gland volume was 64.35±27.88 cc (range 19.9 to 160.9 cc).
An ANOVA revealed a significantly smaller (p<O.OOI) prostate gland volume in patients
with PCa (55.14±3.14 cc) compared to those without PCa (69.72±2.40 cc). The majority
(96%) of tumors diagnosed were assigned a Gleason score. Table 4.2 outlines the
frequency distribution of Gleason scores. Ninety percent (N=64) of patients were
diagnosed with moderately differentiated tumors (Gleason score of 5 to 7).
Approximately 6% (N=4) of patients had well differentiated tumors (Gleason score of 0
to 4), whereas the remaining 4% (N=3) of patients had poorly differentiated tumors
(Gleason score of 8 to 10).
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Table 4.2: Patients and Gleason Score Distribution
Gleason score Frequency ofPatients
0 2
3 1
4 1
6 31
7 33
8 3
4.4 Clinical Tests
Table 4.3 summarizes the results of each clinical test including TRUS, Age-PSA,
PSAD, and %fPSA. There were 43 and 178 patients who tested positive on the TRUS
and Age-PSA, respectively. When a cutoff of 0.12 and 0.15 ng/ml/cc was employed for
PSAD, 81 and 53 patients had positive test results, respectively. %fPSA identified 143
(cutoff 23%) and 154 (cutoff 25%) positive patients, respectively.
Table 4.3: Summary Clinical Test Results
Clinical Test Patients Positive Patients Negative
TRUS 43
Age-PSA 178
PSAD (0.12 ng/ml/cc) 81
PSAD (0.15 ng/ml/cc) 53
%fPSA (23%) 143
%fPSA (25%) 154
158
21
120
148
58
47
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The mean serum PSA level was 6.79±1.61 ng/ml (range of 4.1 to 10.0 ng/ml).
The mean PSAD level was 0.13±0.06 ng/ml/cc (range of 0.043 to 0.39 ng/ml/cc).
Finally, the mean %fPSA level was 21.21±33.79% (range of 3.87 to 470.59%). Table 4.4
summarizes serum PSA, PSAD, and %fPSA levels in patients diagnosed with and
without PCa. Serum PSA levels and PSAD levels were significantly higher (p<0.05) in
patients with PCa than without PCa. Patients diagnosed with PCa also had significantly
lower %fPSA levels (p<0.05) compared to those patients who were diagnosed without
PCa.
Table 4.4: Serum PSA, PSAD, and %fPSA Levels in Patients
With and Without Prostate Cancer
+PCa
Serum PSA levels
PSAD levels
%fPSA levels
7.10±0.19 ng/ml
0.15±0.007 ng/ml/cc
13.25±3.87%
6.60±0.14 ng/ml*
0.11±0.005 ng/ml/cct
25.85±2.96%*
* Level of significance (p<0.05).
t Level of significance (p<O.OOI).
4.5 Positivity Criterion For Free-To-Total Prostate Specific Antigen Ratio
Figure 4.1 illustrates the ROC curve used to determine specific cutoffs for
%fPSA. Appendix 9 displays the sensitivity, specificity, and positive likelihood ratio for
various cutoffs of %fPSA. In order to achieve a minimum sensitivity of 0.90 and 0.95,
the cutoffs ~23% and ~25% were utilized, respectively. Patients were considered
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positive for PCa if they had obtained a %fPSA value that was less than or equivalent to
the specific cutoff that was employed.
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Figure 4.2. Receiver Operator Characteristic Curve for Free-to-Total
Prostate Specific Antigen Ratio
Based on ROC curve analysis, the results demonstrate that a minimum sensitivity
of 0.90 could be established at a cutoff of 23%. Other studies including Catalona et al.
(1998), Haese et al (2002), and Vessella et al. (2000) found that a minimum sensitivity of
0.90 could be established by using a cutoff ranging from 22% to 24%. In the present
study, a minimum sensitivity of 0.95 is established by utilizing a cutoff of 25%. Catalona
et al. (1998, 2000a, 2000b) and Vessella et al. (2000) found similar results as these
studies used a cutoff of 25% and 26%, respectively, to obtain a sensitivity of 0.95.
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4.6 Stage II Screening Efficacy and Contribution of Clinical Tests and Algorithms
Appendix 10 outlines the true positives, false positives, false negatives, and true
negatives with corresponding sensitivity, specificity, and positive likelihood ratio for
each independent and combined clinical tests. In terms of the independent clinical tests,
%fPSA (cutoff 25%) provided the highest sensitivity (0.95±0.05). Although TRUS had
the lowest sensitivity (0.35±0.11), this clinical test proved to have the highest specificity
(0.87±0.06) and positive likelihood ratio (2.69±0.12). The lowest specificity (O.10±0.05)
and positive likelihood ratio (0.99±0.09) was achieved by Age-PSA.
For algorithms consisting of two tests, the highest sensitivity (0.97±0.04) was
demonstrated by TRUSI%fPSA (cutoff 25%) and Age-PSA/%fPSA (cutoff 23% and
25%). Although the lowest sensitivity (0.61±0.11) was established by the TRUS/PSAD
(cutoff 0.15 ng/ml/cc) algorithm, it also provided the highest specificity (0.71±0.08) and
positive likelihood ratio (2.10±0.14). The lowest specificity (0.08±0.05) was
demonstrated by TRUSIAge-PSA, Age-PSA/PSAD (cutoff 0.12 ng/ml/cc), and Age-
PSA/%fPSA (cutoff 25%). The TRUSIAge-PSA algorithm also achieved the lowest
positive likelihood ratio (0.99±0.08).
For three combined clinical tests, eight clinical algorithms produced the highest
sensitivity (0.99±0.02). The highest specificity (0.34±0.08) and positive likelihood ratio
(1.46±O.09) was achieved by the combination of TRUS, PSAD (cutoff of 0.15 ng/ml/cc),
and %fPSA (cutoff 23%). There were two algorithms that achieved lowest sensitivity
(0.95±0.05) and three algorithms that demonstrated the lowest specificity (0.06±0.04).
The TRUSIAge-PSA/PSAD (cutoff 0.12 ng/ml/cc) algorithm had the lowest positive
likelihood ratio (1.01±0.07).
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When all four clinical tests were employed, the results were similar for each
algorithm. The sensitivity, specificity, and positive likelihood ratio was 1.00, 0.06±0.04,
and 1.06±0.04, respectively.
The results of Cohen's Kappa statistic for each clinical test and algorithm are
outlined in Appendix 11. There were 12 clinical tests/algorithms that did not demonstrate
significant agreement (p>0.05) with the biopsy. %fPSA (cutoff 23%) demonstrated the
highest amount of significant agreement (p<O.OOOl) with the gold standard, whereas the
clinical algorithm Age-PSNPSAD (cutoff 0.12 ng/ml/cc) showed the least amount of
agreement (p>0.05) with the gold standard.
The AUe was calculated for each clinical test and algorithm and is presented in
Appendix 12. The greatest AUC (O.67±0.041) was demonstrated by the TRUS/PSAD
(cutoff 0.12 ng/ml/cc) algorithm. The TRUS/Age-PSA algorithm demonstrated the
lowest area under the curve (O.49±0.042).
Appendix 13 outlines both positive and negative predictive values and
corresponding confidence intervals for each clinical test and algorithm. For independent
clinical tests, TRUS indicated the highest PPV (O.61±0.15), whereas Age-PSA achieved
the lowest PPV (O.36±0.07) and NPV (O.62±0.21). The highest NPV, 0.92±0.08, was
calculated for %fPSA (cutoff 25%)
Among two test algorithms, the TRUS/Age-PSA algorithm had the lowest PPV
(O.36±0.07) and NPV (O.59±0.23). The highest PPV (O.55±0.11) was demonstrated by
TRUS/PSAD (cutoff 0.15 ng/ml/cc), whereas TRUS/%fPSA (cutoff 25%) had the highest
NPV (O.95±0.07).
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For algorithms that incorporated three clinical tests, TRUS/Age-PSAIPSAD
(cutoff 0.12 and 0.15 ng/ml/cc) had the lowest PPV at 0.37±0.07. TRUS/Age-
PSA/PSAD (cutoff 0.12 ng/ml/cc) also had the lowest NPV at 0.67±0.27. The highest
PPV (0.46±0.08) was demonstrated by TRUSIPSAD (cutoff 0.15 ng/ml/cc)/%fPSA
(cutoff 23%). The highest NPV (0.97±0.06) was achieved by TRUSIPSAD (cutoff 0.12
and 0.15 ng/ml/cc)/%fPSA (cutoff 25%). The PPV and NPV were 0.38±0.07 and 1.00,
respectively for every algorithm that incorporated four clinical tests.
McNemar chi-square was used to determine significant differences between
sensitivity, specificity, PPV, and NPV of clinical tests and algorithms that demonstrated a
minimum sensitivity of 0.90 (Appendix 15). The sensitivity, specificity, and positive and
negative predictive values for these clinical tests and algorithms are outlined in Appendix
14. The results are presented using a numbering system for each clinical test and
algorithm for the McNemar chi-square results. There were 29 clinical tests or algorithms
that were examined using the McNemar Chi-square (Appendix 15).
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Chapter V
Discussion
5.1 Introduction
There has been extensive research conducted on determining the efficacy of
clinical tests in stage II screening for prostate cancer. Unfortunately, these clinical
studies have demonstrated a significant degree of variability. This could be attributed to
the failure to incorporate appropriate methodological standards. Among the weaknesses
evident in these studies are an inappropriate spectrum of patients, unacceptable gold
standard for confirming a diagnosis of prostate cancer, and failure to prevent researcher
bias by blinding the test results. These methodological flaws may have led to an
overstatement or understatement of the results of clinical tests, thereby decreasing the
confidence for physicians and researchers in the study results.
This study has taken every precaution to ensure that an appropriate spectrum of
patients was enrolled, that an acceptable gold standard for diagnosing prostate cancer was
utilized on all patients, and that researcher blindness was implemented. For a study to
have enrolled an appropriate spectrum of patients, the study sample must include patients
who are of appropriate age, who have varying degrees of severity, as well as different but
commonly confusing conditions. The current study included individuals with mild to
severe pea as determined by a Gleason score ranging from 0 to 8. In addition, this study
also included patients with disorders that are commonly confused with prostate cancer
including benign prostatic hyperplasia, prostatic atrophy, high grade prostatic
intraepithelial neoplasia, and inflammation. The age distribution of patients, and Gleason
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score of the tumors diagnosed are consistent with the literature. Approximately 86% of
our patients with prostate cancer were over the age of 60 (Canadian Cancer Society,
2003). In addition, the majority of tumors diagnosed were moderately differentiated with
Gleason scores ranging from 5 to 7 (Farkas, Schneider, Perrotti, Cummings, & Ward,
1998; Schwartz, Grignon, Sakr, & Wood Jr., 1999).
The biopsy procedure is regarded as the gold standard for diagnosing pea (Hodge
et aI., 1989;,Rabbani et aI., 1998). Under normal conditions, a minimum of six biopsy
cores are taken from the prostate gland (Presti Jr., 2000). Each patient underwent at least
a sextant biopsy in the current study. Patients with abnormally large prostate glands had
more than six biopsy cores taken. Since every patient underwent the gold standard
biopsy, a confirmed diagnosis was made. Bias was prevented as patients were not
assumed to be positive or negative for cancer based on the results of the clinical tests.
Therefore, the overall validity of this clinical trial was enhanced.
For researcher blinding to occur, results of the confirmed diagnosis and the
clinical screening tests must be interpreted independently. To ensure that blinding
occurred in this study, various physicians performed the serum PSA and %fPSA testing,
while a separate physician performed the TRUS-guided biopsy procedure. Finally,
biopsy cores were independently examined by a pathologist to confirm a diagnosis of
prostate cancer. Had the screening tests or gold standard been appraised without
precautions to preserve objectivity in their interpretation, expectation bias could have
been introduced (Reid et aI., 1995). Expectation bias can incorrectly enhance sensitivity,
specificity, predictive values, and likelihood ratios.
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5.2 Subject Demographics
The mean age of the patients in this current study (63.55 years) is consistent with
other studies (Dincel et aI., 1999; Luboldt et aI., 2001a; Vessella et aI., 2000). Benign
prostatic hyperplasia was the most prevalent benign condition in the current sample. This
is not surprising considering that benign prostatic hyperplasia is considered the most
common condition for elevating serum PSA levels (Barrett, 2000), and the prevalence
rate of BPH has been known to inflate to 77% (Simpson, Fisher, Lee, Russell, &
Garraway, 1996).
The current study found that patients diagnosed with PCa had a significantly
smaller prostate gland volume than patients diagnosed with benign prostatic conditions.
Catalona et aI. (2000a) also found a significant difference in prostatic volume between
patients diagnosed with and without PCa for both Caucasians and African American
patients. Benign conditions, particularly BPH, have been shown to increase prostate
volume (Anderson, Roehrbom, Schalken, & Emberton, 2001; Arrighi, Metter, Guess, &
Fozzard, 1991). The mechanism for this increase in size appears to be an increase in
fibrous tissue (Ishigooka et aI., 1996).
Serum PSA levels were greater among patients with PCa. Haese and colleagues
(2002) also observed higher serum PSA levels in PCa patients. Serum PSA levels can
increase by as much as 3.5 ng/ml/gm when PCa is present but only 0.3 ng/ml/gm in BPH
patients (Kabalin et aI., 1995; Stamey et aI., 1989). In addition, the patients in this study
diagnosed with PCa were significantly older. This could contribute to greater serum PSA
levels since serum PSA levels can increase by as much 3.2% per year (Oesterling,
Jacobsen et aI., 1993). Although prostate volume can affect serum PSA levels, the
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prostate volume would need to increase by 10 cc to observe a 38% increase in serum PSA
levels (Babaian et aI., 1992). The presence of cancer and age could help explain why
patients with PCa have a significantly higher serum PSA level.
PSAD is determined by serum PSA divided by the volume of the prostate
(Benson, Whang, Pantuck et aI., 1992; Brawer et aI., 1993). PSAD levels in this current
study differed significantly between patients with PCa and those diagnosed with benign
prostatic conditions. Both Dincel et aI. (1999) and Luboldt et aI. (2001b) observed this
difference with larger PSAD levels found in PCa patients. Typically patients with BPH
demonstrate larger prostates (Anderson et aI., 2001) and lower levels of serum PSA than
patients diagnosed with PCa (Stamey et aI., 1989). Therefore, the probability of being
diagnosed with PCa increases as a patient's PSAD level rises.
Patients with benign prostatic conditions had nearly twice the %fPSA levels as
those diagnosed with prostate cancer. This is consistent with current research (Catalona
et aI., 1998, 2000a, 2000b; Dincel et aI., 1999; Haese et aI., 2002; Luboldt et aI., 2001b;
Martinez-Pineiro et aI., 2000; Vessella et aI., 2000). Serum PSA circulates through the
blood in two forms: bound serum PSA and free serum PSA (Presti Jr., 2000). The serum
PSA produced by BPH is likely to be free, whereas the serum PSA produced by PCa is
more likely to be bound (Littrup & Bailey, 2000). As a result, men with PCa typically
have a lower level of free PSA than those without PCa (Littrup & Bailey, 2000; Lukes et
aI., 2001). Therefore, a lower %fPSA increases the probability the patient has PCa.
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5.3 Efficacy of Clinical Tests
Efficacy is defined as the extent to which a specific intervention, procedure,
regimen, or service produces a beneficial result under ideal conditions (Last, 2001; U.S.
Congress, 1976). An ideal condition refers to the stage II screening test being employed
in a tertiary setting. Calculated sensitivity and specificity were the primary focus in
determining the efficacy of these independent clinical tests and algorithms. Sensitivity
refers to the proportion of individuals with a particular disease who demonstrate a
positive test result (Hulley & Cummings, 1988). Since urologists attempt to maintain a
high detection rate (Dincel et aI., 1999; Prestigiacomo & Stamey, 1997), a sensitivity of
at least 0.90 is imperative. Specificity refers to the proportion of individuals without a
particular disease who have a negative test result. In the context of the current study,
enhanced specificity of a clinical test or algorithm decreases the number of unnecessary
biopsies being conducted. Since the purpose of this study was to maintain a high
detection rate as well as prevent the occurrence of unnecessary biopsies, sensitivity and
specificity are both important when examining the efficacy of independent clinical tests
and algorithms.
5.3.1 Transrectal Ultrasound
The transrectal ultrasound is frequently utilized to further evaluate patients when
either the DRE and/or serum PSA test demonstrates an abnormal result (Cooner et aI.,
2002; Littrup & Bailey, 2000). When TRUS is utilized, tumors generally appear as
hypoechoic areas (Lee et aI., 1986; Sheth et aI., 1991). However, quite often, hypoechoic
lesions can resemble BPH (Tzai et aI., 1995), ejaculatory ducts (Shinohara et aI., 1989),
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prostatitis (Hamper et aI., 1991), or prostatic intraepithelial neoplasia (Sheth et aI., 1991).
These factors can contribute to a lack of sensitivity for TRUS. Although the results in
this study were superior to those found by Deliveliotis and colleagues (1998), the TRUS
displayed poor utility as it demonstrated an unacceptable sensitivity (0.35±0.11). The
lack of sensitivity (0) found by Deliveliotis et aI. (1998) could be attributed to the lack of
subjects that were enrolled in their study (34) and the low prevalence rate of PCa (9%).
The specificity calculated in this study (0.87±0.06) was higher than that calculated by
Deliveliotis et aI. (1998) (0.81). In addition, the TRUS has been shown to be a subjective
test and therefore the results are often dependent upon the operator (Wolf Jr. et aI., 1993).
The lack of efficacy demonstrated by the TRUS in stage II screening for PCa suggests
that it should not be employed, particularly as an independent clinical test.
5.3.2 Age-Specific Reference Range Prostate Specific Antigen
Age-PSA accounts for increases in serum PSA due to conditions that are more
prevalent in older patients such as BPH (el-Galley et aI., 1995). Unlike serum PSA that
utilizes a specific cutoff (2:4.0 ng/ml) to screen patients, the Age-PSA employs a
positivity criteria based on specific age categories (Oesterling, Jacobsen, et aI., 1993).
This test maximizes sensitivity for younger patients, while exploiting specificity of older
patients (el-Galley et aI., 1995). In this study, Age-PSA exhibited a high sensitivity
(0.89±0.07), but poor specificity (0.10±0.05). The sensitivity of Age-PSA was higher in
this study than that demonstrated by Catalona et aI. (2000b) (0.80). However, Age-PSA
specificity was more than twice that found in the current study (0.27). The lack of
specificity demonstrated by Age-PSA may be attributed to the large 10-year intervals
Stage II Screening for Prostate Cancer 119
utilized for each age category. For example, Age-PSA suggests that a 50-year-old patient
should have a comparable serum PSA level to a 59 year old. Age-PSA also suggests that
a patient may experience a substantial increase in his serum PSA level when he turns 50,
60, or 70 years of age. These factors may contribute to the low specificity of Age-PSA.
Future research should consider using smaller age intervals (eg., 5 years). It is speculated
that Age-PSA would attain a higher specificity, while maintaining a high sensitivity. The
results of this study suggest Age-PSA is not efficacious as an independent clinical test in
stage II screening of prostate cancer due mainly to a low specificity.
5.3.3 Prostate Specific Antigen Density
As previously mentioned, PSAD examines the amount of serum PSA being
produced in relation to the volume of the prostate gland. Prostate specific antigen density
is based on the principle that normal prostatic tissue and BPH require a specific amount
of stromal support to sustain normal function (Benson & Olsson, 1994). Cancerous
tissue does not adhere to this rule. In addition, benign tumors grow by expansion,
whereas cancerous tumors grow by expansion and infiltration (Benson et aI., 1993;
Benson & Olsson, 1994). Since patients with PCa have higher serum PSA levels and
smaller prostate volumes compared to cancer free patients, higher PSAD levels increase
the likelihood that a patient will have PCa. Typically, cutoffs of 0.12 and 0.15 ng/ml/cc
are utilized for PSAD (Benson, Whang, Olsson et aI., 1992; Dincel et aI., 1999; Seamen
et aI., 1993). A higher sensitivity is attained when a cutoff of 0.12 ng/ml/cc is employed.
Conversely, PSAD will exhibit a higher specificity at a cutoff of 0.15 ng/ml/cc. The
discrepancies in the results of PSAD between this study and other studies could be a
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result of an inability by urologists to accurately measure the volume of the prostate gland.
The accuracy of PSAD relies on the ability to measure the volume of the prostate gland
(Van Iersel et aI., 1995; Zlotta et aI., 1997). Therefore, the slightest error in measuring
the .volume of the prostate can produce inaccurate results for PSAD. Intra-observer
estimates of prostate volume using TRUS have 15.5% variability and 93% reliability,
whereas inter-observer estimates have a 21.9% variability and 87% reliability (Tong,
Cardinal, McLoughlin, Downey, & Fenster, 1998). In this study, at cutoffs of 0.12 and
0.15 ng/mllcc, PSAD demonstrated high specificities of 0.70±0.08 and 0.83±0.07,
respectively. However, at cutoffs of 0.12 and 0.15 nglmllcc, PSAD demonstrated modest
sensitivities of 0.58±O.11 and O.42±0.11, respectively. The efficacy of PSAD at both
cutoffs is considered poor mainly due to low sensitivity. Therefore, PSAD should not be
used as an independent clinical test in stage II screening of prostate cancer.
5.3.4 Free-to-Total Prostate Specific Antigen Ratio
Free-to-total prostate specific antigen ratio examines the amount of free serum
PSA in relation to the total serum PSA level. A greater amount of free serum PSA will
decrease the probability for a positive diagnosis of PCa (Catalona et aI., 2000a, 2000b;
Vessella et aI., 2000). Presently, an accepted cutoff for %fPSA has yet to be determined
since different researchers apply various positivity criteria to determine the %fPSA cutoff
(American Urological Association, 2000; Lein et aI., 1998; Martinez-Pineiro et al., 2000).
The decision for an optimal cutoff depends on the desire for the highest level of cancer
detection versus a reduction in the false positive rate (Littrup & Bailey, 2000). For the
purpose of this study, two cutoffs were utilized for %fPSA. These cutoffs were based
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upon a minimum sensitivity of 0.90 and 0.95. When set at a sensitivity of 0.90 and 0.95,
Martinez-Pineiro et al. (2000) calculated the specificity of %fPSA to be 0.39 and 0.32,
respectively. These results are similar to the current study. At a sensitivity of 0.90,
Vessella et al. (2000) also demonstrated a similar specificity (0.40) as the current study.
Although %fPSA is susceptible to false negatives, it provides the highest specificity of
any clinical test while maintaining a sensitivity of 0.90 or better. Although the 25%
cutoff for %fPSA had a higher sensitivity and negative predictive value, the 23% cutoff
had a higher specificity, positive likelihood ratio, Cohen's Kappa statistic, area under the
ROC curve, and positive predictive value. Therefore %fPSA, at a cutoff of 23%, is
advocated by this study to be the most efficacious independent clinical test. At a 23%
cutoff %fPSA detected 92% of cancers and prevented 41 % of unnecessary biopsies.
5.4 Efficacy of Clinical Algorithms
Since clinical tests are not completely accurate, a sequence of tests is typically
administered to make a diagnosis (Knapp & Miller, 1992). Two types of multiple testing
exist including parallel and serial. During the screening of PCa, parallel testing is
typically employed as it was in the current study. Parallel testing, which is usually
performed during emergency situations or routine physical examinations, utilizes a series
of clinical tests performed in succession until a positive identification is made from one
of the clinical tests (Knapp & Miller, 1992). When parallel testing is used, both the
sensitivity and negative predictive value increase, while the specificity decreases (Knapp
& Miller, 1992). These results were observed in this study. Serial testing involves a
series of clinical tests administered simultaneously without any regard for their individual
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results. Each clinical test within the algorithm must demonstrate a positive result to be
considered positive for a disease. Serial testing is employed when rapid assessment is
unnecessary or when other available tests are expensive or risky (Knapp & Miller, 1992).
When serial testing is used, specificity and positive predictive value increases. Efficacy
refers to the extent to which a specific regimen or procedure produces a beneficial result
under ideal conditions (Last, 2001; U.S. Congress, 1976). In this study, efficacy was
primarily measured in terms of sensitivity and specificity. The PSAD (cutoff 0.15
ng/ml/cc) and %fPSA (cutoff 23%) algorithm was the most efficacious clinical algorithm
in stage II screening for prostate cancer. Not only did this algorithm maintain a high
sensitivity (>0.90), but it was able to reduce 38% of unnecessary biopsies. Among
algorithms with a minimum sensitivity of 0.90, this algorithm also had the highest
positive likelihood ratio and area under the curve. This algorithm also achieved the third
highest Cohen's Kappa statistic. This is similar to Ozen et ale (2001) who concluded the
PSAD/%fPSA algorithm was useful for stage II screening patients for PCa. However,
%fPSA is simpler, easier, and less expensive to administer than the PSAD (cutoff 0.15
ng/ml/cc)/%fPSA (cutoff 23%) algorithm and therefore %fPSA (cutoff 23%) is
advocated by this study. Figure 6.1 demonstrates the suggested clinical algorithm in
screening patients for Pea.
5.5 Limitations
Four limitations were recognized in this research which could have comprised the
study results. These limitations include an exaggerated prevalence rate compared to the
general population, lack of subject demographics, failure to incorporate all possible
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clinical test into the research study, and the DRE being administered by several
physicians.
A high prevalence can distort the sensitivity, specificity, and positive and negative
predictive values of a clinical test or algorithm. This study demonstrated a higher
prevalence of PCa (37%) than would be expected in the general population (0.6%). As
the prevalence of a disease decreases, it becomes less likely that an individual with a
positive test result will actually have the disease and more likely the test result will
represent a false positive (Hulley & Cummings, 1988). Therefore, when a clinical test is
administered to the general population from a clinical setting, the results would be altered
due to a decrease in the prevalence rate. Consequently, the results from this study could
represent a prevalence bias when the clinical tests or algorithms are utilized in the general
population.
Subject demographics including weight, height, and race would be valuable
information in describing the spectrum of patients in this study. Information about the
stage of tumors diagnosed would also be beneficial to this study. When details about the
sample of patients are not provided, the calculated results could have limited clinical
relevance (Reid et aI., 1995). To successfully apply the results of a study into a clinical
practice, information pertaining to the demographics of a sample is required.
Four of the most common clinical tests utilized to assess patients with an
intermediate serum PSA and benign DRE were evaluated in this study. However,
another clinical test, PSA velocity, is also used to screen this particular group of patients.
PSA velocity examines the change in serum PSA levels over time from successive serum
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samples (Lynn, Collins, & O'Reilly, 2000). This study failed to obtain blood samples
from patients on different occasions, thus making it impossible to measure PSA velocity.
This study incorporated numerous physicians to perform digital rectal
examinations. As previously mentioned, Turner and Brewster (2000) found that 41 % of
medical students and 16% of interns/residents did not feel confident in their ability to
provide an opinion pertaining to a patient having PCa based on a DRE finding.
Physicians conducting digital rectal examinations in the current study may have had
minimal experience at performing this clinical test. In addition, since DRE is a subjective
clinical test (Applewhite et aI., 2001; Naito et aI., 1988), one physician's opinion may
have been different from another physicians. Information on physician's experience was
not provided as this study was based on secondary data analysis. Unsure of their ability
to correctly perform a DRE, physicians could incorrectly screen a patient query of PCa.
It is not known how this limitation would influence the results of this study.
Nevertheless, this is a limitation in the current study and should be acknowledged in
future research.
5.6 Future Research
In the future, research should examine the use of clinical stage II screening tests
in a less prevalent setting, the use of a serial protocol in the screening for pea, modifying
clinical tests, and utilize decision analysis to evaluate survival rates compared to the
monetary savings achieved through the use of specific clinical tests and algorithms.
Clinical stage II screening tests including TRUS, PSAD, and %fPSA are performed in a
tertiary setting where a prevalence bias for a disease can be found. Future studies should
Stage II Screening for Prostate Cancer 125
adopt these clinical tests in a primary setting that presents a lower prevalence rate of PCa.
By applying these clinical tests in a primary setting, the results would be more applicable
to the general population and useful for the general practitioner.
This research utilized a parallel protocol for each clinical algorithm. A parallel
protocol implies that if one clinical test within the clinical algorithm is positive, then the
patient is suspected of PCa (Knapp & Miller, 1992). Therefore, it would require a
unanimous series of negative tests for a patient not to be suspected of PCa. A serial
protocol requires a unanimous series of positive tests for the patient to be suspected of
PCa. A serial protocol would help to improve the specificity of a clinical algorithm and
thus reduce the number of unnecessary biopsies performed (Knapp & Miller, 1992). To
date, no study has utilized a serial approach to determine the efficacy of clinical
algorithms in stage II screening for pea in patients with an intermediate serum PSA and
normal DRE.
Age-PSA is a clinical test that is easily calculated and utilized in stage II
screening patients who have an intermediate serum PSA level and a normal DRE result.
However, Age-PSA is not considered a useful stage II screening tool as it contributes to a
decreased specificity compared to other clinical tests. Future research should examine
the affects of utilizing smaller age categories for Age-PSA. It is hypothesized that this
modification would increase the specificity of the test, while maintaining the integrity of
sensitivity.
Finally, future research needs to examine the value of increasing specificity at the
expense of a diminishing sensitivity. For example, %fPSA (cutoff 23%) prevents seven
unnecessary biopsies from occurring and reduces needless spending compared to utilizing
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a cutoff of 25%. However, a cutoff of 23% may result in the death of three additional
patients. Is the monetary savings to the health care system worth these three additional
deaths? With additional information including direct and indirect cost of screening
patients and the utilization of a decision analysis this question could be more accurately
addressed.
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Chapter VI
Conclusions
6.1 Conclusions
In the context of this study, the following conclusions were made based on this
sample of stage II patients with intermediate serum PSA and benignDRE.
• With the exception of Age-PSA, every clinical test demonstrated a significant
reduction in the number of unnecessary biopsies performed.
• TRUS, Age-PSA, and PSAD are not efficacious independent clinical tests in stage
II screening of prostate cancer.
• %fPSA is the only efficacious individual clinical test in stage II screening of
prostate cancer.
• The most useful clinical algorithm for stage II screening prostate cancer was
PSAD at a cutoff of 0.15 ng/ml/cc and %fPSA at a cutoff of 23%.
• In general, individual clinical tests attained higher specificities than clinical
algorithms. However, clinical algorithms attained higher sensitivities than
independent clinical tests.
• %fPSA (cutoff of 23%) is advocated by this study.
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Figure 6.1. Clinical Algorithm In Screening Patients For Prostate Cancer
6.2 Future Research Considerations
Prostate cancer is the most commonly diagnosed cancer and third leading cancer
contributing to death in Canadian men. Future research should focus on developing a
new method of stage II screening that maintains a high sensitivity with an enhanced
specificity. Several new clinical tests appear to show promise including PSA complexed
to ul-antichymotrypsin (Saika et aI., 2002) and percent free PSAD (Baltaci et aI., 2003).
Future research is also required to further evaluate the results of this current study in a
less prevalent setting. By administering these clinical tests in a less prevalent
environment, researchers will be able to determine their true usefulness in the general
population.
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Appendix 3 - Summary of TNM and ABeD Systems
TNM System ABeD System Description
A1
A2
01
01
80
C2
81
81
82
C1
C1
C1
C2
No evidence of tumor
Tumor found incidentally in tissue resected from prostate. The
involves < 5% of tissue resected
Tumor found incidentally in tissue resected from prostate. The
involves> 5% of tissue resected
Tumor cannot be palpated during ORE, but is identified
by elevated serum PSA levels
Tumor involves half (or less) of one prostate lobe
Tumor involves more than half of one prostate lobe
Tumor involving both prostate lobes
Tumor extends outside of the prostate on one side
Tumor extends outside of the prostate on both sides
Tumor invades one or both seminal vesicles
Tumor invades the bladder neck and/or external sphincter
and/or rectum
Tumor invading additional areas surrounding the prostate
No regional lymph node metastasis
Metastasis in a single lymph node ~ 2cm
Metastasis in a lymph node> 2cm, but < 5 cm, or multiple
lymph nodes none> 5cm
N3 01 Metastasis in a lymph node> 5 cm
MO No metastasis
M1 02 Distant metastasis, including distant lymph nodes and spine
TO
T1a
T1c
T1b
T4b
NO
N1
N2
T2a
T2b
T2c
T3a
T3b
T3c
T4a
Bostwick, D. G., MacLennan, G. T., & Larson, T. R. (1999). American Cancer Society: Prostate cancer, revised edition. New York:
Villard Books.
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Appendix 4 - Chart Summary of Stage II Screening Literature
Article
Reference
Catalona et al.
(1998)
Catalona et al.
(2000a)
Catalona et al.
(2000b)
Clinical
Tests
%tPSA
%tPSA
Age-PSA
PSAD
%tPSA
=
Reference
Standard
TRUS-guided biopsy
6 biopsy cores
TRUS-guided biopsy
6 biopsy cores
TRUS-guided biopsy
6 biopsy cores
Blind
Comparison
Yes
No
Yes
Patient
Spectrum
773 patients
379 +CaP & 394 ·CaP
Inappropriate
726 patients
357 +CaP & 369 'CaP
Appropriate
773 patients
379 +CaP & 394 -CaP
Inappropriate
Diagnostic
Utility
- Using the %tPSA test can reduce the
number of unnecessary biopsies performed
on patients.
- %tPSA (22): Sens: 0.90, Spec: 0.29.
PPV: 0.55, NPV: 0.75.
LR: 1.27.
- %tPSA (25): Sens: 0.95, Spec: 0.20.
PPV: 0.53, NPV: 0.79.
LR: 1.19.
- A cutoff of 25% reduced the number of
unnecessary biopsies performed in both
races, while detecting 95% of cancers.
Whites:
- %tPSA (25): Sens: 0.95, Spec: 0.20.
PPV: 0.54, NPV: 0.81.
LR: 1.19.
Blacks:
- %PSA (25): Sens: 0.95, Spec: 0.17.
PPV: 0.51, NPV: 0.78.
LR: 1.15.
- %tPSA demonstrated a significantly
higher sensitivity than Age-PSA.
- %tPSA established similar results to
that of PSAD (0.078).
- %tPSA can be used in place of PSAD.
- Age-PSA: Sens: 0.80, Spec: 0.27.
PPV: 0.51, NPV: 0.59.
LR: 1.10.
- PSAD (0.078): Sens: 0.95, Spec: 0.19.
- PSAD (0.15): Sens: 0.59.
- %tPSA (25): Sens: 0.95, Spec: 0.20.
PPV: 0.53, NPV: 0.79.
LR: 1.19.
==
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Cookson et al.
(1995)
Deliveliotis et al.
(1998)
Dincel et al.
(1999)
PSAD
TRUS
PSAD
PSAD
%fPSA
TRUS-guided biopsy
6 biopsy cores
TRUS-guided biopsy
6 biopsy cores
TRUS-guided biopsy
6 biopsy cores
No
No
No
44 patients
8 +CaP & 36 -CaP
Inappropriate
42 patients originally
34 patients
3 +CaP & 31-CaP
Inappropriate
95 patients
20 +CaP & 75 -CaP
Inappropriate
- PSAD did not discriminate between
patients with prostate cancer and patients
with benign prostatic disease.
- PSAD (0.15): Sens: 0.13, Spec: 0.61.
PPV: 0.07, NPV: 0.76.
LR: 0.33.
- PSAD is a valuable test in the screening
for prostate cancer.
- PSAD (0.15): Sens: 1.00, Spec: 0.45.
PPV: 0.15, NPV: 1.00.
LR: 1.82.
- TRUS: Sens:O, Spec: 0.81.
PPV: 0, NPV: 0.89.
LR:O.
- The prostate malignancy index proved to
be more efficacious than PSAD (0.12) and
%fPSA (38 & 39).
- However, both PSAD and %fPSA could
enhance the accuracy of serum PSA.
- PSAD (0.12): Sens: 0.60, Spec: 0.75.
PPV: 0.39, NPV: 0.88.
LR: 2.40.
- PSAD (0.15): Sens: 0.50, Spec: 0.93.
PPV: 0.67, NPV: 0.88.
LR: 7.14.
- %fPSA (38): Sens: 0.90, Spec: 0.11.
PPV: 0.21, NPV: 0.80.
LR: 1.01.
- %fPSA (39): Sens: 0.95, Spec: 0.11.
PPV: 0.22, NPV: 0.89.
LR: 1.07.
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Haese et al. %tPSA TRUS-guided biopsy No 1,602 patients originally - To minimize the number of unnecessary
(2002) 6 biopsy cores 756 patients biopsies, a cutoff of 18% should be
226 +CaP & 530 -CaP utilized for %tPSA.
Appropriate - %tPSA (24): Sens: 0.91, Spec: 0.24.
PPV: 0.34, NPV: 0.86.
LR: 1.20.
Klingler et al. PSAD TRUS-guided biopsy No 77 patients originally - PSAD (0.15) did not significantly reduce
(1998) 6 biopsy cores 28 patients number of unnecessary biopsies.
7 +CaP & 21 -CaP - PSAD (0.15): Sens: O.
Inappropriate
Luboldt et al. PSAD TRUS-guided biopsy No 11,644 patients originally - PSAD can reduce the number of
(2001a) <6 biopsy cores Sample size unknown unnecessary biopsies.
262 +CaP - PSAD (15): Sens: 0.75, Spec: 0.44.
Inappropriate PPV: 0.20.
LR: 1.34.
Luboldt et al. %fPSA TRUS-guided biopsy Yes 11,644 patients originally - %tPSA can enhance the specificity
(2001b) 6 biopsy cores 633 patients of PSA-based detection and decrease
91 +CaP & 542- CaP the number of unnecessary biopsies.
Inappropriate - %tPSA (20): Sens: 0.95, Spec: 0.15.
PPV: 0.16, NPV: 0.95.
LR: 1.12.
Martinez-Pineiro et al. %fPSA TRUS-guided biopsy No 180 patients - At a cutoff of 22%, %fPSA can
(2000) 6 biopsy cores 40 +CaP & 140 -CaP reduce the number unnecessary
Inappropriate biopsies, while still detecting 95% of
cancers.
- %tPSA (20): Sens: 0.90, Spec: 0.39.
PPV: 0.30, NPV: 0.93.
LR: 1.48.
- %tPSA (22): Sens: 0.95, Spec: 0.32.
PPV: 0.29, NPV: 0.96.
LR: 1.40.
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Ozen et al. PSAD TRUS-guided biopsy No 134 patients - The combined use of %fPSA (21 %) and
(2001) %fPSA 6 biopsy cores 10 +CaP & 124 -CaP PSAD (0.18) can increase the specificity
PSAD & %fPSA Inappropriate of serum PSA testing (55%), while
maintaining a sensitivity of 90%.
- PSAD (0.15): Sens: 0.67, Spec: 0.61.
PPV: 0.13, NPV: 0.96.
LR: 1.72.
- %fPSA (30): Sens: 0.91, Spec: 0.21.
PPV: 0.08, NPV: 0.96.
LR: 1.15.
- PSAD (0.18) & % fPSA (21):
Sens: 0.90, Spec: 0.55.
PPV: 0.14, NPV: 0.99.
LR: 2.00.
Vessella et al. %fPSA TRUS-guided biopsy No 692 patients originally - %fPSA can help physicians reduce the
(2000) 6 biopsy cores 297 patients number of unnecessary biopsies
100 +CaP & 197 -CaP performed when serum PSA levels are
Inappropriate intermediate (4.0 to 10.0 ng/ml) and DRE
results are benign.
- %fPSA (24): Sens: 0.90, Spec: 0.40.
PPV: 0.43, NPV: 0.89.
LR: 1.50.
- %fPSA (26): Sens: 0.96, Spec: 0.27.
PPV: 0.40, NPV: 0.93.
LR: 1.32.
Vleeming et al. PSAD TRUS-guided biopsy No 144 patients originally - PSAD does not discriminate between
(1996) 4 or 6 biopsy cores 73 patients patients with prostate cancer and patients
5 +CaP & 68 -CaP without prostate cancer.
Inappropriate - However, Age-PSA can reduce the
number of unnecessary diagnostic tests.
- PSAD (0.15): Sens: 0.60, Spec: 0.50.
PPV: 0.08, NPV: 0.94.
LR: 1.20.
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Appendix 5 - Post-hoc Sample Size Determination
The post-hoc sample size determination outlined below was calculated based on a 95% confidence level
and degrees of error ranging from 5 to 10%. The initial population size (N) of 446 represents the total number of
patients referred to the Princess Margaret Hospital over the course of this study. Expected proportions (p*q) for
prevalence (0.37), sensitivity (0.89), and specificity (.10) were selected from the least accurate clinical test (ie. age-
specific PSA test) in the current study.
Initial Population Expected Proportion Percent Confidence Percent Error Sample Size
N(446) p*q Za % n
Prevalence (0.37) 0.2331 95% 10 60
9 71
8 87
7 107
6 134
5 170
4 219
Sensitivity (0.89) 0.0979 95% 10 32
9 38
8 47
7 60
6 78
5 104
4 144
3 205
Specificity (0.10) 0.09 95% 10 29
9 36
8 44
7 56
6 73
5 98
4 137
3 196
2 285
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Appendix 6 - Consent Form
~THE1ORONTO"HOSPITAL
CON SEN T FORM
General Division
200 Elizabeth Street
Toronto, Ontario M5G 2C4
Western Division
399 Bathurst Street
Toronto, Ontario M5T 288
I have been asked to participate in a study which is designed to
evaluate if a new blood test, PSA ratio, is effective in
detecting prostate cancer.
The test will involve taking a small sample of blood from my arm.
There is a possibility of temporary bruising from the withdrawal
of blood.
I am aware that the study may not benefit me specifically, but
that it should improve understanding of the diagnosis of prostate
disorders.
I have had the opportunity to discuss this study with
Dr. or his delegate and my questions have been
answered to my satisfaction.
If I have any further questions, I may call Dr. Toi at (416) 340-
4800, ext 8844.
1 may also call Dr. Gordon Hardacre at (416) 603-5681 who is not
involved in this trial but who can answer questions about
participating in a research study.
Any information about me learned during this stUdy will be
confidential and neither my name nor any other identifying
particulars will be made available to anyone other than the
investigators or appear in any publication without prior approval
from me.
I consent to take part in the study with the understanding that I
may withdraw at any time without prejudice to my treatment.
I have been offered a copy of this form.
Dated at The Toronto Hospital this day of , 199
---
Patient's Signature
Witness' Signature
(Stamp TTH 10 card)
Name of person
obtaining consent
Professional
Relationship
Signature
A Unittersit\1 of Toronto affiUatl'.d hati,.fkl ~a1"P: t~(lrhjn(Tand rp.~pnYrh rpntrp
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Appendix 7 - Ethics Form
DATE: Jllty lft.2M
FltOM: J'oof'4_m, (::hair
TO:
'11WI project I'Illll been approved fi
~FJhics~som
ld ofJuly 16, 2112 to MIl)' )1, zot),~ to fUJI RIm mtifi<::lldoo at1he
1'1:Ie approvalJUybe~ up.m request TIle" ,,'IWW~
Advurse(lf
in1heview
If~ in1he~ofII heahh tild1lt)', at II fldIooL (If~ instinttioo (If commWlity~ it is 1he
~ibi1ity of ipal,1JMIlIdgator to eM'llN that and approvals of1ho5e ftll::ilitles (If instinttions
are:~ and filed with the REB pri(lf bJ the· •. •
lbe~il.Poley~entrcqttims that ooaoin&N~ be monitclnld. A PiMl R.illp(lrt is requlr<:d b'all~,
with lastin& tm:ll'e tblm one
year will 00l1tlICt you wI:lm
tbisform
~. THETORONTO"HOSPITAL
PSA RATIO data form:
Name:
ID:
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Appendix 8 - Data Form
General Division
200 Elizabeth Street
Toronto, Ontario M5G 2C4
Western Division
399 Bathurst Street
Toronto, Ontario M5T 2S8
(Stamp TTH IO,card)
Exam Date:
DOB:
Patient consent: 1 no 2 yes
Recent UTI: 1 no 2 yes
Recent manipulation: 1 no 2 yes
Pt being followed from
before start of study: 1 no 2 yes
Pt had prior exam as
part of this study: ] 1 no 2 yes
Referral 1?SA: Date:
1?SA value:
1?SA source (lab) : 1 TTB 2 other
Referral ORE: 1 neg 2 pos
Examined by: 1 AT [ 2 OM ] 3MB [ ] 4 WT
Prostate volume:
Ultrasound pos for CA: l 1 no l 2 yes
Pathology: 1 Benign, 2 low PIN, 3 HiPIN
4 Atypia, 5 Microca,
6 Cancer (Gleason )
---
Comments:
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Appendix 9 - Cutoffs for the Free-to-Total Prostate
Specific Antigen Ratio Test
CutoffFor TP FP FN TN Sens Spec LR
%fPSA Test A B C D A/(A+C! D/(B+D) (Sens/l-Spec)
3% 0 0 74 127 0 1.00 0
4% 2 0 72 127 0.03 1.00 0
5% 4 0 70 127 0.05 1.00 0
6% 5 1 69 126 0.07 0.99 7.00
7% 10 2 64 125 0.14 0.98 7.00
8% 21 3 53 124 0.28 0.98 14.00
9% 24 8 50 119 0.32 0.94 5.33
10% 31 10 43 117 0.42 0.92 5.25
11% 37 13 37 114 0.50 0.90 5.00
12% 43 15 31 112 0.58 0.88 4.83
13% 45 22 29 105 0.61 0.83 3.59
14% 47 26 27 101 0.64 0.80 3.20
15% 51 33 23 94 0.69 0.74 2.65
16% 54 40 20 87 0.73 0.69 2.36
17% 56 47 18 80 0.76 0.63 2.05
18% 56 49 18 78 0.76 0.61 1.95
19% 58 56 16 71 0.78 0.56 1.77
20% 58 59 16 68 0.78 0.54 1.70
21% 62 65 12 62 0.84 0.49 1.65
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Cutoff For TP FP FN TN Sens Spec LR
%fPSA Test A B C D A/(A+C) D/(B+D) (Sens/i-Spec)
22% 66 70 8 57 0.89 0.45 1.62
23% 68 75 6 52 0.92 0.41 1.56
24% 68 79 6 48 0.92 0.38 1.48
25% 70 85 4 42 0.95 0.33 1.42
26% 71 87 3 40 0.96 0.32 1.41
27% 71 89 3 38 0.96 0.30 1.37
28% 71 92 3 35 0.96 0.28 1.33
29% 71 97 3 30 0.96 0.24 1.26
30% 71 100 3 27 0.96 0.21 1.22
31% 72 104 2 23 0.97 0.18 1.18
32% 72 107 2 20 0.97 0.16 1.16
33% 72 113 2 14 0.97 0.11 1.09
34% 72 114 2 13 0.97 0.10 1.08
35% 72 117 2 10 0.97 0.08 1.05
36% 73 118 1 9 0.99 0.07 1.07
37% 73 119 1 8 0.99 0.06 1.05
38% 74 120 0 7 1.00 0.06 1.06
39% 74 121 0 6 1.00 0.05 1.05
40% 74 123 0 4 1.00 0.03 1.03
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Appendix 10 - Sensitivity and Specificity Analysis for Clinical
Tests and Algorithms
Clinical TP FP FN TN Sens Spec LR
Test/Algorithm A B C D A/(A+C) D/(B+D) (Sens/l-Spec)
TRUS 26 17 48 110 0.35 0.87 2.69
AgePSA 64 114 8 13 0.89 0.10 0.99
PSAD (0.12) 43 38 31 89 0.58 0.70 1.93
PSAD (0.15) 31 22 43 105 0.42 0.83 2.47
%fPSA (23) 68 75 6 52 0.92 0.41 1.56
%fPSA (25) 70 84 4 43 0.95 0.34 1.44
TRUS/Age PSA 67 117 7 10 0.91 0.08 0.99
TRUS/PSAD (0.12) 53 49 21 78 0.72 0.61 1.85
TRUS/PSAD (0.15) 45 37 29 90 0.61 0.71 2.10
TRUS/%fPSA (23) 70 81 4 46 0.95 0.36 1.48
TRUS/%fPSA (25) 72 89 2 38 0.97 0.30 1.39
Age-PSAIPSAD (0.12) 68 117 6 10 0.92 0.08 1.00
Age-PSAIPSAD (0.15) 68 116 6 11 0.92 0.09 1.01
Age-PSA/%fPSA (23) 72 116 2 11 0.97 0.09 1.07
Age-PSA/%fPSA (25) 72 117 2 10 0.97 0.08 1.05
PSAD (0. 12)/%fPSA (23) 69 84 5 43 0.93 0.34 1.41
PSAD (0. 12)/%fPSA (25) 71 87 3 40 0.96 0.32 1.41
PSAD (0. 15)/%fPSA (23) 69 79 5 48 0.93 0.38 1.50
PSAD (0. 15)1%fPSA (25) 71 86 3 41 0.96 0.32 1.41
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Clinical TP FP FN TN Sens Spec LR
Test/Algorithm A B C D A/(A+C) D/(B+D) (Sens/l-Spec)
TRUS/Age-PSAIPSAD (0.12) 70 119 4 8 0.95 0.06 1.01
TRUS/Age-PSAIPSAD (0.15) 70 118 4 9 0.95 0.07 1.02
TRUS/Age-PSAI%fPSA (23) 73 119 1 8 0.99 0.06 1.05
TRUS/Age-PSAI%fPSA (25) 73 119 1 8 0.99 0.06 1.05
Age-PSAIPSAD (0. 12)/%fPSA (23) 73 118 1 9 0.99 0.07 1.07
Age-PSAIPSAD (0. 12)1%fPSA (25) 73 118 1 9 0.99 0.07 1.07
Age-PSAIPSAD (0. 15)/%fPSA (23) 73 117 1 10 0.99 0.08 1.08
Age-PSAIPSAD (0. 15)/%fPSA (25) 73 117 1 10 0.99 0.08 1.08
TRUS/PSAD (0. 12)/%fPSA (23) 71 89 3 38 0.96 0.30 1.37
TRUS/PSAD (0. 12)/%fPSA (25) 73 92 1 35 0.99 0.28 1.38
TRUS/PSAD (0. 15)/%fPSA (23) 71 84 3 43 0.96 0.34 1.46
TRUS/PSAD (0. 15)/%fPSA (25) 73 91 1 36 0.99 0.28 1.38
TRUS/Age-PSAIPSAD (0.12)/
%fPSA (23) 74 120 0 7 1.00 0.06 1.06
TRUS/Age-PSAIPSAD (0.12)/
%fPSA(25) 74 120 0 7 1.00 0.06 1.06
TRUS/Age-PSAIPSAD (0.15)/
%fPSA(23) 74 119 0 8 1.00 0.06 1.06
TRUS/Age-PSAIPSAD (0.15)/
%fPSA(25) 74 119 0 8 1.00 0.06 1.06
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Appendix 11 - Kappa Agreement for Clinical Tests and Algorithms
Clinical Likelihood
Test/Algorithm Sensitivity (Cl) Specificity (Cl) Ratio (Cl) ZK
TRUS 0.35 (0.24 - 0.46) 0.87 (0.81 - 0.93) 2.69 (2.57 - 2.81) 3.61t
Age-PSA 0.89 (0.82 - 0.96) 0.10 (0.05 - 0.15) 0.99 (0.90 - 1.08) -0.20
PSAD (0.12) 0.58 (0.47 - 0.69) 0.70 (0.62 - 0.78) 1.93 (1.79 - 2.07) 3.95 t
PSAD (0.15) 0.42 (0.31 - 0.53) 0.83 (0.76 - 0.90) 2.47 (2.34 - 2.60) 3.79 t
%fPSA (23) 0.92 (0.86 - 0.98) 0.41 (0.32 - 0.50) 1.56 (1.45 - 1.67) 4.91 t
%fPSA(25) 0.95 (0.90 - 1.00) 0.34 (0.26 - 0.42) 1.44 (1.34 - 1.54) 4.55 t
TRUS/Age-PSA 0.91 (0.84 - 0.98) 0.08 (0.03 - 0.13) 0.99 (0.91 - 1.07) -0.40
TRUS/PSAD (0.12) 0.72 (0.62 - 0.82) 0.61 (0.52 - 0.70) 1.85 (1.72 - 1.98) 4.50 t
TRUS/PSAD (0.15) 0.61 (0.50 - 0.72) 0.71 (0.63 - 0.79) 2.10 (1.96 - 2.24) 4.43t
TRUS/%fPSA (23) 0.95 (0.90 - 1.00) 0.36 (0.28 - 0.44) 1.48 (1.38 - 1.58) 4.87 t
TRUS/%fPSA (25) 0.97 (0.93 - 1.01) 0.30 (0.22 - 0.38) 1.39 (1.30 - 1.48) 4.65 t
Age-PSAIPSAD (0.12) 0.92 (0.86 - 0.98) 0.08 (0.03 - 0.13) 1.00 (0.92 - 1.08) -0.07
Age-PSAIPSAD (0.15) 0.92 (0.86 - 0.98) 0.09 (0.04 - 0.14) 1.01 (0.93 - 1.09) 0.13
Age-PSA/%fPSA (23) 0.97 (0.93 - 1.01) 0.09 (0.04 - 0.14) 1.07 (1.01 - 1.13) 1.67
Age-PSA/%fPSA (25) 0.97 (0.93 - 1.01) 0.08 (0.03 - 0.13) 1.05 (0.99 - 1.11) 1.50
PSAD (0. 12)/%fPSA (23) 0.93 (0.87 - 0.99) 0.34 (0.26 - 0.42) 1.41 (1.31- 1.51) 4.35 t
PSAD (0. 12)/%fPSA (25) 0.96 (0.91 - 1.01) 0.32 (0.24 - 0.40) 1.41 (1.32 - 1.50) 4.62 t
PSAD (0. 15)/%fPSA (23) 0.93 (0.87 - 0.99) 0.38 (0.30 - 0.46) 1.50 (l.40 - 1.60) 4.84 t
PSAD (0. 15)1%fPSA (25) 0.96 (0.91 - 1.01) 0.32 (0.24 - 0.40) 1.41 (1.32 - 1.50) 4.67 t
t Kappa significant agreement (ZK2: 1.96).
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Clinical Likelihood
Test/Algorithm Sensitivity (CI) Specificity (Cl) Ratio (Cl) ZK
TRUS/Age-PSAJPSAD (0.12) 0.95 (0.90 - 1.00) 0.06 (0.02 - 0.10) 1.01 (0.94 - 1.08) 0.26
TRUS/Age-PSAJPSAD (0.15) 0.95 (0.90 - 1.00) 0.07 (0.03 - 0.11) 1.02 (0.95 - 1.09) 0.47
TRUS/Age-PSAI%fPSA (23) 0.99 (0.97 - 1.01) 0.06 (0.02 - 0.10) 1.05 (1.00 - 1.10) 1.61
TRUS/Age-PSAI%fPSA (25) 0.99 (0.97 - 1.01) 0.06 (0.02 - 0.10) 1.05 (1.00 - 1.10) 1.61
Age-PSAJPSAD (0.12)1
%fPSA (23) 0.99 (0.97 - 1.01) 0.07 (0.03 - 0.11) 1.07 (1.02 - 1.12) 1.79
Age-PSAJPSAD (0.12)1
%fPSA (25) 0.99 (0.97 - 1.01) 0.07 (0.03 - 0.11) 1.07 (1.02 - 1.12) 1.79
Age-PSAJPSAD (0.15)/
%fPSA (23) 0.99 (0.97 - 1.01) 0.08 (0.03 - 0.13) 1.08 (1.03 -1.13) 1.96 t
Age-PSAJPSAD (0.15)1
%fPSA(25) 0.99 (0.97 - 1.01) 0.08 (0.03 - 0.13) 1.08 (1.03 - 1.13) 1.96 t
TRUSIPSAD (0.12)/%tPSA (23) 0.96 (0.91 - 1.01) 0.30 (0.22 - 0.38) 1.37 (1.28 - 1.46) 4.43t
TRUSIPSAD (O.12)/%tPSA (25) 0.99 (0.97 - 1.01) 0.28 (0.20 - 0.36) 1.38 (1.30 - 1.46) 4.64 t
TRUSIPSAD (0. 15)/%tPSA (23) 0.96 (0.91 - 1.01) 0.34 (0.26 - 0.42) 1.46 (1.37 - 1.55) 4.85 t
TRUSIPSAD (0. 15)/%tPSA (25) 0.99 (0.97 - 1.01) 0.28 (0.20 - 0.36) 1.38 (1.30 - 1.46) 4.79t
TRUSIAge-PSAJPSAD (0.12)
%fPSA (23) 1.00 0.06 (0.02 - 0.10) 1.06 (1.02 - 1.10) 2.06 t
TRUSIAge-PSAJPSAD (0.12)
%tPSA (25) 1.00 0.06 (0.02 - 0.10) 1.06 (1.02 - 1.10) 2.06 t
TRUSIAge-PSAJPSAD (0.15)
%tPSA (23) 1.00 0.06 (0.02 - 0.10) 1.06 (1.02 - 1.10) 2.24 t
TRUSIAge-PSAJPSAD (0.15)
%tPSA (25) 1.00 0.06 (0.02 - 0.10) 1.06 (1.02 - 1.10) 2.24 t
t Kappa significant agreement (ZK2: 1.96).
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Appendix 12 - Area Under the Curve Accounted for by Clinical Tests
and Algorithms
Clinical
Test/Algorithm
TRUS
Age-PSA
PSAD (0.12)
PSAD (0.15)
%fPSA (23)
%fPSA (25)
TRUS/Age-PSA
TRUSIPSAD (0.12)
TRUSIPSAD (0.15)
TRUS/%fPSA (23)
TRUS/%fPSA (25)
Age-PSAIPSAD (0.12)
Age-PSAIPSAD (0.15)
Age-PSA/%fPSA (23)
Age-PSA/%fPSA (25)
PSAD (0. 12)/%fPSA (23)
PSAD (0. 12)1%fPSA (25)
PSAD (0. 15)/%fPSA (23)
AUC(SEj
0.61 (0.042)
0.50 (0.043)
0.64 (0.041)
0.62 (0.042)
0.66 (0.041)
0.64 (0.041)
0.49 (0.042)
0.67 (0.041)
0.66 (0.041)
0.65 (0.041)
0.64 (0.041)
0.50 (0.042)
0.50 (0.042)
0.53 (0.043)
0.53 (0.042)
0.64 (0.041)
0.64 (0.041)
0.66 (0.041)
Clinical
Test/Algorithm
PSAD (0. 15)/%fPSA (25)
TRUS/Age-PSAIPSAD (0.12)
TRUS/Age-PSAIPSAD (0.15)
TRUS/Age-PSA/%fPSA (23)
TRUS/Age-PSA/%fPSA (25)
Age-PSAIPSAD (0. 12)/%fPSA (23)
Age-PSAIPSAD (0. 12)/%fPSA (25)
Age-PSAIPSAD (0. 15)/%fPSA (23)
Age-PSAIPSAD (0. 15)1%fPSA (25)
TRUSIPSAD (0. 12)/%fPSA (23)
TRUSIPSAD (0. 12)/%fPSA (25)
TRUSIPSAD (0. 15)1%fPSA (23)
TRUSIPSAD (0. 15)1%fPSA (25)
TRUS/Age-PSAIPSAD (0. 12)1%fPSA (23)
TRUS/Age-PSAIPSAD (0. 12)/%fPSA (25)
TRUS/Age-PSAIPSAD (0. 15)1%fPSA (23)
TRUS/Age-PSAIPSAD (0. 15)/%fPSA (25)
AUC(SEj
0.64 (0.041)
0.51 (0.042)
0.51 (0.042)
0.53 (0.042)
0.53 (0.042)
0.53 (0.043)
0.53 (0.043)
0.53 (0.043)
0.53 (0.043)
0.63 (0.042)
0.63 (0.042)
0.65 (0.041)
0.64 (0.041)
0.53 (0.043)
0.53 (0.043)
0.53 (0.043)
0.53 (0.043)
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Appendix 13 - Positive and Negative Predictive Values
of Clinical Tests and Algorithms
Clinical
Test/Algorithm
TRUS
Age-PSA
PSAD (0.12)
PSAD (0.15)
%tPSA (23)
%tPSA(25)
TRUS/Age-PSA
TRUSIPSAD (0.12)
TRUSIPSAD (0.15)
TRUS/%tPSA (23)
TRUS/%tPSA (25)
Age-PSAIPSAD (0.12)
Age-PSAIPSAD (0.15)
Age-PSA/%tPSA (23)
Age-PSA/%tPSA (25)
PSAD (0. 12)1%tPSA (23)
PSAD (0. 12)/%tPSA (25)
PSAD (0. 15)1%tPSA (23)
PSAD (0. 15)/%tPSA (25)
PPV(CI)
0.61 (0.46 - 0.76)
0.36 (0.29 - 0.43)
0.53 (0.42 - 0.64)
0.59 (0.46 - 0.72)
0.48 (0.40 - 0.56)
0.46 (0.38 - 0.54)
0.36 (0.29 - 0.43)
0.52 (0.42 - 0.62)
0.55 (0.44 - 0.66)
0.46 (0.38 - 0.54)
0.45 (0.37 - 0.53)
0.37 (0.30 - 0.44)
0.37 (0.30 - 0.44)
0.38 (0.31 - 0.45)
0.38 (0.31 - 0.45)
0.45 (0.37 - 0.53)
0.45 (0.37 - 0.53)
0.47 (0.39 - 0.55)
0.45 (0.37 - 0.53)
NPV(CI)
0.70 (0.63 - 0.77)
0.62 (0.41 - 0.83)
0.74 (0.66 - 0.82)
0.71 (0.64 - 0.78)
0.90 (0.82 - 0.98)
0.92 (0.84 - 1.00)
0.59 (0.36 - 0.82)
0.79 (0.71 - 0.87)
0.76 (0.68 - 0.84)
0.92 (0.84 - 1.00)
0.95 (0.88 - 1.02)
0.63 (0.39 - 0.87)
0.65 (0.42 - 0.88)
0.85 (0.66 - 1.04)
0.83 (0.62 - 1.04)
0.90 (0.81 - 0.99)
0.93 (0.85 - 1.01)
0.91 (0.83 - 0.99)
0.93 (0.85 - 1.01)
Clinical
Test/Algorithm PPV(CI)
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NPV(CI)
TRUS/Age-PSAIPSAD (0.12)
TRUS/Age-PSAIPSAD (0.15)
TRUS/Age-PSAI%fPSA (23)
TRUS/Age-PSAI%fPSA (25)
Age-PSAIPSAD (0. 12)/%fPSA (23)
Age-PSAIPSAD (0. 12)/%fPSA (25)
Age-PSAIPSAD (0. 15)/%fPSA (23)
Age-PSAIPSAD (0. 15)/%fPSA (25)
TRUSIPSAD (0. 12)1%fPSA (23)
TRUSIPSAD (O.12)1%fPSA (25)
TRUSIPSAD (0. 15)/%fPSA (23)
TRUSIPSAD (0. 15)/%fPSA (25)
TRUS/Age-PSAIPSAD (0. 12)/%fPSA (23)
TRUS/Age-PSAIPSAD (0. 12)/%fPSA (25)
TRUS/Age-PSAIPSAD (0. 15)/%fPSA (23)
TRUS/Age-PSAIPSAD (0. 15)/%fPSA (25)
0.37 (0.30 - 0.44)
0.37 (0.30 - 0.44)
0.38 (0.31 - 0.45)
0.38 (0.31 -0.45)
0.38 (0.31 - 0.45)
0.38 (0.31 - 0.45)
0.38 (0.31 - 0.45)
0.38 (0.31 - 0.45)
0.44 (0.36 - 0.52)
0.44 (0.36 - 0.52)
0.46 (0.38 - 0.54)
0.45 (0.37 - 0.53)
0.38 (0.31 - 0.45)
0.38 (0.31 - 0.45)
0.38 (0.31 - 0.45)
0.38 (0.31 - 0.45)
0.67 (0.40 - 0.94)
0.69 (0.44 - 0.94)
0.89 (0.69 - 1.09)
0.89 (0.69 - 1.09)
0.90 (0.71 - 1.09)
0.90 (0.71 - 1.09)
0.91 (0.74 - 1.08)
0.91 (0.74 - 1.08)
0.93 (0.85 - 1.01)
0.97 (0.91 - 1.03)
0.94 (0.87 - 1.01)
0.97 (0.91 - 1.03)
1.00
1.00
1.00
1.00
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Appendix 14 - McNemar Chi-Square Legend
Clinical
Test/Algorithm Sens Spec PPV NPV
1) %fPSA(23) 0.92 0.41 0.48 0.90
2) %fPSA(25) 0.95 0.34 0.46 0.92
3) TRUSIAge-PSA 0.91 0.08 0.36 0.59
4) TRUS/%fPSA (23) 0.95 0.36 0.46 0.92
5) TRUS/%fPSA (25) 0.97 0.30 0.45 0.95
6) Age-PSAIPSAD (0.12) 0.92 0.08 0.37 0.63
7) Age-PSAIPSAD (0.15) 0.92 0.09 0.37 0.65
8) Age-PSAI%fPSA (23) 0.97 0.09 0.38 0.85
9) Age-PSAI%fPSA (25) 0.97 0.08 0.38 0.83
10) PSAD (0. 12)/%fPSA (23) 0.93 0.34 0.45 0.90
11) PSAD (0. 12)1%fPSA (25) 0.96 0.32 0.45 0.93
12) PSAD (0. 15)1%fPSA (23) 0.93 0.38 0.47 0.91
13) PSAD (0. 15)/%fPSA (25) 0.96 0.32 0.45 0.93
14) TRUS/Age-PSAIPSAD (0.12) 0.95 0.06 0.37 0.67
15) TRUS/Age-PSAIPSAD (0.15) 0.95 0.07 0.37 0.69
16) TRUS/Age-PSAI%fPSA (23) 0.99 0.06 0.38 0.89
17) TRUS/Age-PSAI%fPSA (25) 0.99 0.06 0.38 0.89
18) Age-PSAIPSAD (0. 12)1%fPSA (23) 0.99 0.07 0.38 0.90
19) Age-PSAIPSAD (0. 12)1%fPSA (25) 0.99 0.07 0.38 0.90
20) Age-PSAIPSAD (0.15)/%fPSA (23) 0.99 0.08 0.38 0.91
21) Age-PSAIPSAD (0.15)/%fPSA (25) 0.99 0.08 0.38 0.91
22) TRUSIPSAD (0. 12)/%fPSA (23) 0.96 0.30 0.44 0.93
23) TRUSIPSAD (0. 12)1%fPSA (25) 0.99 0.28 0.44 0.97
24) TRUSIPSAD (0. 15)/%fPSA (23) 0.96 0.34 0.46 0.94
25) TRUSIPSAD (0. 15)/%fPSA (25) 0.99 0.28 0.45 0.97
26) TRUS/Age-PSAIPSAD (0. 12)1%fPSA (23) 1.00 0.06 0.38 1.00
27) TRUS/Age-PSAIPSAD (0. 12)1%fPSA (25) 1.00 0.06 0.38 1.00
28) TRUS/Age-PSAIPSAD (0. 15)1%fPSA (23) 1.00 0.06 0.38 1.00
29) TRUS/Age-PSAIPSAD (0. 15)/%fPSA (25) 1.00 0.06 0.38 1.00
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Appendix 15 - Chi-Square Analysis of Clinical Tests
and Algorithms
Clinical
Test/Algorithm
1) %tpSA (23)
Measure of
Interest
Sens
Spec
Significant Difference With Clinical Test
or Algorithm Number
26-29
3,6-9, 14-21,23,25-29
PPV 3,6
~V 3,6,7,14
3) TRUS/Age-PSA
5) TRUSI%tpSA (25)
7) Age-PSAIPSAD (0.15)
Sens
Spec
~V
Spec
~V
Sens
Spec
~V
16-21,23,25-29
4,5,10-13,22-25
4,5, 10-13,22-29
6-9, 14-21,26-29
6,7,14,15
26-29
10-13,22-25
10-13, 22-25
10-13,22-25
Clinical Measure of
Test/Algorithm Interest
10) PSAD (0.12)/%fPSA (23) Sens
Spec
NPV
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Significant Difference With Clinical Test
or Algorithm Number
26-29
14-21,26-29
14
12) PSAD (0. 15)1%fPSA (23) Sens
Spec
NPV
26-29
14-21,26-29
14,15
14) TRUS/Age-PSAlPSAD (0.12) Sens
Spec
NPV
26-29
22-25
22-25
16) TRUS/Age-PSAI%fPSA (23) Spec
18) Age-PSAIPSAD (0.12)/%fPSA (23) Spec
20) Age-PSAIPSAD (0. 15)1%fPSA (23) Spec
22-25
22-25
22-25
22) TRUSIPSAD (0.12)/%fPSA (23) Spec 26-29
24) TRUSIPSAD (0. 15)1%fPSA (23) Spec 26-29
